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Probing the in vivo economy of amyloid beta-protein during the development of 
Alzheimer’s disease-type pathology 
 
 
Despite intense therapeutic and diagnostic focus on dyshomeostasis of 
amyloid β-peptide (Aβ) in Alzheimer’s disease (AD), we still lack insight into the 
in vivo economy of Aβ in the normal and diseased brain.  Thus, my thesis 
research focused on understanding the dynamics of Aβ in the living brain during 
the development of AD-type pathology.  Using in vivo microdialysis, I showed that 
the steady-state level of Aβ that remains diffusible in the hippocampal interstitial 
fluid (ISF) of awake, behaving hAPP transgenic mice falls as Aβ steadily 
accumulates in the brain parenchyma.  In accord, I observed distinct dispositions 
of microinjected radiolabeled Aβ in plaque-rich versus plaque-free mice, 
suggesting that cerebral amyloid deposits rapidly sequester newly released Aβ.  
This provides the first in vivo evidence from controlled animal experiments for the 
hypothesis that soluble Aβ42 in human cerebrospinal fluid (CSF) falls in AD 
because it is sequestered into insoluble parenchymal deposits as the disease 
develops.  My data further show that the association of Aβ with insoluble 
parenchymal deposits is not irreversible, as acute inhibition of γ-secretase in 
plaque-rich mice failed to lower ISF Aβ42, whereas it did in plaque-free mice.  
Hence, the ISF in plaque-rich mice seems to be a reservoir for both newly   iv 
produced Aβ and Aβ that diffuse off of cell membrane- and plaque-bound 
deposits. 
Finally, I showed that Aβ dimers, which are known to be potent synaptic 
neurotoxins, are undetectable in the aqueous compartments of the central 
nervous system, i.e., the brain ISF and CSF, in hAPP transgenic mice.  Acute 
injection of Aβ dimers into living wild-type mice showed a rapid sequestration of 
the dimers away from the hippocampal ISF pool and a higher recovery in the 
membrane-bound pool than in the cytosolic pool of the brain homogenates.  
Interestingly, I found that the Aβ recovered in the membrane-bound pool was 
tightly associated with endogenous GM1 ganglioside.  Taken together, my results 
suggest that Aβ dimers, and probably higher oligomers, are rapidly sequestered 
away from the ISF and bind to GM1 ganglioside-enriched lipid membranes, such 
as raft-like microdomains of secreted vesicles or on the plasma membranes of 
neurons and other cells. v   
   
 
I dedicate this dissertation to my mother, Young Ae Shim, who has truly 
exemplified the humble and unconditional love of Christ. 
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Alzheimer’s disease: brief introduction  
On November 3 1906, Alois Alzheimer presented a talk at the 37
th Meeting 
of the Southwest German Psychiatrists in Tübingen, Germany, entitled “Über 
eine eigenartige Erkrankung der Hirnrinde”, which when translated into English is 
“On a peculiar disease process of the cerebral cortex”.  In this seminal talk 
(which was surmised shortly thereafter into a three-page report (Alzheimer, 
1907)), Alzheimer described his first encounter in 1901 with a then-51-year old 
patient, Auguste Deter, who displayed clinical characteristics of memory and 
cognitive disturbances and whose brain, which upon her death in 1906 Alzheimer 
performed an autopsy on, showed the neuropathological features of dense 
neurofibrils (later identified to be tangles) and minute miliary foci (later identified 
as senile plaques), along with glial inflammation in cerebral cortical areas 
(Alzheimer, 1907; Graeber et al., 1998) (Figure 1.1 shows Auguste Deter’s brain 
tissue sections, taken from Graeber and Mehraein, 1999). 
First designated Alzheimer’s disease (AD) by Emil Kraeplin (Alzheimer’s 
mentor) in 1910 (Möller and Graeber, 1998), AD is a progressive neurological 
disorder of which the earliest clinical symptoms involve impaired declarative 
(particularly episodic) memory and general cognitive impairment, such as 
impaired judgment, decision-making, and orientation (Selkoe, 2002; Blennow et 
al., 2006).  AD is recognized today as the most prevalent neurodegenerative 
disease and the most common form of dementia.  The prevalence of AD 
worldwide is projected to quadruple from the estimated 26.6 million afflicted in  3 
 
Figure 1.1. Auguste Deter’s brain tissue sections show typical amyloid plaque 
deposition (A and B) and neurofibrillary tangles (C and D).  (A-C) Bielschowsky 
silver impregnation; (D) a drawing of a tangle by Alzheimer in 1907.  Figure 
modified from Graeber and Mehraein, 1999. 
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2006 to 106.23 million by 2050 (Brookmeyer et al., 2007).  Brookmeyer et al. 
(2007) further stated that “If interventions could delay both disease onset and 
progression by a modest 1 year, there would be nearly 9.2 million fewer cases of 
the disease in 2050, with nearly the entire decline attributable to decreases in 
persons needing a high level of care”.  However, today, there remains the 
unfulfilled need for some effective treatment, let alone a cure.  This worrisome 
outlook is due to a belated clinical diagnosis of the disease, well after 
pathogenesis has progressed for years, and hence a considerable delay in the 
effort to intervene (Golde et al., 2011; Selkoe, 2011; Sperling et al., 2011). 
Until recently, a definitive diagnosis of AD required tissue samples of the 
medial temporal lobe and cortical areas of the brain (which is acquired at autopsy, 
or much less commonly, during biopsy) to ensure the presence of the two 
pathological hallmarks of AD: neuritic (“senile”) plaques, in which the β-amyloid 
protein (Aβ) is the primary extracellular component (Glenner and Wong, 1984b; 
Masters et al., 1985; Selkoe et al., 1986) and the intraneuronal tangles, which are 
non-membrane bound masses of paired helical filaments composed primarily of 
hyperphosphorylated tau (Grundke-Iqbal et al., 1986; Kosik et al., 1986; Nukina 
and Ihara, 1986).  It is important to note that neurofibrillary tangles are not unique 
to AD but found in a range of neurodegenerative diseases (Joachim et al., 1987).   
With continuing advances in biomedical research, there has been a 
remarkable progress in the development of biomarkers for AD, which not only 
enhances the hope of detecting AD earlier, but also has helped confirm the   5 
previous histopathological studies and, importantly, advanced our understanding 
of the pathogenesis.  A prime example is the use of magnetic resonance imaging 
(MRI) and positron emission tomography (PET), where the findings have nicely 
complemented earlier histopathological evidence that the first structural and 
functional changes occur in the medial temporal lobe (for e.g., Braak et al., 1999; 
Blennow et al., 2006) (Figure 1.2, taken from Blennow et al., 2006), shows 
representative MRI and PET scans of Pittsburg compound B (PIB) and 
fluorodeoxyglucose (FDG) of an AD patient compared to those of a non-AD 
human control).  Furthermore, recent work using functional MRI has linked 
function (hippocampal hyperactivation and impaired default network deactivation) 
with structural changes (amyloid deposition and cortical thinning in the inferior 
temporal gyrus and areas of the medial and lateral parietal cortices) (Sperling et 
al., 2009; Putcha et al., 2011). 
 
AD: a disease of the synapse 
Enhanced synapse loss in the temporal and frontal cortices is one of the 
histopathological alterations that differentiate AD from normal brain aging (West 
et al., 1994).  The statistical correlation between cognitive decline and synapse 
loss in the hippocampus and association cortices is far stronger than the 
correlations between cognitive impairment and counts of amyloid plaques or 
neurofibrillary tangles (DeKosky and Scheff, 1990; Terry et al., 1991; Coleman 
and Yao, 2003).  Furthermore, in some amyloid precursor protein (APP)   6 
 
Figure 1.2. PIB, MRI, and FDG-PET images from a Control (a 69-year old 
cognitively normal with an MMSE score of 30) and an AD (a 71-year old with mild 
Alzheimer’s disease with an MMSE score of 21).  For AD, there is a marked PIB 
retention in conjunction with an FDG scan with temporoparietal and frontal 
hypometabolism.  Scale bars: standardized uptake values (SUV) for PIB and 
FDG.  Figure directly taken from Blennow et al., 2006. 
   7 
transgenic mouse lines, the numbers of synaptophysin-positive presynaptic 
terminals and microtubule-associated protein (MAP2)-positive neurons are 
significantly less than in non-transgenic controls already at a very young age (~3 
mo in the J9 line and ~8 mo in the J20 line), well before these mice develop 
amyloid plaques (Hsia et al., 1999; Mucke et al., 2000; Palop et al., 2003; 
Shankar et al., 2009).  Importantly, the physical degeneration of synapses in the 
hippocampus appears to precede neuronal death (Walsh and Selkoe, 2004). 
Several quantitative studies using electron microscopy and immunohistochemical 
staining for synaptic markers (Terry et al., 1991; Masliah et al., 2001) as well as 
microarray studies of brain tissues from AD cases and APP transgenic mice (Yao 
et al., 2003) all provide strong evidence that AD is primarily, and at least initially, 
a disorder of synaptic function. 
 
Dyshomeostasis of Aβ  
One of the earliest biomarker changes indicative of AD in humans, even 
before clinical symptoms emerge, is thought to be low levels of the Aβ42 peptide 
in cerebrospinal fluid (CSF) of subjects who have begun developing cerebral 
amyloid deposition.  (Figure 1.3A (taken from Fagan et al., 2009) shows a 
negative correlation between levels of Aβ42 in CSF of cognitively normal elderly 
and their cortical PIB binding potential.)  Importantly, the decline of Aβ42 peptide 
precedes the rise of the levels of tau and phosphorylated tau in the CSF    8 
(reviewed in Craig-Schapiro et al., 2009; Golde et al., 2011).  (Figure 1.3B (taken 
from Snider et al., 2009) shows that the rate of cognitive decline (by the clinical 
demential rating, CDR) in a period of 7 years is greatest in humans with steady 
state levels of Aβ42 < 319 pg/ml in their CSF.)  Dyshomeostasis of Aβ42, therefore, 
is currently thought to mark the earliest events in AD pathogenesis. 
Although factors other than Aβ dyshomeostasis are likely to contribute 
importantly to the pathogenesis of AD (Pimplikar et al., 2010), evidence for Aβ 
dyshomeostasis being the principal driving force in AD comes from multiple 
levels, including genetics.  That individuals with trisomy 21 (Down’s syndrome) 
invariably develop diffuse plaques and vascular deposits (Olson and Shaw, 1969), 
in which Aβ is the principal component (Glenner and Wong, 1984a), led to the 
cloning of the gene that encodes Aβ, APP (amyloid precursor protein) (Kang et 
al., 1987).  Subsequently, several missense mutations within the APP gene were 
identified in families with hereditary AD or the closely related hereditary cerebral 
hemorrhage with amyloidosis (HCHWA)-Dutch syndrome; the first two mutations 
identified were the E693Q (“Dutch”) (Levy et al., 1990; Van Broeckhoven et al., 
1990) and the V717I (“London”) (Goate et al., 1991).  These findings helped 
support the Aβ cascade hypothesis, which stated that an imbalance between 
production and clearance of the Aβ peptide leads to its gradual accumulation and 
the forming of plaques, initiating the AD pathological cascade (Selkoe, 1991; 
Hardy and Higgins, 1992; Hardy and Selkoe, 2002).  One recent version of the 
amyloid hypothesis of AD is detailed in Figure 1.4 (taken from Haass, 2010).   9 
 
Figure 1.3. (A) All cognitively normal adults (i.e., CDR = 0) with cortical amyloid 
(i.e., mean cortical PIB binding potential ≥ 0.16) had low amounts of Aβ42 in their 
CSF (i.e., < 500 pg/ml).  Figure taken directly from Fagan et al., 2009.  (B) Rate 
of cognitive decline (by CDR) in a period of 7 years is greatest in humans with 
steady state levels of Aβ42 < 319 pg/ml in their CSF.  Figure taken directly from 
Snider et al., 2009.   10 
 
Figure 1.4. One recent version of the amyloid cascade hypothesis, which states 
that an imbalance between production and clearance of the Aβ peptide leads to 
its gradual accumulation and the forming of plaques, initiating the AD 
pathological cascade (originally put forth by Selkoe and Hardy (Selkoe, 1991; 
Hardy and Higgins, 1992; Hardy and Selkoe, 2002)).  Here, the author annotated 
unattended questions in red.  Figure taken directly from Haass, 2010.   11 
Shortly after the discovery of the APP gene and some of its AD-causing 
mutations, Aβ was found to be normally secreted from cells (Haass et al., 1992; 
Shoji et al., 1992) and to be present in CSF and plasma of non-AD humans 
(Seubert et al., 1992).  These findings led to the revelation of the proteolytic 
mechanism for APP (and other single transmembrane substrates): the concept of 
regulated intramembrane proteolysis (RIP), whereby type 1 membrane proteins 
(such as APP) first undergo regulated shedding of their ectodomains by 
membrane-anchored proteases (mostly ADAMs), after which the membrane-
retained stubs are cleaved within their transmembrane domains (TMDs) to 
release small hydrophobic peptides (such as Aβ) into the extracellular space.  In 
the APP amyloidogenic pathway, the holoprotein is first processed by β-site APP-
cleaving enzyme (BACE) and then by the γ-secretase complex (Haass and 
Selkoe, 2007), which is a 4-member complex composed of presenilin-1 (or -2), 
Aph1, Pen2, and nicastrin (De Strooper, 2003).  The second cleavage liberates 
the APP intracellular domain (AICD) (cut at the intramembranous “ε-site” within 
the β-CTF of APP) into the cytoplasm and Aβ peptides (cut at the “γ-site” in the 
TMD of the β-CTF) and released into vesicle lumens or the extracellular space).  
The variable γ-cutting site is of great pathogenic importance: the longer the Aβ 
peptide (i.e., the more C-terminal within the β-CTF TMD γ-secretase cleaves), 
the greater its hydrophobicity and propensity to oligomerize (Haass and Selkoe, 
2007).  Current evidence suggests that soluble low-n Aβ oligomers (e.g., Aβ 
dimers, trimers, dodecamers, etc.), but not Aβ monomers, mediate   12 
synaptotoxicity (Walsh and Selkoe, 2007).   
To date, all AD-causing mutations in APP occur either within or 
immediately flanking the Aβ region (Haass and Selkoe, 2007).  The only other 
two dominantly transmitted AD-causing genes are PSEN1 (Presenilin 1) and 
PSEN2 (Presenilin 2) (reviewed in De Strooper et al., 2012), and these have 
turned out to be the catalytic center of γ-secretase (Wolfe et al., 1999).  Missense 
mutations in either presenilin gene lead to increased Aβ42/Aβ40 ratios and in at 
least some examples, increased Aβ43/Aβ40 ratios (Saito et al., 2011).  On the 
other hand, altered clearance (as opposed to production) of Aβ can promote Aβ 
accrual and plaque deposition: for e.g., loss of neprilysin, an Aβ-degrading 
protease, in mice increased the half-life of Aβ in the extracellular space and 
accelerated plaque deposition (Farris et al., 2007).  Overexpression of low-
density lipoprotein receptor, which facilitates Aβ transport across the blood brain 
barrier (Nazer et al., 2008), can lessen amyloid deposition in mice (Kim and Tsai, 
2009).  Importantly, by far the most significant genetic risk factor for AD, APOE4, 
is thought to play a central role in the dyshomeostasis of Aβ by impairing Aβ 
clearance from the interstitial fluid (ISF) and brain and thus promoting Aβ 
accumulation and plaque deposition (DeMattos et al., 2004; Castellano et al., 
2011; Cerf et al., 2011). 
Despite the evidence for a key role of Aβ dyshomeostasis in AD 
pathogenesis, the in vivo economy of Aβ is poorly understood.  Recent studies 
utilizing elegant in vivo techniques in both humans and APP transgenic mouse   13 
models have enhanced our understanding of the dynamics of Aβ in the living 
brain, both as regards normal physiological activities such as sleep or neuronal 
activation (Cirrito et al., 2005; Bateman et al., 2006; Brody et al., 2008; Cirrito et 
al., 2008; Bero et al., 2011) and in pathological setting, its relationship with 
plaque deposition and synaptic density (Cirrito et al., 2003; Spires et al., 2005; 
Kang et al., 2007; Meyer-Luehmann et al., 2008; Koffie et al., 2009; Yan et al., 
2009; Mawuenyega et al., 2010; Hong et al., 2011).  The secretion of Aβ into the 
ISF upon APP proteolysis is thought to require clathrin-mediated endocytosis 
(Cirrito et al., 2008) and to be regulated by synaptic/neuronal acitivity (Cirrito et 
al., 2005; Bero et al., 2011), consciousness (Brody et al., 2008), stress (Kang et 
al., 2007), and the sleep-wake cycle (Kang et al., 2009).  Using an intravenous 
infusion of stable 
13C6-leucine and its incorporation into APP and thus Aβ 
peptides in CSF, the dynamics of Aβ in non-AD normal humans and its 
dyshomeostasis in AD patients have been elegantly analyzed (Bateman et al., 
2006).  Here, the rates of new Aβ production in cognitively normal individuals and 
AD patients were found to be comparable, but the Aβ clearance rates were 
significantly different; clearance rates in cognitively normal humans were ~7.6% 
per hour for Aβ42 and 8.3% per hour for Aβ40, whereas in AD subjects, they were 
lower at ~5.3% per hour for Aβ42 and 5.2% per hour for Aβ40 (Mawuenyega et al., 
2010). 
The complex relationship between the secreted soluble Aβ species and 
the formation of insoluble amyloid plaques is also becoming better understood   14 
through usage of the in vivo tools described above.  Emerging evidence suggests 
that the insoluble amyloid fibrils that comprise plaques may not directly confer 
neurotoxicity but sequester small, diffusible assemblies of Aβ that have been 
shown to potently alter synaptic structure and function (Walsh and Selkoe, 2007).  
That plaques may be relatively inert sinks for small, synaptotoxic oligomeric 
species was shown nicely by using amyloid plaque cores isolated directly from 
AD human brain: plaque cores themselves failed to impair LTP, but upon 
solubilizing them with formic acid (Selkoe et al., 1986), the cores released Aβ 
dimers and other oligomers which then impaired LTP (Shankar et al., 2008).  The 
“plaques as sinks” hypothesis was further validated in vivo during this thesis 
research by measuring the half-lives of radioiodiniated Aβ in ISF of mice with or 
without plaque deposition (Hong et al., 2011).  However, the plaques may not act 
solely as inert sinks; they also seem to act as a local contributor of potentially 
synaptotoxic Aβ oligomers (Cirrito et al., 2003; Spires et al., 2005; Koffie et al., 
2009; Hong et al., 2011).  Array tomography studies have shown that there is a 
halo of Aβ peptides intimately surrounding a plaque, and their relative levels have 
a strong negative correlation with local synaptic density (Koffie et al., 2009).  The 
complexity of the in vivo dynamics of Aβ before, during, and after plaque 
formation has been particularly well shown using in vivo microdialysis in APP 
transgenic mouse models (Cirrito et al., 2003; Hong et al., 2011).  In addition, the 
rate of plaque formation and growth has been studied in living mouse brains 
using in vivo multi-photon imaging, albeit with sometimes conflicting results.  For   15 
example, in Yan et al. (2009), plaques grew over a period of weeks before 
reaching a mature size, whereas in Meyer-Luehmann et al. (2008), the growth of 
plaques stabilized within 24 hours of their first appearance. 
Finally, the recent in vivo studies have also revealed an intricate 
relationship among neuronal activity, levels of Aβ production, and degree of 
plaque deposition, a relationship that perhaps can account for the region-specific 
vulnerability observed in AD.  Areas of the human brain that develop the most Aβ 
deposits may also have among the highest basal rates of metabolic and neural 
activity (Buckner, 2005; Sperling et al., 2009).  The hippocampus is a unique 
region that has high neuronal activity and synaptic plasticity in the adult central 
nervous system (Nicoll and Malenka, 1999).  Neuronal activity has been shown 
to directly modulate the production of Aβ (Kamenetz et al., 2003 (in slices); Cirrito 
et al., 2005 (in ISF)).  Furthermore, a recent study showed that regions with 
higher levels of plaque deposition (such as the hippocampus and the piriform 
cortex) had higher levels of steady-state ISF Aβ, compared to regions with lower 
amounts of plaques (such as the striatum and barrel cortex) (Bero et al., 2011).  
Aβ may in turn impact neuronal activity, either as a negative regulator (i.e., by 
inhibiting long-term potentiation (LTP) and facilitating long-term depression (LTD) 
(for e.g., Li et al., 2009) or as a positive driver to induce aberrant excitatory 
neuronal activity (Palop et al., 2006; Palop et al., 2007).  In particular, soluble 
assemblies of Aβ have been shown to inhibit the induction of LTP and alter 
dendritic spine density through a pathway that requires NMDA-type glutamate   16 
receptors (NMDARs), calcineurin and cofilin, and such synaptic dysfunction and 
loss can be specifically prevented by antibodies to Aβ and by a small molecule 
inhibitor of Aβ aggregation (Townsend et al., 2006; Shankar et al., 2007).  These 
signaling elements are part of a well-described pathway leading from synaptic 
activity to the induction of LTD (Mulkey et al., 1994; Cummings et al., 1996; 
Nagerl et al., 2004). 
   
Soluble Aβ oligomers as the prime synaptotoxic offenders 
Extensive research during the last 15 years has suggested that specific 
forms of Aβ may contribute importantly to the onset of a subtle, intermittent 
impairment of hippocampal neuronal function (Lambert et al., 1998; Walsh et al., 
2002; Kamenetz et al., 2003; Lesné et al., 2006).  In particular, evidence using 
Aβ directly isolated from human AD cortex shows that soluble dimers may act as 
the smallest oligomeric unit capable of exerting synaptotoxicity (McLean et al., 
1999; Klyubin et al., 2008; Shankar et al., 2008; Li et al., 2009; Mc Donald et al., 
2010; O'Nuallain et al., 2010; Li et al., 2011) and tau-altering effects (Jin et al., 
2011).  Such Aβ dimers may then quickly form metastable protofibrils that remain 
synaptotoxic (O'Nuallain et al., 2010).  Although the precise biochemical nature of 
an array of potentially neurotoxic oligomers – dimers, trimers, Aβ*56, Aβ-derived 
diffusible ligands (ADDLs), annular complexes and large protofibrils – is still 
under debate (Haass and Selkoe, 2007; Roychaudhuri et al., 2008; Benilova et   17 
al., 2012), there is a growing consensus that the Aβ forms which exert such 
synaptotoxic effects are the species that remain pre-fibrillar and soluble in the 
extracellular space (reviewed in Walsh and Selkoe, 2007).  Importantly, an AD-
causing APP mutation that was recently discovered in certain AD families leads 
to the production of Aβ species lacking residue E22 within the Aβ region of APP, 
and this results in rapid formation (and apparent stabilization) of Aβ oligomers 
(Tomiyama et al., 2008); in accord, a mouse model carrying this mutation led to 
synaptic and neuronal loss in the complete absence of amyloid plaques 
(Tomiyama et al., 2010).  In an in vitro study comparing multiple synthetic 
Aβ42/Aβ40 ratios, the ratio which was the most effective at inhibiting synaptic 
activity and affecting neuronal viability was the ratio at which amyloid fibril 
formation was delayed and smaller oligomeric species stabilized (Kuperstein et 
al., 2010).  Interestingly, amyloid fibrils could be reverted to a heterogeneous 
mixture of soluble, oligomeric intermediate species upon incubation with lipids 
(brain total extracts, sphingolipids, or GM1 ganglioside) and the previously inert 
fibrils now induced altered tau phosphorylation and memory impairment in mice 
(Martins et al., 2008).  By SEC, the oligomeric species released upon fibril 
incubation with lipids eluted as ~9 kDa globular protein fractions, but by other 
biophysical methods, such as the 18-angles static light scattering, the species 
was considered to be a heterogeneous mixture of ~80-500 kDa assemblies 
(Martins et al., 2008). 
Where and how these synaptotoxic low n Aβ assemblies are generated   18 
and regulated and whether they are bound to other proteins are important 
questions that yet need to be answered in order to elucidate the exact steps 
behind the initiation of AD, with attendant therapeutic implications.  The precise 
mechanism of how Aβ oligomers act as the principal synaptotoxic species is still 
under debate.  As mentioned above, both the LTP-inhibiting and LTD-facilitating 
effects of Aβ are thought to be mediated in part through NMDA receptors (Wu et 
al., 1995; Molnar et al., 2004; Wang et al., 2004; Kelly and Ferreira, 2006; Li et 
al., 2009; Li et al., 2011).  In particular, soluble Aβ oligomers were recently 
shown to disrupt neuronal glutamate uptake and thereby potentially overactivate 
extrasynaptic NR2B-containing NMDA receptors (Li et al., 2009; Li et al., 2011).  
The search for a particular receptor for Aβ oligomers has yielded a true 
“embarrassment of riches” (Selkoe, 2011); the candidate list is extensive, 
including α7-nicotinic acetylcholine receptor (Wang et al., 2000), insulin receptors 
(De Felice et al., 2009), NMDA receptors (De Felice et al., 2007) and AMPA 
receptors (Zhao et al., 2010).  The newest member in this far-from-exclusive club 
is the cellular prion protein (PrP
c) (Laurén et al., 2009).  Aβ has also been found 
to bind specifically to molecular chaperones present in extracellular fluids 
including CSF, i.e., apolipoprotein E (ApoE) (Strittmatter et al., 1993) and 
apolipoprotein J (ApoJ, also known as clusterin) (Ghiso et al., 1993). 
The PrP
c/Aβ interaction has been a hotbed of controversy ever since 
Laurén et al. (2009) reported PrP
c as an apparent receptor for synthetic Aβ42 
oligomers, i.e., Aβ42 peptides assembled into spherical particles of 5-6 nm   19 
diameter that run at ~150 kDa on SDS-PAGE.  This work did not find evidence 
that PrP
c acted as a receptor for “fresh Aβ monomers”, i.e., Aβ that runs where 
monomers are expected to elute by non-denaturing SEC but on SDS-PAGE runs 
as monomers, trimers and tetramers.  Using 30-200 nM synthetic Aβ42 
preparations, Laurén et al. (2009) reported that PrP
c mediates ~50% of the 
binding of these oligomers to hippocampal neurons, that residues 95-105 of PrP
c 
are the primary determinant of binding, and that PrP
c is required for Aβ’s 
inhibition of LTP in hippocampal slices.  Prior to this study, PRNP, the gene 
encoding human prion protein, has been found to be a potential AD susceptibility 
gene (Bertram et al., 2007), where the PRNP codon 129 polymorphism may act 
as a risk factor for AD (Dermaut et al., 2003; Riemenschneider et al., 2004).  
However, Laurén et al.’s findings were soon disputed by the Malinow laboratory, 
which showed that PrP
c was not required for synthetic Aβ’s effect on dendritic 
spine loss or LTP inhibition (Kessels et al., 2010).  Laurén et al. argued that the 
failure of Kessels et al. to repeat the PrP
c dependency of Aβ on LTP inhibition 
could be partially due to a dosage issue (1 μM was used in Kessels et al. vs. 30-
100 nM was used in Lauren et al.).  Similarly, two laboratories reported conflicting 
data when crossing an established transgenic mouse model of AD with a mouse 
model null for PrP
c (i.e., PrnP -/-).  One group crossed APP/PS1 double 
transgenic mice with PrnP -/- mice and observed that whereas the levels of APP, 
Aβ and astrogliosis remain unchanged upon the loss of PrP
c, there was a rescue 
(to levels of wild-type mice) of axonal degeneration, loss of synaptic markers   20 
(synaptophysin and PSD-95), and impairment of spatial learning and memory (by 
Morris water maze test) (Gimbel et al., 2010).  On the contrary, another group 
that crossed hAPP transgenic mice (the J20 line) with PrnP -/- mice observed 
that abnormalities of learning and memory were retained in the absence of PrP
c, 
arguing that PrP
c does not play any role in Aβ-induced memory impairment 
(Cissé et al., 2011).  Several other labs have joined in the controversy, reporting 
data either in support of (Chen et al., 2010; Chung et al., 2010; Barry et al., 2011; 
Freir et al., 2011; Resenberger et al., 2011; Kudo et al., 2012) or against 
(Balducci et al., 2010; Calella et al., 2010) a critical role of PrP
c for Aβ to 
suppress cognitive function.  Other labs utilized a more natural source of Aβ, i.e., 
AD brain-derived Aβ low n oligomers, and found that these human AD brain-
derived species were ineffective in inhibiting LTP in PrnP -/- hippocampal slices 
(Freir et al., 2011), and that pretreating rats with a Fab fragment binding to 
epitope 96-104 of PrP
c rescued the ability of AD brain-derived Aβ to inhibit LTP in 
vivo (Barry et al., 2011).  Interestingly, treating plaque-rich APP/PS1 transgenic 
mice with an anti-PrP
c antibody (6D11) rescued behavioral deficits without 
ameliorating plaque burden (Chung et al., 2010).  The binding in vitro of Aβ 
oligomers, but not monomers or fibrils, to the N-terminal region of PrP
c was 
verified using surface plasmon resonance (SPR) and site-directed spin labeling, 
and the apparent dissociation constant for the interaction was calculated to be 
~70 nM Aβ (Chen et al., 2010).  One laboratory reported Aβ to be co-
immunoprecipitated with PrP
c in both hAPP transgenic mice and human AD   21 
brains; however, key controls were missing in this study, so interpretation of their 
data should be taken with caution (Gao et al., 2010).  Finally, an alternative, 
protective role of PrP
c has been suggested: transfection of PrP
c decreased Aβ 
and soluble APPβ fragments in SH-SY5Y cells; conversely, knockdown of 
endogenous PrP
c increased Aβ and soluble APPβ in mouse N2a cells and the 
authors suggested the regulation by PrP
c of APP processing was by its direct 
inhibition of BACE-1 through glycosylaminoglycans (Parkin et al., 2007). 
Using an elaborate single-molecule imaging technique (Renner et al., 
2008; Triller and Choquet, 2008), synthetic Aβ oligomers (sometimes called 
ADDLs) have been shown to induce aberrant clustering of metabotropic 
glutamate receptors (mGluR), thereby disrupting the normal dynamics of synaptic 
components (Renner et al., 2010).  As Aβ oligomers have also been shown to 
increase localization of PrP
c to the cell surface (Caetano et al., 2011), it is 
possible that Aβ targets a specific protein receptor, such as the PrP
c or other 
synaptic components, and “overstabilizes” their presence on the cell membrane, 
thereby inducing “pathological signaling platforms” (Renner et al., 2010).  
Alternatively, the hydrophobic Aβ peptide may bind to certain lipids on plasma 
membranes, instead of a specific protein receptor, and exert subtle 
physicochemical properties of membranes (for e.g., by interfering with membrane 
fluidity, dynamics of membrane lipids and proteins, or ion permeability), which 
may in turn affect various proteins that are expressed on the membrane surface.  
    22 
Soluble Aβ oligomers: their existence in vivo    
The dazzling state of confusion in research regarding the mechanisms of 
Aβ oligomers can be blamed on the heterogeneity of Aβ sources used by 
different laboratories (e.g., synthetic versus natural) and to lack of clarity about 
the precise structural nature (e.g., dimers, trimers, dodecamers, ADDLs, etc), as 
noted above.  To date, Aβ oligomers from natural sources (for e.g., cell culture 
media and AD brain homogenates) have been isolated using variable 
homogenization and/or concentration protocols, raising concerns whether they 
“really exist in vivo” (Haass, 2010), and thus the call for Aβ oligomers to be 
identified in biological fluids, primarily the CSF, has intensified in the past few 
years (Benilova et al., 2012).  There has been a few reports on Aβ oligomers 
existing in CSF and plasma of humans developing AD (for e.g., Klyubin et al., 
2008; Fukumoto et al., 2010; Gao et al., 2010; Villemagne et al., 2010); however, 
the interpretation of these various assays has been difficult due to vague 
definitions of the precise oligomeric unit the assays are detecting and whether 
one can really exclude the detection of Aβ monomers.  In this regard, our lab has 
recently designed two ELISAs that specifically detect a range of soluble Aβ 
oligomers (from dimers to prefibrillar oligomers) but not Aβ monomers.  These 
ELISAs sensitively detect low amounts of synthetic soluble Aβ oligomers (≤ 30 
pg/ml) as well as natural, soluble Aβ oligomers isolated from AD brains.  Utilizing 
these two oligomer-specific ELISAs (o-ELISAs), we failed to detect any soluble 
Aβ oligomers in CSF samples from 13 human individuals (Yang et al., submitted).    23 
Furthermore, we failed to detect any low molecular weight Aβ oligomers, 
including dimers, in the ISF of APP transgenic mice, which has abundant Aβ, 
regardless of age or degree of plaque deposition (Hong et al., 2011).  However, 
these results do not necessarily support critics’ doubts as to whether low n Aβ 
oligomers exist in vivo; instead, they suggest that the low n Aβ oligomers may not 
exist in the aqueous biological fluids, but due to their substantial hydrophobicity, 
they may be sequestered away from the extracellular fluid onto membranes 
and/or existing aggregates (plaques) (I address this concept further in Chapter 4). 
  
Aβ and lipids, particularly GM1 ganglioside 
Hydrophobicity plays a crucial role in Aβ oligomerization.  The most 
hydrophobic stretch of Aβ, aa 29-42, is thought to be helically wound in the lipid 
environment and changes in the aa 41 and 42 of Aβ induce changes in 
conformation that allow aberrant exposure of hydrophobic amino acids, thereby 
leading to increased propensity to aggregate.  Aβ fibrils have β-sheet structure 
where the mid-region of Aβ, in particular aa 19-28, is buried.  Mutations in APP 
and PSEN that increase the Aβ42/Aβ40 ratio are AD-causing (for e.g., APP 
V717F; PSEN1 L166P) (Suzuki et al., 1994; Duff et al., 1996; Scheuner et al., 
1996) and in both AD patients and transgenic mouse models of AD, Aβ42 is the 
primary Aβ component in the senile amyloid plaques, despite the fact that Aβ40 is 
produced at much higher levels.  The additional isoleucine and alanine at the C-  24 
terminus of Aβ42 are considered to increase its hydrophobicity and thus its 
propensity to oligomerize to a much greater degree than Aβ40.  Indeed, the 
substitution of these two hydrophobic amino acids to hydrophilic residues greatly 
lessens the peptide’s aggregation propensity (Kim and Hecht, 2005).  
Given that hydrophobicity is a key feature of Aβ oligomers, there very well 
may not be a specific target protein receptor for Aβ.  Instead, the hydrophobic Aβ 
oligomers, once released into the extracellular space, may quickly be 
sequestered to certain microdomain on plasma membranes of cells or to certain 
lipid vesicles.  As the γ-secretase complex cleaves the APP C-terminal stub 
within the plasma membrane, Aβ may well retain some hyrophobic affinity for 
lipids.  This could in turn explain why there seem to be so many candidate protein 
“receptors” for Aβ; as noted above, the hydrophobic Aβ peptide may “target” 
certain lipid molecules and exert subtle physicochemical properties on 
membranes, which may in turn affect various proteins that traverse the 
membrane or are anchored to it (e.g., PrP
c). 
One appealing candidate for a lipid that could bind hydrophobic forms of 
Aβ is GM1 ganglioside.  Gangliosides are glycosphingolipids composed of a 
hydrophilic sialic acid moiety exposed to the external environment and a 
hydrophobic membrane-embedded ceramide moiety (Fishman and Brady, 1976) 
(Figure 1.5 shows structure for GM1 ganglioside and proposed biosynthetic 
pathways for the major gangliosides in the mammalian brain (from Sheikh et al., 
1999)).  Gangliosides are particularly enriched in the nervous system, as    25 
 
Figure 1.5. (A) Structure of GM1 ganglioside.  (B) Proposed biosynthetic 
pathways for the major gangliosides in the mammalian brain; figure modified from 
Sheikh et al., 1999. 
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compared to other cellular membranes, and their composition changes during 
development (Svennerholm and Gottfries, 1994; Sonnino et al., 2007).  In 
particular, using immunoelectron microscopy, the GM1 ganglioside was found to 
be localized onto the pre- and postsynaptic membranes of the external plexiform 
layer of rabbit retina and rat cerebral cortex (Hansson et al., 1977).  The study of 
GM1 ganglioside was advanced when the B-subunit of cholera toxin was found to 
specifically bind to GM1 ganglioside but not other gangliosides such as Gd1b or 
GT1 (Holmgren et al., 1973; King and van Heyningen, 1973; van Heyningen, 
1974). 
Studies have shown that total methanol/chloroform-extractable 
gangliosides were significantly decreased in AD brain tissue (Svennerholm and 
Gottfries, 1994) and the concentration of GM1 (and to some extent, GM2) 
gangliosides were increased in the CSF of AD patients (Blennow et al., 1991).  
However, GM1 ganglioside achieved special attention in AD research when 
GM1-bound Aβ monomers were identified in membrane fractions of AD brains 
with diffuse plaques (Yanagisawa et al., 1995).  Sucrose gradient fractions 
contained Aβ1-42 species that migrated at ~5 kDa by denaturing PAGE, and 
delipidation brought the altered migration down to the usual 4 kDa monomer 
position.  Furthermore, the Aβ antibody, 4G8, could not recognize the 5 kDa 
species (suggesting that this species had a masked epitope at aa 17-24), and 
treatment with methanol (but not with SDS, chloroform or acetone) revealed the 
epitope.  Finally, the 5 kDa Aβ band was reactive with cholera toxin, which binds   27 
specifically to GM1 ganglioside.  As the 5 kDa species was observed only in 
brains that contained diffuse plaques, but not in typical AD brains that were rich 
with mature (fibrillar) amyloid plaques or in non-AD cortices, the authors 
speculated that the 5 kDa GM1 ganglioside-bound Aβ monomer could be a “seed” 
for amyloid fibril formation.  Several biophysical studies that followed the 
Yanagisawa et al. (1995) paper supported the view that Aβ, upon binding to GM1 
ganglioside on neuronal membranes, undergoes a conformational change that 
confers a higher propensity to aggregate, thus acting as an endogenous seed 
(reviewed in (Ariga et al., 2008; Yanagisawa, 2011)).  Briefly, Aβ upon binding to 
GM1 ganglioside-containing lipid vesicles (but not to sphingomyelin or various 
anionic phospholipid vesicles) underwent a conformational change from random 
coil to β-sheet rich structure (McLaurin and Chakrabartty, 1996; Choo-Smith and 
Surewicz, 1997); upon binding, the ganglioside-containing vesicles greatly 
accelerated Aβ fibril formation in vitro (Choo-Smith et al., 1997; Hayashi et al., 
2004).  In particular, the sialic acid of GM1 seems to be a critical recognition site, 
and the other sugar groups in the ganglioside seem to help mediate the 
interaction (e.g., there is ~3-fold higher binding to GM1 than GM2, which lacks a 
galactose residue.  The ranking of in vitro Aβ binding affinity (from high nM to low 
μM) was GD1a = GT1b > GM1 > GM2 (Choo-Smith et al., 1997).  However, in 
vesicles that include sphingomyelin and cholesterol, i.e., liposomes of lipid raft-
like composition, Aβ bound to GM1 gangliosides displayed the most rapid fibril 
formation compared to liposomes containing GT1b, GD1b or GD1a (Kakio et al.,   28 
2002).  Furthermore, the concentration of GM1, and to a lesser extent, GM2, was 
increased in detergent-resistant membranes isolated from the frontal cortices of 
early AD brains as compared to membranes from non-AD brains (Molander-Melin 
et al., 2005).  Finally, a monoclonal antibody that was raised specifically against 
GM1 ganglioside-bound Aβ isolated from membrane fractions of human brains 
with diffuse plaques (i.e., the 4396C antibody) (Yanagisawa et al., 1997) 
immunostained the neuropil but not plaques and immunoprecipitated a cholera 
toxin- and Aβ-positive band from membrane fractions of brains of nonhuman 
primates (Hayashi et al., 2004).  Taken together, these results suggest that GM1 
ganglioside may act as a type of surface lipid “receptor” for Aβ.  However, further 
studies are necessary to characterize the GM1 ganglioside-bound Aβ complex 
(some of which I address in Chapter 4). 
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Chapter 2 
 
Dynamic analysis of amyloid β in behaving mice reveals opposing changes 
in interstitial fluid versus parenchymal amyloid β during age-related plaque 
formation 
 
 
 
 
 
Contributions: 
Experiments were designed by Soyon Hong and Dennis Selkoe.  Bicine-
urea/SDS PAGE experiments were performed by Omar Quintero-Monzon.  Aβ 
ELISAs were performed by Beth Ostaszewski, Ting Yang, and Soyon Hong.  All 
other experiments were performed by Soyon Hong. 
 
 
Publication: 
Parts of this chapter have been published in the Journal of Neuroscience 
31(44):15861-9.      45 
Introduction 
After decades of investigative focus on amyloid plaques in Alzheimer’s 
disease (AD), recent findings have led to a conceptual shift.  Emerging evidence 
suggests that the insoluble amyloid fibrils that comprise plaques may not directly 
confer neurotoxicity but sequester small, diffusible assemblies of amyloid β-
peptide (Aβ) that have been shown to potently alter synaptic structure and 
function (Walsh and Selkoe, 2007).  The recognition of Aβ oligomers as highly 
bioactive assemblies has furthered interest in detecting and analyzing soluble 
forms of the peptide for mechanistic, diagnostic and therapeutic purposes.  
Although factors other than Aβ dyshomeostasis contribute importantly to the 
pathogenesis of AD (Pimplikar et al., 2010), virtually all potentially disease-
modifying treatments currently under development are focused on decreasing or 
neutralizing this neurotoxic peptide.  Moreover, a reduced CSF level of Aβ42 in 
subjects with incipient or very early AD is one of the most promising biomarkers.  
Despite this therapeutic and diagnostic focus, we still lack insight into the in vivo 
economy of the most soluble forms of Aβ in the brain during the development of 
AD-type pathology. 
Interstitial fluid (ISF) is the extracellular fluid that bathes the cells within a 
specific tissue region.  As soluble Aβ is released by neurons, the ISF represents 
the pool of Aβ that may best reflect the physiological secretion and fate of soluble 
Aβ species, giving insight to the functions of Aβ in the normal environment and 
also the earliest, subtle changes that occur in AD.  Moreover, ISF is the main     46 
“trade center” between plasma and brain.  The production of water through 
oxidation of glucose within brain cells and movement of plasma water from the 
brain vasculature across the blood-brain-barrier (BBB) contributes to the 
formation of ISF, which finds its way into the ventricular and cranial subarachnoid 
cerebrospinal fluid (CSF) (Shen et al., 2004).  Thus, CSF content is influenced to 
a significant extent by the composition of solutes entrained in the brain ISF.  
The in vivo microdialysis technique is the only known method that allows 
the collection of ISF from the hippocampi of awake, behaving mice.  Based on 
the principle of simple diffusion, soluble molecules within the extracellular fluid 
with molecular weights (MW) that are much smaller than the MW cutoff (MWCO) 
of the semi-permeable probe membrane will cross the microdialysis membrane 
into microdialysate.  Using in vivo microdialysis, Cirrito et al. (2003) have shown 
that soluble Aβ can be collected directly from ISF of a mouse hippocampus on a 
dynamic time scale, exclusive from other CNS compartments.  Moreover, this 
technique allows for delivery of anti-Aβ antibodies or other potential drugs via 
reverse microdialysis or through the injection cannula attached to the 
microdialysis probe without further manipulation of the tissue or handling of the 
animal.  The advantages of this particular delivery are (1) tissue around the probe 
can be repaired before delivery begins; (2) it avoids the brain trauma caused as 
the solution is ejected from the injector tip; and (3) there is no net change in fluid. 
Here, to gain insight into the in vivo economy of the most soluble forms of 
Aβ in the brain during the development of AD-type pathology, I used brain     47 
microdialysis in awake and behaving hAPP transgenic mice to gain an 
understanding of Aβ dynamics before and during the process of Aβ plaque 
formation.  Microdialysis in mouse models of AD and even human subjects is 
providing important insights into the dynamics of normal ISF Aβ economy (Brody 
et al., 2008; Cirrito et al., 2008; Kang et al., 2009) and may help identify the 
earliest, most subtle Aβ changes that occur as AD-type neuropathology begins.  
Given the power of this in vivo sampling method, I performed hippocampal 
microdialysis on > 40 freely moving J20 transgenic mice of increasing age as a 
model of cerebral Aβ accumulation, and we searched for changes in the quality 
and quantity of Aβ species as the brain accrues insoluble deposits and 
undergoes neuronal and glial injury.  We systematically analyzed the nature of 
endogenous Aβ over time using sensitive sandwich ELISAs, immunoprecipitation 
(IP)-Western blotting (WB), native and denaturing polyacrylamide gel 
electrophoresis (PAGE), and size-exclusion chromatography (SEC).  We then 
complemented these analyses by assessing the fate of radiolabeled Aβ 
microinjected at physiological concentrations as a surrogate of newly secreted 
Aβ, and the results help explain the fall of Aβ42 in the CSF of humans with AD.  
Taken together, these experiments describe the in vivo dynamics of the most 
soluble pool of brain Aβ during the process of AD-type amyloid plaque formation. 
 
Results 
Biochemical analysis of Aβ peptides that remain soluble in the brains of young,      48 
behaving hAPP transgenic mice 
To examine the quality and quantity of Aβ that remains soluble and of low 
molecular weight in ISF in vivo (termed ISF Aβ herein), we used a microdialysis 
probe with a 35 kDa MWCO membrane in mice expressing familial AD-mutant 
human APP (expressing APP V717F/KM670/671/NL transgene) (Mucke et al., 
2000).  When we intraperitoneally injected Compound E, a potent and brain-
penetrant γ-secretase inhibitor (Grimwood et al., 2005; Yan et al., 2009), total 
ISF Aβ captured in microdialysates fell rapidly (t1/2 ~2 h) to baseline (Figure 
2.1A), showing that most of the ISF Aβ we sample by microdialysis in young 
transgenic mice represents newly synthesized APP cleavage products.  To 
capture the Aβ species that best reflect the physiological levels, we performed 
microdialysis at a slow perfusion rate of 0.2 μl/min for up to 72 hours, as this 
allows optimal exchange of free Aβ into the probe.  ISF samples were 
immunoprecipitated with a polyclonal Aβ antiserum (AW8), and the precipitates 
were separated by denaturing PAGE and blotted with pooled monoclonal 
antibodies to the N-terminus (6E10) and mid-region (4G8) of Aβ.  The ISF Aβ 
was separated by conventional SDS-PAGE into two species: a 4 kDa monomer 
and a novel ~5 kDa species, which ran roughly half the time as a band (Figure 
2.1B) and the other half as a smear (Figure 2.4A).  We did not detect dimers 
(which run at ~6.5 kDa in these gels; Figure 2.1B) by IP/WB in the ISF of any of 
the > 40 mice we examined in this study, regardless of age.  In vitro (test-tube) 
microdialysis of synthetic Aβ40 showed that our 35 kDa MWCO membrane      49 
Figure 2.1. ISF Aβ obtained by microdialysis from behaving 3 mo J20 hAPP 
transgenic mice. 
 
(A) Rapid decline of ISF Aβ (t1/2 ~2 h) upon acute γ-secretase inhibition in vivo in 
3 mo transgenic (vs. wild-type littermate) mice.  ISF sampled hourly at 1 μl/min; 
Compound E injected at time = 0 h.  (B, C) ISF collected at 0.2 μl/min were IP’ed 
with AW8 Aβ antiserum and subjected to two types of SDS-PAGE: (B) 
Conventional SDS-PAGE separates ISF Aβ into a ~4 kDa (monomers) and a ~5 
kDa Aβ-immunoreactive species (lane 3).  No dimers were detected in ISF (but 
can be seen in the TBS-extract of a 24 mo transgenic (lane 2) or in synthetic Aβ 
(lane 1)).  WB: 6E10+4G8.  (C) Bicine/urea SDS-PAGE resolved ISF Aβ into 3 
bands comigrating with synthetic Aβ1-38, Aβ1-40, and Aβ1-42, plus a fourth faint 
band corresponding to Aβ1-39.  WB: 6E10.  (D) Using 6E10 Aβ triplex ELISA, we 
quantified Aβx-38, Aβx-40 and Aβx-42 in ISF.  Mean ± s.e.m.: 635 ± 70, 1937 ± 311 
and 592 ± 58 pg/ml, respectively; N = 7 mice.  (E) Interpolated zero flow method. 
Mean ± s.e.m.; N = 3-4 mice.     50 
 
 
Figure 2.1 (Continued). ISF Aβ obtained by microdialysis from behaving 3 mo 
J20 hAPP transgenic mice. 
 
 
     51 
allowed passage of dimers; however, their diffusion efficiency was low compared 
to that of monomers (Figure 4.1), suggesting that the lack of dimers in the ISF 
samples could be due to the detection limit of the technique.  Next, we analyzed 
the mouse ISF by bicine/urea SDS-PAGE, which electrophoretically separates 
Aβ peptides of different lengths (Klafki et al., 1996).  ISF Aβ was resolved into 
three principal bands comigrating with synthetic Aβ1-38, Aβ1-40, and Aβ1-42, plus a 
fourth faint band comigrating with Aβ1-39 (Figure 2.1C).  Using a multiplex ELISA, 
we confirmed the bicine/urea gel result that Aβ40 is the most abundant Aβ in ISF 
(Figure 2.1D).  The Aβ42/Aβ40 ratio in the ISF of young, plaque-free J20 
transgenic mice was calculated to be ~0.3.  Using the interpolated zero flow 
method (Jacobson et al., 1985; Cirrito et al., 2003) (Figure 2.1E), we estimated 
the total soluble Aβ concentrations in hippocampal ISF of 3 mo transgenic to be 
~1.2 nM. 
 
ISF Aβ decreases with age as Aβ in brain parenchyma accrues  
To elucidate how amyloid plaque development and maturation affect the 
steady-state levels of brain ISF Aβ, we sampled ISF from the hippocampi of living 
J20 transgenic mice at three ages: pre-plaque (~3 mo), early plaque deposition 
(~12 mo), and abundant and mature plaque deposition (~24 mo) (Figure 2.2A).  
The levels of holoAPP and its C-terminal fragments generated by β- and α-
secretases were constant over the 3-24 mo ISF sampling period (Figure 2.2B), 
suggesting that Aβ production via APP proteolytic processing does not change      52 
Figure 2.2. Amyloid plaques develop and mature with age in J20 APP transgenic 
mice, without significant changes in full-length APP or in its proteolytic processing 
by β- or α-secretases. 
 
(A) Hippocampal sections from fixed J20 APP transgenic brains were paraffin-
embedded, then stained for Aβ using R1282 polyclonal antibody.  3 mo sections 
were virtually plaque-free, whereas some plaques had formed by 12 mo.  By 24 
mo, abundant diffuse and dense-core plaques populated the hippocampus.  (B) 
Representative blot of brain lysates of 3 mo transgenic, 24 mo transgenic and 
wild-type littermate loaded onto denaturing SDS-PAGE, then blotted for full-
length APP (FL-APP) and its C-terminal fragments (CTFs) (WB: polyclonal C7) or 
to α-tubulin (WB: polyclonal tubulin-alpha).  (C) Summary ratios of 
immunoreactive signals at 24 mo over 3 mo transgenic mice, for FL-APP and 
CTFs normalized to the α-tubulin signal.  N = 3 mice per group; signal 
quantification by Licor Odyssey®.     53 
  
 
Figure 2.2 (Continued). Amyloid plaques develop and mature with age in J20 
APP transgenic mice, without significant changes in full-length APP or in its 
proteolytic processing by β- or α-secretases.     54 
appreciably over age. 
As quantified by multiplex Aβ ELISA, all three Aβ peptides measured in 
ISF (Aβx-38, Aβx-40, and Aβx-42) decreased over time to levels that were 
significantly reduced by 24 mo (Figures 2.3A-C show absolute values; Figure 
2.3D shows proportional levels).  As the individual peptides fell to different 
degrees, the Aβ42/Aβ40 ratio in the ISF shifted from 0.3 at 3 mo transgenic mice 
to 0.13 at 24 mo transgenic mice. 
We estimated that the total soluble Aβ concentrations in hippocampal ISF 
decreased from ~1.2 nM in 3 mo transgenic to ~0.5 nM in 24 mo transgenic (see 
Table 2.1 for concentrations of individual Aβ peptides in hippocampal ISF of 3 mo 
and 24 mo transgenic).  The similar % recovery of microdialyzable Aβ at 3 and 
24 mo (measured at 5 flow rates) indicates that the age-dependent decrease in 
ISF Aβ is not due to technical issues with the microdialysis system (Figure 2.3E).  
We measured analytes other than Aβ present in the ISF to see whether they are 
also altered with age, in particular, lactate, pyruvate, and glycerol.  The ratio of 
lactate to pyruvate is an established marker of the redox state of cells; glycerol is 
an integral component of cellular membranes, and changes in its level can reflect 
degradation of membranes (Ungerstedt and Rostami, 2004).  Neither the lactate-
to-pyruvate ratio nor the level of glycerol in ISF changed significantly during our 
3-24 mo sampling period (Figure 2.3F-G), suggesting that the decrease in Aβ is 
not associated with altered intermediary metabolism or perturbation of cell 
membrane integrity.     55 
Figure 2.3. Levels of soluble ISF Aβ < 35 kDa in the brain fall with age.   
 
(A-D) ISF was sampled from the hippocampi of 3 mo (pre-plaque), 12 mo (early 
plaque deposition), and 24 mo (abundant, mature plaques) J20 transgenic mice.  
Using Aβ triplex ELISAs, we found that Aβx-38 (A), Aβx-40 (B), and Aβx-42 (C) all 
decreased with age (means ± s.e.m.; N = 7, 4, 7 mice at 3, 12 and 24 mo, 
respectively).  One-way ANOVA, followed by Bonferroni test: *P < 0.05, **P < 
0.01 and ***P < 0.001 vs. 3 mo values; 
#P < 0.05 vs. 12 mo values.  (D) 
Proportional levels of Aβ38, Aβ40 and Aβ42, where each peptide was normalized 
to its level at 3 mo. Aβ42 declined the most (80% by 24 mo vs. 3 mo).  ***P value 
< 0.0001 by two-way ANOVA with age as a variant.  (E) At 0.2 μl/min, the 
perfusion rate used to collect all ISF samples in Figures 2.3 and 2.4, we obtained 
comparable % recoveries of microdialyzable Aβ in the two extreme ages (~63 
±3% in 3 mo transgenic and ~66 ±2% in 24 mo transgenic; means ± s.e.m.; N = 
3-4 mice).  (F-G) Ratios of lactate to pyruvate (F) and glycerol levels (G) in the 
ISF microdialysates were not altered with age (means ± s.e.m.; N = 3-8 mice). 
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Figure 2.3 (Continued). Levels of soluble ISF Aβ < 35 kDa in the brain fall with 
age. 
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Table 2.1. Theoretical concentrations of microdialyzable ISF Aβ in vivo at zero 
flow rate. 
 
  Aβ38 (pg/ml)  Aβ40 (pg/ml)  Aβ42 (pg/ml)  Aβ42:Aβ40 
3 mo  24 mo  3 mo  24 mo  3 mo  24 mo  3 mo  24 mo 
[ISF Aβ] of 
J20 
transgenic 
mice 
930  658  2975  1231  880  166  0.30  0.13 
 
 
Concentrations of endogenous hippocampal ISF Aβ38, Aβ40, and Aβ42 were 
calculated by extrapolating the curves generated from the interpolated zero-flow 
method to zero PR (see Figure 2.6).  Ratios of Aβ42/Aβ40 in the ISF of 3 mo and 
24 mo transgenic were calculated to be ~0.30 and 0.13, reflecting a higher drop 
of Aβ42 vs. Aβ40 in 24 mo transgenic mice. 
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Next, we sought to identify the pathophysiological relationship between 
ISF Aβ and the accrual of increasingly less soluble Aβ in brain parenchyma 
during the development of AD-type neuropathology.  Using a sensitive IP-WB 
method (Walsh et al., 2002; Shankar et al., 2008), we compared the quantity and 
type of Aβ in ISF obtained in vivo with three pools of brain parenchymal Aβ 
isolated from the same mice right after the dialysis: Tris-buffered saline (TBS) 
extract (traditionally defined as the “soluble Aβ fraction”), detergent (SDS) extract 
(aggregated and membrane-associated Aβ), and formic acid (FA) extract (Aβ 
from highly insoluble deposits, including plaque cores (Masters et al., 1985; 
Selkoe et al., 1986)).  As reported previously in the J20 line and other APP 
transgenic mice (Johnson-Wood et al., 1997; Hsia et al., 1999; Mucke et al.; 
Kawarabayashi et al., 2001; Shankar et al., 2009), we observed an age-
dependent rise in levels of all three pools of parenchymal Aβ (Figure 2.4A).  Both 
the SDS and FA extracts rose sharply with age (Figure 2.4A, D-E).  Aβ in the 
TBS extract did not rise substantially until 24 mo, an age at which we regularly 
observed SDS-stable dimers in this fraction (Figure 2.4A, C).  In contrast to these 
age-dependent rises in parenchymal Aβ, there was a decline in the ISF.  We 
observed a 50% decrease in total absolute ISF Aβ levels between 3 and 12 mo 
(Figure 2.4B), before there was an appreciable rise in the TBS extract (Figure 
2.4C).  We next analyzed the values in each mouse to determine what portion of 
its TBS-soluble Aβ remains dialyzable in vivo, and observed a 5-fold decline in 
the ISF/TBS ratio between 3 and 12 mo (Figure 2.4F).  When normalized to total      59 
Figure 2.4. Aβ in all pools of brain parenchyma accrue with age while those that 
remain diffusible in the ISF declines. 
  
(A) Representative IP-WB’s of Aβ species in four pools: (1) ISF, and (2) TBS-
extracted (“TBS ext”), (3) SDS-extracted (“SDS ext”) and (4) FA-extracted (“FA 
ext”) pools from brains of the same mice right after microdialysis.  All pools 
(except the FA ext, which was lyophilized and straight-loaded onto the gel) were 
IP’ed with AW8 and blotted with 6E10 and 4G8.  Synthetic Aβ run alongside for 
quantification.  Perfusion buffer (PB) and Tris-buffered saline (TBS) were IP’ed 
as negative controls.  (B-E) Quantification of IP-WB’s from 21 mice shows (B) 
~50% decrease in absolute values of ISF Aβ between 3 mo and 12 mo (NS by 1-
way ANOVA followed by Bonferroni test) with a sharp (C-E) rise in TBS-, SDS-, 
and FA-extracted Aβ (pg per mg wet brain tissue).  (F, G) Ratios of ISF to TBS-
soluble Aβ (F) or to total parenchymal Aβ (G) calculated for each mouse and 
shown as mean ratio ± s.e.m.; N = 7 mice per group.  Aβ quantified by Licor 
Odyssey® imaging and analyzed by 1-way ANOVA and Bonferroni test: **P < 
0.01 and ***P < 0.001 vs. 3 mo; 
#P < 0.05 and 
##P < 0.01 vs. 12 mo.     60 
 
 
Figure 2.4 (Continued). Aβ in all pools of brain parenchyma accrue with age 
while those that remain diffusible in the ISF declines. 
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brain parenchymal Aβ, the relative ISF level declined even more (Figure 2.4G).  
Thus, all Aβ pools in brain parenchyma rise with age, while that which remains 
diffusible in ISF in vivo sharply declines.  Furthermore, the bicine/urea SDS-
PAGE showed the principal Aβ peptides present in ISF and TBS extracts from 
same mice from three age groups, 3 mo, 12 mo, and 24 mo and their relative 
levels in ISF and the corresponding TBS extract (Figure 2.5). 
 
Altered dynamics of soluble Aβ in plaque-rich vs. plaque-free mice 
Sampling the ISF at slower perfusion rates (which allows more efficient 
dialysis of ISF solutes) revealed age-dependent changes in ISF Aβ (Figure 2.6).  
In particular, this method revealed significantly decreased diffusion of 
endogenous Aβ40 and Aβ42 into the microdialysis probe in 24 mo than 3 mo 
transgenic mice.  To better understand the basis for this marked decrease in 
recovery of diffusible ISF Aβ in the presence of abundant plaques, we 
approximated the fate of newly secreted Aβ molecules by exogenously 
administering radiolabeled soluble Aβ.  We acutely injected soluble synthetic 
[
125I]Aβ1-40 at a physiological concentration (1 nM) via a small cannula attached to 
the microdialysis probe into the hippocampal ISF of either age 3-7 mo (plaque-
free) or age 24-27 mo (plaque-rich).  We then measured the ability to recover the 
radiolabeled peptide from the ISF by microdialysis.  From the ISF of the plaque-
rich mice, we recovered only 45% of the injected peptide that was recovered from 
the ISF of plaque-free mice (p < 0.0001) (Figure 2.7A).  The amounts of the     62 
 
 
Figure 2.5. Aβ peptides that are microdialyzable in the ISF decline with age while 
the total Aβ in the brain homogenates that are extractable in saline increase.   
 
Representative blot of bicine/urea SDS-PAGE in three age groups, 3 mo, 12 mo, 
and 24 mo, showing the principal Aβ peptides present and their relative 
expression levels in ISF and TBS extracts from the same transgenic mice.  IP: 
AW8, WB: 6E10.  Note the relative decrease of the individual Aβ peptides in ISF 
and their corresponding rise in the TBS extract.     63 
 
 
Figure 2.6. Microdialysis at slower perfusion rates reveals age-dependent 
changes in ISF Aβ. 
 
ISF were collected from hippocampi of 3 mo (plaque-free) and 24 mo (plaque-
rich) transgenic mice while varying the perfusion rate (PR).  Samples were then 
quantified using 6E10 Aβ triplex ELISA.  (A-C) At PR 1 μl/min, no age-dependent 
changes in all 3 peptides were detectable; however, at slow PRs (especially 0.2 
μl/min), significant differences were noted, particularly in Aβ40 and Aβ42.  (D) Sum 
of the three Aβ peptides measured (total Aβ).  Values = means ± s.e.m., N = 3-7 
mice; P values by 2-way ANOVA and Bonferroni test. 
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injected [
125I]Aβ that were recovered at the two ages correlated well with the 
respective endogenous Aβ concentrations in the ISF before injection: the [
125I]Aβ 
levels observed in the first hour and the endogenous Aβ levels just before 
injection were both high in young mice and both low in old mice (Figure 2.7B), 
indicating that the acutely injected radiopeptide achieves a similar equilibrium as 
the endogenous Aβ has at steady state.  We hypothesized that in plaque-rich 
mice, the acutely administered monomer is more readily incorporated into their 
abundant Aβ deposits and thus is less recoverable in the ISF.  To address this 
idea, we quantified the radioactivity retained in the TBS extracts of brain.  We 
saw a substantially higher amount of the fresh, exogenous radiopeptide retained 
in the TBS extracts of the older mice (Figure 2.7C).  In the short time frame we 
conducted these analyses (i.e., the first 90 minutes after administration), we did 
not detect significant levels of radioactivity in the SDS and FA fractions.  Taken 
together, these results suggest that in plaque-burdened mice, newly generated 
soluble Aβ released into the ISF readily accrues onto parenchymal deposits, 
accounting for its lower steady-state level in the ISF. 
 
The level of ISF Aβ42 in plaque-rich mice is minimally affected by acute γ-
secretase inhibition 
To assess whether the ISF Aβ we measure in plaque-rich older transgenic 
mice also represents recent APP cleavage products, as we had determined in 
young plaque-free transgenic mice (Figure 2.1A), we acutely inhibited γ-    65 
secretase in vivo with Compound E.  There was a rapid decline of Aβ38 and Aβ40 
(~60% fall in the first 3 h; t1/2 ~1.9 h and ~2.3 h, respectively), whereas Aβ42 
declined significantly less (~20% fall) (Figure 2.7D-E).  In contrast, all 3 peptides 
fell together in young plaque-free transgenic mice during the first 5 h after 
shutting down new production with Compound E (Figure 2.7F).  As Aβ42 is the 
species reported to accumulate much more into plaques than the other, more 
abundantly generated Aβ peptides in both AD patients and APP mice (Iwatsubo 
et al., 1994; Johnson-Wood et al., 1997), these results suggest that most of the 
soluble Aβ42 peptide that populates the ISF pool in plaque-rich mice is not 
derived primarily from new Aβ biosynthesis but rather from the large reservoir of 
less soluble Aβ42 in the brain parenchyma.  The results also indicate that acute γ-
secretase inhibition is less effective in lowering Aβ42 in plaque-rich brains. 
 
Discussion 
Although factors other than Aβ dyshomeostasis contribute importantly to 
the pathogenesis of AD (Pimplikar et al., 2010), most potentially disease-
modifying treatments currently under development are focused on decreasing or 
neutralizing this neurotoxic peptide.  Moreover, a reduced CSF level of Aβ42 in 
subjects with incipient or very early AD is one of the most promising biomarkers.  
Despite this therapeutic and diagnostic focus, we still lack insight into the in vivo 
economy of soluble Aβ in the brain as AD-type pathology forms.  Here, we used 
the powerful method of brain microdialysis in awake, behaving hAPP transgenic     66 
Figure 2.7. Dynamic shift in the in vivo economy of Aβ once plaques develop. 
 
(A-C) Soluble synthetic [
125I]Aβ1-40 at a physiological concentration (1 nM) was 
injected intra-hippocampally via a small cannula on the microdialysis probe in 
wake, behaving mice at 3-7 mo (plaque-free) or 24-27 mo (plaque-rich), and 
radioactivity was recovered in the ISF by microdialysis (A) and from the TBS 
extracts of the brains (B).  Means normalized to amounts in the plaque-free mice 
(100%) ± s.e.m.; N = 3-4 mice per group; P values are 1-tailed t tests vs. 3-7 mo.  
(C) Amount of [
125I]Aβ recovered in the first hour of injection plotted versus the 
endogenous Aβ levels sampled from same mice before injection.  (D-F) The level 
of ISF Aβ42 is minimally affected by Compound E in plaque-rich mice.  (D) 
Representative graph of hourly ISF Aβ levels after Compound E injection (0 h) 
into 24 mo plaque-rich mice while collecting their brain ISF at 0.6 μl/min.  Levels 
were normalized to levels of each Aβ species before injection.  (E) Quantification 
of the individual ISF Aβ peptides in 24 mo plaque-rich mice for the first 5 hour 
post-injection (means ± s.e.m., N = 3 mice; P value is by 1-way ANOVA).  (F) 
Hourly ISF Aβ levels after Compound E injection (0 h) in a 3 mo plaque-free 
transgenic mouse.     67 
 
 
Figure 2.7 (Continued). Dynamic shift in the in vivo economy of Aβ once plaques 
develop. 
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mice to gain understanding of the dynamics of the most soluble forms of Aβ in 
the hippocampus before and during the process of Aβ plaque formation.  Our 
results show that Aβ peptides which remain soluble and of low molecular weight 
in the interstitial fluid in vivo decrease significantly – both absolutely (Figures 2.3 
and 2.4) and especially in relation to the soluble Aβ extractable from brain 
membranes (Figures 2.4D and 2.5) – as plaques accumulate.  Aβ42 decreases 
the most among the three major Aβ peptides in the ISF; in accord, Aβ42 rises the 
most in the less soluble Aβ pools in the brain parenchyma (Figures 2.3 and 2.5), 
keeping with its documented primary role in oligomerization and plaque 
formation.  (Figures 2.8A-C provide summaries of the temporal changes 
documented in this study.) 
Of special clinical relevance is that our discovery of an age-dependent 
decrease in ISF Aβ42 may be analogous to the widely-documented selective 
decrease in soluble Aβ42 in human (AD) CSF (Motter et al., 1995).  In humans, 
CSF levels of Aβ42 appear to relate inversely to amyloid plaque burden, degree of 
brain atrophy and severity of cognitive deficits in humans (Motter et al., 1995; 
Fagan et al., 2009; Shaw et al., 2009).  Our dynamic studies of the change in 
endogenous ISF Aβ and of the fate of radiolabeled Aβ before vs. after plaque 
initiation offer strong evidence from controlled animal experiments for the 
hypothesis that soluble Aβ42 in humans falls in the CSF because it is 
sequestered into increasingly insoluble parenchymal deposits as AD develops. 
What are the driving forces leading to the sharp decline of diffusible Aβ      69 
Figure 2.8. Summary of the temporal changes in the four Aβ brain pools. 
 
(A) Decreases with age in all three in vivo ISF Aβ peptides measured by 6E10 
Aβ triplex sandwich ELISA (see Figure 2.3 for details).  (B) The fold-decrease 
measured by ELISA (significant between 3 and 24 mo by two-way ANOVA; see 
Figure 2.2) is comparable to the fold-decrease measured by IP-WB (though the 
latter was not significant by one-way ANOVA; see Figure 2.4 for details).  The 
total amount measured by IP-WB analysis method was only ~30% of the total 
amount measured by ELISA.  (C) IP-WB analysis of Aβ in brain tissue.  By ~24 
mo, there was a steep increase in insoluble (SDS- and FA-extracted) Aβ.  The 
TBS-extracted Aβ from the same mice did not rise until 24 mo and then only very 
slightly. Values = means ± s.e.m. from Figures 2.3 and 2.4. 
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Figure 2.8 (Continued). Summary of the temporal changes in the four Aβ brain 
pools. 
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species as AD-like pathology progresses with age?  The constant levels of both 
full-length APP and the CTFs generated by α- and β-secretases suggest that the 
fall we observe is not due to a decrease of cellular production of Aβ.  We also 
saw no evidence for a perturbation of cell membrane integrity, a change in an 
indicator of intermediary metabolism, or altered spontaneous behavior (eating, 
exploring, grooming, etc.) in the mice, arguing against general cytotoxicity or cell 
death as an explanation for the drop.  Thus, we obtained no evidence that 
decreased neuronal activity or decreased Aβ production explains the drop in 
soluble ISF Aβ as mice accrue amyloid deposits.  Rather, the decrease in ISF Aβ 
occurred simultaneously with rises of insoluble Aβ in the SDS- and FA-
extractable pools (Figures 2.3-2.4).  Furthermore, the distinct dispositions of 
soluble radiolabeled Aβ injected at physiological concentrations directly into the 
ISF in plaque-free vs. plaque-rich animals provide insight into a shift in Aβ 
economy: in plaque-rich mice, Aβ becomes rapidly less diffusible and more 
associated with the loosely membrane-bound (TBS-extractable) pool (Figure 
2.6).  This dynamic shift leads us to hypothesize that once an Aβ peptide binds to 
membranes and/or plaques, it is sequestered there and becomes less diffusible, 
at least temporarily, leading to decreased recovery during microdialysis, 
consistent with a report of lengthened Aβ clearance time in old vs. young APP 
transgenic mice (Cirrito et al., 2003). 
Indirect evidence for a converse pathway suggests that such membrane 
association is not irreversible.  Our finding that upon acute γ-secretase inhibition     72 
there was significantly less fall in ISF specifically of Aβ42 (which is much more 
abundant in plaques) suggests that plaques contribute to a dynamic equilibrium 
between soluble and insoluble Aβ42 pools in the brain and thus help regulate the 
steady state of ISF Aβ in aged mice (see Figure 2.9 for a model).  This concept is 
consistent with evidence that amyloid plaques in APP transgenic mice appear to 
act as a local reservoir of “loosely-associated” Aβ that can diffuse from plaques 
and populate a halo of oligomeric and monomeric Aβ immediately surrounding 
the amyloid core (Spires et al., 2005; Koffie et al., 2009).  It will be interesting to 
see whether acute alteration of one particular Aβ pool (e.g., via agents such as 
antibodies that can selectively bind aggregated Aβ or agents that only sequester 
the fully soluble ISF pool) will have transient or lasting effects on the equilibrium 
maintained among the Aβ pools. 
Interestingly, we have not detected SDS-stable dimers in any of our ISF 
microdialysates to date, which could be due in part to the limits of detection.  
Using a test-tube model of our microdialysis technique, we found that synthetic 
Aβ dimers (~8 kDa) crossed over the 35 kDa MWCO membrane; however, the 
diffusion efficiency of dimers was poor in comparison to that of monomers (Figure 
4.1).  Therefore, we cannot exclude the existence of low levels of soluble dimers 
in the ISF of hAPP transgenic mice.  On the other hand, our results may instead 
suggest that soluble dimers and other oligomers do not actually exist per se in 
the most diffusible brain pool (ISF); rather, newly formed oligomers (with their 
exposed hydrophobic amino acids) may distribute quickly onto hydrophobic     73 
Figure 2.9. A hypothetical model of Aβ in vivo dynamics before vs. after plaque 
formation based on data in Chapter 2. 
 
Several factors contribute to steady-state Aβ levels in brain ISF.  There is a 
constant supply of Aβ in the ISF pool generated by new APP processing (Aβ40 >> 
Aβ38 = Aβ42 > Aβ39), and this generation appears to change little with age. ISF Aβ 
can be proteolytically degraded, cleared locally by glia and/or transported across 
the blood brain barrier (BBB).  Soluble Aβ starts aggregating at an early age in 
brain parenchyma, as evidenced by the > 500 kDa TBS-extractable pool as well 
as an SDS-extractable pool in 3 mo, plaque-free mice.  The most abundant pools 
in a plaque-free brain are the ISF pool and the SDS-extractable pool.  In a 
plaque-rich brain, however, equilibrium between pools is greatly altered by the 
overwhelming amount of aggregated Aβ, which act as a sink, thereby diminishing 
the steady-state ISF pool.  Plaques may also act as a contributor to the ISF pool, 
where Aβ42, the most abundant peptide in plaques (and also the most 
decreased in the ISF) diffuses back into the ISF. 
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Figure 2.9 (Continued). A hypothetical model of Aβ in vivo dynamics before vs. 
after plaque formation based on data in Chapter 2. 
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surfaces (cell membranes and/or amyloid deposits).  I address this question 
further in Chapter 4. 
As regards the implications of our findings for the pathophysiology of AD, it 
will be important in future studies to attempt to detect any bioactivity of the ISF 
Aβ pool at the different plaque stages of APP transgenic mice.  Whereas the ISF 
of young, plaque-free mice acts as a reservoir for mainly the acute cellular 
production of Aβ, ISF in plaque-rich mice seems to be a reservoir for both  
new Aβ production and Aβ that diffuses from membrane- and plaque-bound 
deposits (as evidenced by the finding that ISF Aβ42 levels do not fall significantly 
upon acute inhibition of γ-secretase).  Whether the Aβ42 that comes off of  
parenchymal deposits into the ISF is pathogenically important (as compared to 
Aβ in the ISF of plaque-free brains) will be important to determine. 
In conclusion, these dynamic analyses provide unique insights into the 
generation of first fully soluble and then increasingly less soluble Aβ species 
during age-related accrual of AD-type amyloid deposits in living animals.  Based 
on the usefulness of these preclinical data, we suggest a provocative approach 
toward potentially extending such studies to humans.  Patients with normal 
pressure hydrocephalus (NPH), which is typified by a clinical triad of subacutely 
developing dementia, incontinence and gait ataxia (Relkin et al., 2005; Shprecher 
et al., 2008), are frequently offered a neurosurgical procedure by which a 
ventriculoperitoneal shunt is inserted to chronically drain the excess ventricular 
CSF to the peritoneal cavity and thus potentially improve the patients’ NPH     76 
symptoms.  Several studies of simultaneously obtained cortical biopsies have 
shown that some or many such shunted patients show amyloid plaques and 
neurofibrillary tangles indistinguishable from those in typical AD patients (Del 
Bigio et al., 1997; Bech et al., 1999; Golomb et al., 2000; Hamilton et al., 2010).  
This co-occurrence suggests that obtaining IRB approval to perform a brief (12-
24 h) placement of a microdialysis probe at the time of an NPH shunt placement 
could enable in vivo analysis of ISF Aβ peptides in humans with varying degrees 
of Aβ deposition.  We propose that such controlled clinical research studies in 
appropriate patients be considered in order to obtain direct information about the 
economy of the most soluble species of brain Aβ (those in ISF) as a function of 
the level of cerebral β-amyloidosis in humans.   
 
Materials and Methods 
Mice 
J20 line carrying huAPP minigene with FAD mutations KM670/671NL and 
V717F was a kind gift of L. Mucke (Gladstone Institute, UCSF) and was 
maintained on a C57BL6 x DBA2 background (Mucke et al., 2000).  All animal 
procedures were approved by the Harvard Medical School Institutional Animal 
Care and Use Committee.   Mice of either sex were used in all experiments.  
  
In vivo Aβ microdialysis     77 
Microdialysis was performed as previously described (Cirrito et al., 2003): 
intracerebral guides were inserted following the coordinates for left hippocampal 
placement (bregma -3.1 mm, 2.5 mm lateral to midline, and 1.2 mm below dura 
at 12° angle).  Perfusion buffer (1.5% bovine serum albumin (BSA) in artificial 
CSF (in mM: 1.3 CaCl2, 1.2 MgSO4, 3 KCl, 0.4 KH2PO4, 25 NaHCO3, and 122 
NaCl, pH 7.35)) was perfused using probes with 35 kDa MWCO membranes 
(BR-2, Bioanalytical Systems) at flow rates 0.2-1 μl/min with an infusion syringe 
pump (Stoelting).  Microdialysates (ISF) were collected using a refrigerated 
fraction collector (Univentor).  Mice were housed in a “Raturn” cage system 
(Bioanalytical Systems), which allows mice to resume normal activities, and were 
subjected to 12 h light/dark cycles. 
 
Interpolated zero-flow method 
The in vivo percent recovery was calculated as previously described 
(Cirrito et al., 2003).  ISF was collected from 3 mo and 24 mo transgenic mice 
while varying the perfusion rates (PR): 1.0, 0.8, 0.6, 0.4, and 0.2 μl/min.  Aβ 
levels were measured using the 6E10 Aβ Triplex ELISA (MesoScale Discovery) 
and the values obtained at each PR were plotted versus the PR.  The 100% 
recovery (i.e. the theoretical maximal amount of exchangeable ISF Aβ species 
occurring at a zero PR) was calculated by extrapolating back the curve to a zero-
flow rate.  Then, for each PR, percent recovery was determined by calculating 
how much %Aβ was captured as compared to the theoretical [Aβ] at zero PR.     78 
Aβ ELISA 
For 6E10 Aβ Triplex ELISA, we used the MSD® 96-well MULTI-SPOT® 
Human (6E10) Abeta Triplex Assay (MesoScale Discovery) following the 
manufacturer’s protocol.  Briefly, ISF samples were loaded in duplicates onto 
MULTI-SPOT® microplates pre-coated with antibodies specific to the C-termini of 
Aβ38, Aβ40, and Aβ42 and detected with SULFO-TAG
TM-labeled 6E10 antibody.  
Light emitted upon electrochemical stimulation was read using the SECTOR® 
Imager 2400A.  For Aβ1-x ELISA, we followed a previously described protocol 
(Townsend et al., 2011).  96-well Nunc MaxiSorp plates were used with 4G8 (to 
Aβ17-24, Covance) as capture and biotinylated 82E1 (to Aβ1-16, IBL) as detection 
antibodies.  Signals were amplified with AttoPhos (Promega) and measured by 
Victor2 fluorescent plate reader (PerkinElmer). 
 
Lactate, pyruvate, and glycerol measurements 
Levels were measured from ISF sampled at 0.2 μl/min using the CMA600 
analyzer at the Yale Center for Clinical Investigation (YCCI) (sensitivities were: 
lactate 0.02 mM, pyruvate 2 μM, and glycerol 2 μM). 
 
Mouse brain sample preparation for biochemical analyses 
Brains were homogenized using a mechanical Dounce homogenizer with 
20 strokes at 4000 rpm in ice-cold TBS (20 mM Tris-HCl, 150 mM NaCl, pH 7.4) 
and protease inhibitors at 4:1 TBS volume:brain wet weight.  Homogenate was     79 
centrifuged for 30 min at 175,000 g in a 4°C TLA100.2 rotor on Beckman TL 100 
(resulting supernatant = “TBS extract”).  Pellet was resuspended in 2% SDS 
using a 18-G needle, heated at 100°C for 10 min and spun at 21,130 g in an 
Eppendorf 5435 for 10 min (resulting supernatant = “SDS extract”).  Pellet was 
washed twice more in SDS then incubated with 88% formic acid at RT for 2 h.  
Resulting supernatant (“FA extract”) was diluted 10X with water and lyophilized. 
 
Immunoprecipitation and Western blot for Aβ 
ISF and brain extracts (except FA extract, which was lyophilized and 
directly reconstituted in LDS sample buffer prior to loading) were IP’ed with AW8 
polyclonal antibody to Aβ (1:100, gift of D. Walsh, BWH) using Protein A (Sigma).  
For conventional SDS-PAGE, a previously described protocol (Shankar et al., 
2008) was followed.  Samples were electrophoresed using 12% Bis-Tris gel and 
MES SDS running buffer (Invitrogen), transferred onto 0.2-μm nitrocellulose, 
boiled, then blotted using monoclonal antibodies 6E10 (to Aβ3-8, Covance) and 
4G8, and visualized using the LiCor Odyssey Infrared Imaging System.  For 
bicine/urea-based SDS PAGE, a previously described system (Klafki et al., 1996) 
was modified.  Briefly, 11% T/2.6% C 8M urea separation gel was overlayered by 
11% T/2.6% C 4M urea spacer gel and 4% T/3.3% C comb gel.  Gels were run at 
12 mA for 1 h, then 34 W for 3.8 h.  Proteins were transferred to PVDF 
membranes, boiled then blotted with 6E10 with congo red and detected using 
HRP and ECL Plus WB Detection Reagent (GE Healthcare).     80 
Immunohistochemistry of brain sections 
J20 APP transgenic brains at ages 3 mo, 12 mo and 24 mo were fixed 
with 10% formalin, paraffin-embedded then sectioned at 8-μm thickness as 
previously described (Lemere et al., 2002).  R1282 polyclonal antibody was used 
to stain Aβ and the immunoreactivity was visualized using the Vector Elite 
horseradish-peroxidase ABC kit (Vector Laboratories) with diaminobenzidine 
(Sigma) as the chromogen.  
 
APP Western blotting 
Mouse brains of 3 mo transgenic, 24 mo transgenic and wild-type 
littermate were homogenized in 1% (v/v) Nonidet P-40 (NP-40) STEN buffer (in 
mM: 150 NaCl, 50 Tris, 2 EDTA) using a Teflon® Dounce homogenizer.  Brain 
lysates were loaded onto 4-12% Bis-Tris gel, electrophoresed with MES SDS 
running buffer, transferred onto 0.2-μm nitrocellulose, then blotted with polyclonal 
antibody C7 (to full-length APP and its C-terminal fragments) and anti-α-tubulin 
polyclonal antibody (Thermo Scientific). 
 
Size-exclusion chromatography 
TBS extracts (250 μl) or synthetic Aβ (2 ng) were eluted at 0.5 ml/min from 
a Superdex 200 10/300GL column (GE Healthcare) with 50 mM ammonium 
acetate, pH 8.5.  Resulting 1-ml fractions were lyophilized, reconstituted in LDS 
sample buffer and heated at 65°C for 10 min.  Samples were subjected to WB     81 
using 3D6 (to Aβ1-5, gift of Elan) and the LiCor Odyssey Infrared Imaging System 
or ECL Plus WB Detection Reagent (GE Healthcare). 
 
Compound E treatment 
Compound E (3 mg/kg, Axxora) was injected intraperitoneally to mice 
undergoing microdialysis.  Half-lives were calculated according to Cirrito et al 
(Cirrito et al., 2003). 
 
Radioactivity assay 
For ISF experiments, 3 μl of 1 nM [
125I]-β-Amyloid(1-40) (PerkinElmer) 
was injected through a combination infusion cannula and microdialysis probe 
(IBR-2, Bioanalytical Systems) at 0.2 μl/min.  ISF was collected hourly at 0.6 
μl/min, paused during the injection, then restarted 1 min after injection.  For TBS 
extractions, 5 μl [
125I]-β-Amyloid(1-40) was injected in paired mice (young and 
old).  1.5 h post injection, brains were harvested for TBS extract preparation.  
125I 
levels were counted using a LS6500 multipurpose scintillation counter (8-min 
counts).  
 
Statistical analysis 
Data was analyzed using PRISM (Graphpad Software) for one-way or two-
way analysis of variance (ANOVA) followed by Bonferroni post-hoc test if means 
were significantly different by ANOVA, or Student’s t test, as appropriate.     82 
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Chapter 3 
 
Saline-extractable amyloid β of APP transgenic mouse brain has properties 
distinct from the truly soluble amyloid β species in interstitial fluid 
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Introduction 
β-amyloid peptide (Aβ) in aqueous extracts of homogenized cerebral 
cortex has been termed by our group and others as the “soluble Aβ” pool and 
thought to be derived from interstitial fluid (ISF) and cytosol, not necessarily from 
particulates such as amyloid deposits (Gravina et al., 1995; Lue et al., 1999; 
McLean et al., 1999; Walsh and Selkoe, 2004; Shankar et al., 2009); the rise in 
this pool was thought to reflect a rise in diffusible Aβ in vivo.  However, our 
bicine/urea SDS-PAGE results (Figure 2.5) indicate that the principal Aβ peptides 
in the saline extracts of brain homogenates markedly differed from the ISF 
collected from the same mice in vivo, even in the brains from young transgenic 
mice which are virtually devoid of plaques.  Therefore, we questioned the 
established view in the field that the saline extracts of post-mortem brain 
homogenates truly reflect the in vivo soluble Aβ peptides that remain diffusible in 
the ISF.  Here, we performed bicine/urea SDS-PAGE, non-denaturing size-
exclusion chromatography (SEC), and native gels to examine the Aβ species in 
the aqueous extracts of Aβ.   
 
Results 
Bicine/urea SDS-PAGE gels showed that the Aβ peptide distribution 
differed between the ISF and Tris-buffered saline (TBS)-extracted pools at all 
ages in APP transgenic mice (Figure 2.5).  Even at age 3 mo, when the brain has 
virtually no plaques (Figure 2.2), Aβ40 was the primary Aβ species in ISF while in 	 ﾠ   89 
the TBS-extracted pool, Aβ42 was already the more abundant peptide at steady 
state, despite the fact that it is generated in much lower amounts than Aβ40.  
Accordingly, the Aβ42/Aβ40 ratio differed markedly between the ISF (low ratio) and 
TBS extract (very high ratio) in the young transgenic mice (Figure 3.1A).  This 
stark difference was enhanced in 24 mo transgenic mice, which had severe 
plaque deposition (Figure 3.1B).  The pronounced difference of the Aβ peptide 
composition between ISF and TBS-extracted pools, particularly in plaque-free 
brains, led us to question the general assumption that the brain Aβ pool which 
comes into solution upon mechanical homognization in physiological buffers 
represents the truly soluble pool (McLean et al., 1999; Walsh and Selkoe, 2004; 
Shankar et al., 2009).  We performed non-denaturing SEC on the TBS extract 
and subjected the resultant SEC fractions to SDS-PAGE for WB analysis.  
Surprisingly, most Aβ in the TBS extracts of plaque-free (3 mo transgenic) mice 
eluted in the void volume of a Superdex 200 SEC column (suggesting a 
molecular weight (MW) > 500 kDa), and this material ran principally as 
monomers when electrophoresed on a denaturing gel (Figure 3.2A, fractions 6-
7).  The SEC elution profiles of TBS extracts from 3 mo (Figure 3.2A) and 24 mo 
(Figure 3.2B) transgenic mice were similar and differed sharply from that of 
synthetic Aβ40 peptide alone (Figure 3.2C).  In accord, Aβ in TBS extracts from 
24 mo transgenic ran as an aggregated, high MW complex on a clear-native 
PAGE gel, whereas synthetic Aβ40 ran close to the dye front (Figure 3.3A).  
Excision of the > 300 kDa region and subsequent denaturation in LDS sample  	 ﾠ   90 
 
 
Figure 3.1. Aβ42/Aβ40 ratios differ markedly between the ISF and saline brain 
extracts of APP transgenic mice. 
 
The principal Aβ peptides in the ISF and TBS extracts of 3 mo and 24 mo 
transgenic mice (Figure 2.5; bicine/urea SDS-PAGE, IP: AW8, WB: 6E10) were 
quantified by ImageJ software and the Aβ42/Aβ40 ratios were calculated.  P value 
by 1-tailed t test; N = 3 each.  
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Figure 3.2. Saline-extractable Aβ of brain parenchyma in its native form appears 
to exist principally in assemblies > 500 kDa. 
 
Non-denaturing SEC of TBS extracts of 3 mo transgenic (A) and 24 mo 
transgenic (B) was performed on a Superdex 200 SEC column followed by SDS-
PAGE of each SEC fraction.  Synthetic Aβ40 was run on the same SEC column 
for comparison (C).  WB: 3D6. 	 ﾠ   92 
 
Figure 3.3. Most Aβ in the saline extracts of transgenic mice run natively as > 
300 kDa.  
 
(A) TBS extracts from 24 mo transgenic and its wt littermate subjected to clear-
native PAGE and blotted for Aβ.  WB: 2G3 and 21F12.  (B) Excision of the > 300 
kDa region and subsequent electrophoresis by denaturing SDS-PAGE showed 
that this high MW material is disassembled into low MW SDS-stable Aβ species.  
WB: 3D6. 
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buffer yielded lower MW Aβ species, including monomers (Figure 3.3B).   
Next, we spiked synthetic Aβ into saline extracts of wild-type (wt) mice ex 
vivo and performed SEC.  We used the S26C Aβ1-40 oligomers, which stays as 
mostly dimers on SDS-PAGE.  In TBS buffer alone, the S26C Aβ eluted mostly at 
the expected dimer position (corresponding to MW ~8 kDa) off the Superdex 75 
SEC column (Figure 3.4A).  However, when we spiked the S26C Aβ into the 
saline extracts of wt mice, we observed an immediate shift of its elution profile 
from the previous dimer fractions toward the void volume fractions of the SEC 
column (corresponding to MW > 70 kDa) (Figure 3.4). 
 
Discussion 
Here, we show that Aβ peptides in aqueous parenchymal extracts differ 
significantly in quality and quantity from those that remain of low MW in the ISF 
pool.  Furthermore, using non-denaturing SEC and native gels, we show that 
much native Aβ in the TBS extracts of APP transgenic mouse brains, even at a 
pre-plaque age of 3 mo, exists in assemblies that size at > 500 kDa, extending 
similar data on the aqueous extracts of AD brains (Shankar et al., 2008).  The 
findings in this Chapter, therefore, raise a concern for the current definition of Aβ 
in aqueous extracts of homogenized cerebral cortex as reflecting the soluble Aβ 
in ISF and cytosol (Gravina et al., 1995; Lue et al., 1999; McLean et al., 1999; 
Walsh and Selkoe, 2004; Shankar et al., 2009).  Instead, the aqueous extracts of 
Aβ may principally reflect aggregated Aβ peptides bound to cell membranes (in  	 ﾠ   94 
 
 
Figure 3.4. Subjection of Aβ dimers to saline extracts of non-transgenic mice 
immediately shifts the SEC elution profile of the Aβ dimers to the void volume of 
the column (> 70 kDa). 
 
Non-denaturing SEC of S26C Aβ in TBS buffer alone (A), S26C Aβ spiked into wt 
TBS extract (B), and wt TBS extract alone (C) were performed with a Superdex 
75 SEC column, followed by SDS-PAGE of each SEC fraction.  WB: 3D6.  (D) 
Elution profile of the S26C Aβ in buffer (in blue) and S26C Aβ in wt TBS extract 
(in red), as quantified by ImageJ software. 
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young mice) and to membranes and plaques (in older mice) but which remain 
water-extractable. 
Given the new understanding that aqueous extracts of brain may not 
reflect the truly diffusible Aβ species in vivo, it will be important to examine the 
nature of synaptotoxicity in the different Aβ pools, including the ISF pool and the 
TBS-extracted pool, which is currently thought to principally contain the 
synaptotoxic oligomeric species.  Interestingly, as noted in Chapter 2, we have 
not detected SDS-stable dimers in any of our ISF microdialysates to date.  
Although we cannot exclude the existence of very low levels of soluble dimers in 
the ISF of hAPP transgenic mice, our results here suggest that soluble dimers 
and other oligomers do not actually exist per se in the most diffusible brain pool 
(i.e., the ISF); rather, newly formed oligomers, with their exposed hydrophobic 
amino acids, may distribute quickly onto hydrophobic surfaces (cell membranes 
and/or amyloid deposits).  The rapid shift of the spiked synthetic Aβ dimers to the 
void volume fractions upon exposure to the wt TBS extract (shown in Figure 3.4) 
provides suggestive data supporting this view.  Most of the Aβ dimers in TBS 
buffer alone eluted at the expected dimer position (Figure 3.4A), arguing against 
mere aggregation of the Aβ.  We have also failed to see a specific interaction (by 
co-immunoprecipitation studies) of candidate binding proteins, such as the 
apolipoprotein E and apolipoprotein J to Aβ (addressed in Appendix 2).  Rather, 
we hypothesize that the hydrophobic Aβ oligomers may rapidly bind to lipid 
membranes, such as raft-like microdomains on lipid vesicles or plasma 	 ﾠ   96 
membranes of neurons and glia.  I address this further in the next Chapter 
(Chapter 4). 
 
Materials and Methods 
Mice 
J20 line carrying hAPP minigene with FAD mutations KM670/671NL and 
V717F was a kind gift of L. Mucke (Gladstone Institute, UCSF) and was 
maintained on a C57BL6 x DBA2 background (Mucke et al., 2000).  All animal 
procedures were approved by the Harvard Medical School Institutional Animal 
Care and Use Committee.   Mice of either sex were used in all experiments.  
  
In vivo Aβ microdialysis 
Microdialysis was performed as previously described (Cirrito et al., 2003): 
intracerebral guides were inserted following the coordinates for left hippocampal 
placement (bregma -3.1 mm, 2.5 mm lateral to midline, and 1.2 mm below dura 
at 12° angle).  Perfusion buffer (1.5% bovine serum albumin (BSA) in artificial 
CSF (in mM: 1.3 CaCl2, 1.2 MgSO4, 3 KCl, 0.4 KH2PO4, 25 NaHCO3, and 122 
NaCl, pH 7.35)) was perfused using probes with 35 kDa MWCO membranes 
(BR-2, Bioanalytical Systems) at flow rates 0.2-1 μl/min with an infusion syringe 
pump (Stoelting).  Microdialysates (ISF) were collected using a refrigerated 
fraction collector (Univentor).  Mice were housed in a “Raturn” cage system 
(Bioanalytical Systems), which allows mice to resume normal activities, and were  	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subjected to 12 h light/dark cycles. 
 
Mouse brain sample preparation for biochemical analyses 
Brains were homogenized using a mechanical Dounce homogenizer with 
20 strokes at 4000 rpm in ice-cold TBS (20 mM Tris-HCl, 150 mM NaCl, pH 7.4) 
and protease inhibitors at 4:1 TBS volume:brain wet weight.  Homogenate was 
centrifuged for 30 min at 175,000 g in a 4°C TLA100.2 rotor on Beckman TL 100 
(resulting supernatant = “TBS extract”).  
 
Immunoprecipitation and Western blot for Aβ 
ISF and brain extracts (except FA extract, which was lyophilized and 
directly reconstituted in LDS sample buffer prior to loading) were IP’ed with AW8 
polyclonal antibody to Aβ (1:100, gift of D. Walsh, BWH) using Protein A (Sigma).  
For conventional SDS-PAGE, a previously described protocol (Shankar et al., 
2008) was followed.  Samples were electrophoresed using 12% Bis-Tris gel and 
MES SDS running buffer (Invitrogen), transferred onto 0.2-μm nitrocellulose, 
boiled, then blotted using monoclonal antibodies 6E10 (to Aβ3-8, Covance) and 
4G8, and visualized using the LiCor Odyssey Infrared Imaging System.  For 
bicine/urea-based SDS-PAGE, a previously described system (Klafki et al., 1996) 
was modified.  Briefly, 11% T/2.6% C 8M urea separation gel was overlayered by 
11% T/2.6% C 4M urea spacer gel and 4% T/3.3% C comb gel.  Gels were run at 
12 mA for 1 h, then 34 W for 3.8 h.  Proteins were transferred to PVDF 	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membranes, boiled then blotted with 6E10 with Congo red and detected using 
HRP and ECL Plus WB Detection Reagent (GE Healthcare). 
 
Size-exclusion chromatography 
TBS extracts (250 μl) or synthetic Aβ (2 ng) were eluted at 0.5 ml/min 
either from a Superdex 200 10/300GL column or a Superdex 75 10/30HR column 
(both from GE Healthcare) with 50 mM ammonium acetate, pH 8.5.  Resulting 1-
ml fractions were lyophilized, reconstituted in LDS sample buffer and heated at 
65°C for 10 min.  Samples were subjected to WB using 3D6 (to Aβ1-5, gift of Elan) 
and the LiCor Odyssey Infrared Imaging System or ECL Plus WB Detection 
Reagent (GE Healthcare). 
 
Clear-native PAGE and subsequent denaturation for SDS-PAGE 
TBS extracts were prepared from homogenized brains of 24 mo 
transgenic and wt littermate, then subjected to non-denaturing clear-native 
PAGE, which separates proteins with pI < 7 based on their intrinsic charge (Wittig 
and Schagger, 2005).  Briefly, samples were electrophoresed using Native PAGE 
4-16% Bis-Tris gel (Invitrogen) with Bis-Tris-HCl, pH 7.0 as anode and Tricine 
Bis-Tris, pH 7.0 as cathode buffers.  Proteins were then transferred onto 0.2-μm 
PVDF (Millipore), boiled and blotted for Aβ using monoclonal antibodies 2G3 and 
21F12 (to Aβ33-40 and Aβ33-42, respectively, gifts of Elan).  For subsequent 
denaturation, we excised two regions of the native PAGE gel following 	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electrophoresis: the > 300 kDa and the 80-230 kDa (based on NativeMark
TM 
Unstained Protein Standard (Invitrogen)).  The diced gels were heated at 100°C 
in denaturing LDS sample buffer and supernatants were electrophoresed using 
12% Bis-Tris gel and MES SDS running buffer (Invitrogen) for Western-blotting 
using monoclonal antibody 3D6 (to Aβ1-5, gift of Elan). Proteins were visualized 
using the LiCor Odyssey Infrared Imaging System. 
 
Statistical analysis 
Data was analyzed by Student’s t test using PRISM (Graphpad Software). 
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Chapter 4 
 
Amyloid β oligomers do not exist in the fluid compartments of the central 
nervous system but instead are rapidly sequestered away from the 
interstitial fluid to associate with GM1 ganglioside on lipid membranes  
 
 
 
 
 
 
 
 
 
Contributions: 
Experiments were designed by Soyon Hong, Beth Ostaszewski, and Dennis 
Selkoe.  Mouse brain sample preparations and Western blots were performed by 
Beth Ostaszewski and Soyon Hong.  In vitro microdalysis was performed by 
Daniel Podlisny and Soyon Hong.  Ting Yang prepared the human brain extracts.  
All other experiments were performed by Soyon Hong.  	 ﾠ   102 
Introduction 
      Using in vivo microdialysis in hAPP transgenic mice (the J20 line; Mucke et 
al., 2000), the steady state levels of amyloid β-protein (Aβ) species which are < 
35 kDa and remain aqueously diffusible in brain interstitial fluid (ISF) fall steadily 
with age as Aβ accumulate in the brain parenchyma (Chapter 2) (Hong et al., 
2011).  In accord, we see distinct dispositions of microinjected Aβ peptide in 
plaque-rich versus plaque-free mice, suggesting that the cerebral amyloid 
deposits can rapidly sequester newly generated Aβ.  The Aβ in the hippocampal 
ISF of these transgenic mice (as analyzed on bicine-urea gels) constitute a 
heterogeneous mixture of principally four Aβ peptides of relative abundance Aβ40 
>> Aβ38 = Aβ42 >> Aβ39.  ISF levels of all four Aβ peptides fall with increasing 
age.  Furthermore, using denaturing SDS-PAGE, we fail to detect any low 
molecular weight (LMW) Aβ oligomers (e.g., dimers, trimers, etc.), but detected 
only monomers in the ISF from more than 25 awake, behaving hAPP transgenic 
mice, regardless of the age of the mice or their extent of amyloid plaque 
deposition (Chapter 2).  Using an in vitro (test tube) version of microdialysis, we 
verified that Aβ dimers (~8 kDa MW) could cross over the microdialysis 
membrane with a MW cutoff (MWCO) of 35 kDa that we had used for the in vivo 
brain microdialysis (Figure 4.1).  Hence, ISF, the most soluble compartment in 
the living brain of hAPP transgenic mice, appear to contain solely Aβ monomers, 
regardless of the extent of plaque deposition.  This finding is significant because 
soluble Aβ dimers and other LMW oligomers (trimers, dodecamers, etc.), but not 	 ﾠ   103 
monomers, have been widely reported to exert synaptotoxic and other adverse 
neural effects (Selkoe, 2011).   
Therefore, here, we explored whether LMW Aβ oligomers, particularly Aβ 
dimers, do or do not exist as free, soluble species in ISF.  We reasoned that due 
to their increased hydrophobicity, dimers may bind to cell membranes, pre-
existing aggregates (e.g., plaques) or other hydrophobic surfaces much more 
rapidly than monomers do.  If so, this could help clarify why dimers, not 
monomers, act as the smallest Aβ unit that exerts synaptotoxic (McLean et al., 
1999; Klyubin et al., 2008; Shankar et al., 2008; Li et al., 2009; Mc Donald et al., 
2010; O'Nuallain et al., 2010; Li et al., 2011), tau-altering (Jin et al., 2011) and 
other pathogenic neuronal effects.  
 
Results 
Aβ oligomers are undetectable in aqueous brain compartments of APP 
transgenic mice 
We first asked whether Aβ oligomers are indeed undetectable in aqueous 
compartments.  Hippocampal ISF was microdialyzed at a slow rate (0.2-0.4 
μl/min) in awake, behaving transgenic mice, a rate low enough to allow recovery 
of ample amounts of soluble Aβ species (see Chapter 2; Hong et al., 2011).  To 
ensure that the apparent lack of oligomers in ISF samples was not simply due to 
ineffective passage of the ~8 kDa dimers and any other LMW oligomers across 
our 35 kDa MWCO membrane, we also collected cerebrospinal fluid (CSF) from 	 ﾠ   104 
 
Figure 4.1. Aβ dimers can cross over the 35 kDa MWCO microdialysis 
membrane, but their crossover efficiency is poor in comparison to that of 
monomers. 
 
In vitro (test tube) microdialysis was performed with synthetic Aβ40 spiked into 
human CSF (251 nM) at 0.2 μl/min perfusion rate for 700 min, then dialysate was 
subjected to IP-WB.  PB (Perfusion buffer) was IP’ed as negative control; SM 
100X, starting material, was diluted 100-fold prior to IP; synthetic Aβ40 was run 
alongside as WB control.  IP: AW8 polyclonal antibody, WB: 6E10 (against Aβ5-9) 
and 2G3 (against Aβ31-40) Aβ monoclonal antibodies. 
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the cisterna magna of anesthetized transgenic mice (DeMattos et al., 2002).  
Using SDS-PAGE and Western blotting (WB), the Aβ in both the ISF and CSF 
from transgenic mice separated into monomers (4 kDa) and a ~5 kDa species, 
but we failed to see Aβ dimers (which runs ~6.5 kDa in these gels) in the ISF or 
the CSF samples (Figure 4.2A).  The apparent lack of Aβ dimers was not due to 
the inability of the polyclonal AW8 Aβ antiserum to immunoprecipitate (IP) 
dimers, as the AW8 antibody IP’ed both the endogenous Aβ dimers in the saline 
extracts of older transgenic mouse brains (Figure 4.2A) and the synthetic Aβ 
dimers (Figure 4.2B).  Next, we used another Aβ antiserum, the R1282 antibody 
(Podlisny et al., 1998), to IP Aβ from ISF and CSF and again detected no Aβ 
species larger than monomers in the samples (Figure 4.2C). 
To verify this apparent lack of LMW Aβ oligomers in ISF and CSF, we 
used two additional methods besides IP-WB to look for oligomers in the aqueous 
compartments: (1) an oligomer-specific ELISA (o-ELISA) that uses the Aβ-N-
terminal monoclonal 3D6 (against Aβ1-5, gift of Elan, plc.) as both the capture and 
(biotinylated) detection antibodies (Yang et al., submitted); and (2) non-
denaturing size-exclusion chromatography (SEC) and assay of the resultant 
fractions with an ELISA that sensitively detect Aβ38, Aβ40, and Aβ42.  Our o-
ELISA specifically recognizes Aβ oligomers of a wide range of sizes including 
dimers, but not monomers, and it documents the rising levels of endogenous Aβ 
oligomers in brain tissues of APP transgenic mice (Yang et al., submitted) (Figure 
4.3A).  The o-ELISA failed to detect any signals in all ISF and CSF samples we 	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Figure 4.2. Low molecular weight Aβ oligomers are not recovered in the ISF or 
CSF of young J20 transgenic mice by IP-WB technique. 
 
Buffer (1.5% BSA in artificial CSF), ISF collected at 0.2 μl/min from the 
hippocampi of living 3 mo transgenic mice, CSF collected from the cisterna 
magna of anesthetized 3 mo transgenic mice, and TBS extracts from 24 mo 
transgenic mice were IP’ed with either AW8 (A) or R1282 (C) Aβ antibodies, and 
subjected to SDS-PAGE.  (A) Aβ from ISF and CSF IP’ed with AW8 Aβ antibody 
were separated into 4 kDa monomers and a ~5 kDa Aβ-immunoreactive species.  
On the other hand, Aβ from TBS extract of a 24 mo transgenic were separated 
into monomers and dimers.  WB: 3D6, 2G3, and 21F12 (against Aβ1-5, Aβ31-40, 
and Aβ33-42, respectively).  (B) Both the synthetic Aβ monomers and dimers were 
IP’ed by the AW8 Aβ antibody.  Start: 2 ng synthetic wt Aβ1-40.  WB: 3D6 and 
6E10.  (C) Aβ from ISF, CSF and TBS extracts IP’ed with R1282 Aβ antibody 
were separated into ~4 kDa monomers only.  Dimers were not detected in ISF, 
CSF or synthetic wt Aβ monomers.  The IP-WB method successfully brought 
down both the endogenous Aβ dimers in the TBS extract of 24 mo transgenic 
and the synthetic S26C Aβ dimers.  WB: 3D6 and 6E10. 	 ﾠ   107 
 
 
Figure 4.2 (Continued). Low molecular weight Aβ oligomers are not recovered in 
the ISF or CSF of young J20 transgenic mice by IP-WB technique. 
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tested, regardless of the age of the transgenic mice (Figure 4.3B).  Using a 
conventional ELISA which uses 266 (against Aβ16-23, gift of Elan) as the capture 
antibody and biotinylated 3D6 as the detection antibody and hence recognizes all 
Aβ1-x species including the monomers (the Aβ1-x ELISA), we confirmed that both 
the ISF and CSF samples, which failed to give any signal in the o-ELISA, did in 
fact contain ample amounts of Aβ (Figure 4.3C).  As a control for the specificity of 
these signals, we saw about half as much Aβ1-x signal in the ISF collected at a 
flow rate of 0.4 μl/min than the ISF collected at 0.2 μl/min (Figure 4.3C), as 
expected with microdialysis.  Furthermore, we spiked the ISF and CSF samples 
with low amounts of synthetic Aβ dimers and got signals at the expected range, 
thereby excluding the possibility that molecules in ISF or CSF interfere with the o-
ELISA signal (Figure 4.3B). 
Next, we combined two non-denaturing methods to further probe Aβ in the 
ISF.  We chromatographed the microdialysates on a Superdex 75 SEC column 
and subjected the resultant fractions to a multiplex ELISA that simultaneously 
and sensitively recognizes low concentrations of endogenous Aβ38, Aβ40, and 
Aβ42 peptides (the 6E10 Aβ triplex ELISA; MesoScale Discovery).  Whereas SEC 
fractions in which Aβ monomers elute gave abundant signals for all three 
peptides, fractions corresponding to where dimers should elute yielded no 
detectable signals from both 3 mo (pre-plaque) and 24 mo (plaque-rich) 
transgenic mice (Figures 4.4A and B).  Using a batch of synthetic Aβ containing 
both dimers and monomers of Aβ, we confirmed that the 6E10 Aβ triplex ELISA 	 ﾠ   109 
Figure 4.3. Aβ oligomers are not detected in either ISF or CSF of J20 mice by the 
Aβ oligomer-specific ELISA. 
 
(A) The o-ELISA did not detect synthetic Aβ monomers, even at a high 
concentration of 10 ng/ml, but it recognized rising levels of endogenous Aβ 
oligomers in TBS extracts of the J20 transgenic mice from 3 mo to 24 mo.  The 
Aβ signals were abolished upon Aβ immunodepletion of the TBS extracts using 
the 3D6 Aβ antibody.  (B) The o-ELISA failed to give any detectable Aβ signal for 
the ISF collected from the hippocampi of living 3 mo transgenic (N=4 mice) or 24 
mo transgenic (N=7 mice).  The o-ELISA also did not yield any signal for the CSF 
collected from the cisterna magna of anesthetized 3 mo transgenic (N=7 mice).  
In contrast, it detected low amounts of synthetic Aβ dimers that were spiked into 
the ISF and CSF samples.  (C) When tested in parallel with a conventional Aβ1-x 
ELISA, the samples that failed to yield any detectable signals in the o-ELISA 
indeed gave ample signal (N=4 for ISF collected at PR 0.2 μl/min; N=10 for ISF 
collected at PR 0.4 μl/min; and N=7 for CSF samples). 	 ﾠ   110 
 
 
Figure 4.3 (Continued). Aβ oligomers are not detected in either ISF or CSF of J20 
mice by the Aβ oligomer-specific ELISA. 
 	 ﾠ   111 
indeed detects dimers and monomers to commensurate degrees (Figure 4.4C-E; 
signals of the SEC fractions by WB (Figure 4.4C) and by 6E10 Aβ triplex ELISA 
(Figure 4.4D) are directly compared in Figure 4.4E).  These results indicate that 
the lack of detectable signals in fractions corresponding to dimers is not due to 
an inability of the 6E10 Aβ triplex ELISA to detect dimers. 
Taken together, the results from three biochemical methods – IP-WB, o-
ELISA, and SEC fractionation – suggest that Aβ dimers do not exist in 
hippocampal ISF and CSF of hAPP J20 transgenic mice at the levels of detection 
of these assays. 
 
Aβ dimers are rapidly sequestered away from the hippocampal ISF pool in vivo 
and principally recovered in a membrane-associated brain pool 
We next examined the half-life of Aβ dimers and monomers in ISF by 
administering low (8-40 nM) concentrations of synthetic Aβ directly into the 
hippocampal ISF of behaving wild-type (wt) mice.  Because Aβ dimers cross over 
the microdialysis membrane with 35 kDa MWCO less readily than Aβ monomers 
do (Figure 4.1), we first sought experimental conditions at which one achieves 
similar crossover efficiency between monomeric and dimeric species.  As the 
monomer source, we used synthetic wt Aβ1-40 monomers (MesoScale Discovery) 
(Figure 4.5A) and as the dimer-enriched source, we used synthetic S26C Aβ1-40 
S26C oligomers (gift of D. Walsh, BWH), which were mostly dimeric and 
contained trace amounts of trimers (Figure 4.5B).  Hence, the Aβ monomers from 	 ﾠ   112 
Figure 4.4. Aβ38, Aβ40, and Aβ42 peptides in the ISF of both 3 mo pre-plaque and 
24 mo plaque-rich transgenic mice are eluted as Aβ monomers by size-exclusion 
chromatography. 
 
(A-B) Non-denaturing SEC of hippocampal ISF from the hippocampi of 3 mo pre-
plaque (A) and 24 mo plaque-rich (B) transgenic mice were performed with a 
Superdex 75 SEC column, followed by analysis of each SEC fraction by 6E10 Aβ 
triplex ELISA.  (C-D) Non-denaturing SEC of synthetic wt Aβ1-40 that contained 
dimers and monomers were performed with the same Superdex 75 SEC column, 
followed by analysis of the SEC fractions by WB on SDS-PAGE (C) and 6E10 Aβ 
triplex ELISA (D).  WB: 3D6 and 6E10.  (E) Elution profiles of the SEC fractions 
of the synthetic Aβ1-40 as analyzed by 6E10 Aβ triplex ELISA (bold line) or WB 
(dotted line). 	 ﾠ   113 
 
 
Figure 4.4 (Continued). Aβ38, Aβ40, and Aβ42 peptides in the ISF of both 3 mo 
pre-plaque and 24 mo plaque-rich transgenic mice are eluted as Aβ monomers 
by size-exclusion chromatography. 	 ﾠ   114 
MesoScale Discovery are termed herein as “Aβ monomers” and the S26C Aβ1-40 
oligomers as “Aβ dimers”.  To keep the Aβ mostly in their original monomeric and 
dimeric forms, we avoided multiple freeze-thaw cycles (O'Nuallain et al., 2010).  
We confirmed that the Aβ that crossed over the microdialysis probe indeed 
reflected their starting material, i.e., the microdialysate of a monomer-enriched 
sample contained mostly monomers (Figure 4.5A) and the microdialysate of a 
dimer-rich sample contained mostly dimers (Figure 4.5B), and the Aβ monomers 
and dimers in the microdialysates stayed as such throughout the time of our 
analysis.  We then performed in vitro microdialysis using a range of Aβ 
concentrations and measured the resultant amount of Aβ in the dialysates with 
the Aβ1-x ELISA.  We found that at concentrations 8 nM for Aβ monomers and 40 
nM for Aβ dimers, comparable crossover efficiencies were achieved between the 
monomers and the dimers at all three perfusion rates we tested (Figure 4.5C).  
Furthermore, using the interpolated zero flow microdialysis method (see Chapter 
2) (Hong et al., 2011), we verified that comparable amounts of microdialyzable 
Aβ were captured for both Aβ monomer-rich and dimer-rich materials at all 
perfusion rates (Figure 4.5D).  Therefore, we chose to pursue the in vivo 
microdialysis studies using Aβ monomers at 8 nM and S26C Aβ dimers at 40 nM 
and at perfusion rate of 0.4 μl/min, as such slow perfusion rates allow a more 
accurate reflection of the theoretical zero-flow rate (see Chapter 2) (Hong et al., 
2011); moreover, the 0.4 μl/min perfusion rate allow for a time resolution by the 
hour. 	 ﾠ   115 
Figure 4.5. Aβ monomers at 8 nM and Aβ dimers at 40 nM have comparable 
crossover efficiencies in vitro. 
 
(A-B) The Aβ in the microdialysates reflected their respective starting materials 
(A: Aβ monomers; B: Aβ dimers) throughout the 24-36 h of the analysis.  IP: 
R1282, WB: 3D6.  (C) Comparable crossover efficiencies were achieved using 8 
nM Aβ monomers (wt) and 40 nM Aβ dimers (S26C) at all three perfusion rates 
tested using in vitro (test tube) microdialysis.  (D) Comparable percentages of 
microdialyzable Aβ were captured for both Aβ monomers and dimers at all 
perfusion rates as analyzed by the interpolated zero flow microdialysis method 
(N=3 sets, where the wt Aβ monomers and the S26C Aβ dimers were 
microdialyzed in pairs side by side). 	 ﾠ   116 
 
Figure 4.5 (Continued). Aβ monomers at 8 nM and Aβ dimers at 40 nM have 
comparable crossover efficiencies in vitro. 
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Once we established conditions at which we observed comparable  
percent Aβ crossing over the membrane in vitro, we acutely administered  
exogenous dimers (at 40 nM) or monomers (at 8 nM) into mouse brain ISF in 
vivo via a cannula attached to the microdialysis probe.  To distinguish between 
the acutely administered Aβ and the endogenously secreted Aβ, we injected 
synthetic Aβ of human sequence into the ISF of wt mice and quantified the 
recovery of the injected human Aβ in the microdialysates using the Aβ1-x ELISA 
(which selectively recognizes human Aβ).  We found that in the first hour post-
injection, a much lower percentage of the injected Aβ dimers was recovered in 
the ISF than for the injected Aβ monomers (Figure 4.6A).  In contrast to our in 
vitro test tube experiments where comparable percentages of Aβ dimers and 
monomers were recovered, the in vivo recovery of injected dimers was less than 
10% of that of injected monomers, and the difference between in vitro and in vivo 
recoveries was highly significant (p < 0.0001) (Figure 4.6B).  The loss from the 
ISF of the injected Aβ dimers happened rapidly (Figure 4.6C: hourly monitoring of 
ISF Aβ pre- and post-injection; inset shows values using a finer y-scale).  The 
reduced recovery of Aβ dimers vs. monomers does not seem to be due to a 
general limit on in vivo diffusion, as ISF levels of urea (frequently used as an 
endogenous reference compound in microdialysis experiments (Ronne-Engström 
et al., 2001; Brody et al., 2008) did not change with Aβ injection (Figure 4.6D).  
We also showed that at the low nanomolar concentrations of Aβ we injected (3 μl 
injections, corresponding to 96-960 pg Aβ), neither the ratio of lactate/pyruvate  	 ﾠ   118 
Figure 4.6. Aβ dimers are much more rapidly sequestered away from the ISF 
pool than the Aβ monomers. 
 
(A) In first hour post-injection, a much lower percentage of the injected Aβ dimers 
was recovered from the ISF than was recovered for the injected Aβ monomers.  
N=6 mice for the monomer-injected, N=5 mice for the dimer-injected.  P = 0.0126 
by two-tailed Student’s t test.  (B) The in vivo recovery of injected dimers was 
8.85 ± 2.81% of that of injected monomers (N=5 pairs), in contrast to the in vitro 
recovery, 102 ± 11.4% (N=3 pairs) (average ± S.E.M.s).  P < 0.0001 between the 
in vitro and in vivo recoveries by two-tailed Student’s t test.  (C) Representative 
hourly monitoring of the injected Aβ monomers (blue triangle) or Aβ dimers (red 
circle) in the ISF of the wt mice before and after injection.  Inset shows values 
using a finer y-scale.  (D-F) Hourly monitoring of urea (D), ratio of lactate over 
pyruvate (E), and glucose (F) in the ISF of wt mice pre- and post-injection of the 
Aβ monomers (blue triangle) or Aβ dimers (red circle).  N=2-4 pairs. 
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Figure 4.6 (Continued). Aβ dimers are much more rapidly sequestered away from 
the ISF pool than the Aβ monomers. 	 ﾠ   120 
(Figure 4.6E) nor the level of glucose (Figure 4.6F) in the ISF was altered. 
At just one hour post-injection, Aβ dimers showed ~8.5-fold less recovery 
when injected into the ISF than did Aβ monomers (Figure 4.6).  When we spiked 
the S26C Aβ oligomers into saline extracts of wt mice ex vivo and performed 
SEC, we observed an immediate shift of its elution profile on a Superdex 75 SEC 
column from the dimer fractions (corresponding to MW ~8 kDa) to the void 
volume fractions (corresponding to MW > 70 kDa) (see Figure 3.4).  These 
results led us to ask what could mediate a rapid shift of the S26C dimers to the 
void volume fractions.  Most of the synthetic Aβ dimers spiked into TBS buffer 
alone eluted at the expected dimer position (Figure 3.4A), arguing against mere 
aggregation of the Aβ.  Rather, we hypothesized that the Aβ could be binding to 
lipid membranes and that the dimers have a higher affinity for them than do 
monomers. 
We then examined the corresponding brain homogenates to see in which 
pool of brain parenchyma we could recover the injected Aβ.  We found that the 
injected Aβ was recovered in both the TBS-soluble extracts (TBS) and the 
membrane-bound extracts (TBS with 1% Triton-X: TBS-Tx) (Figure 4.7A).  The 
proportion of Aβ recovered in the membrane-bound extract after the injection of 
Aβ dimers was much higher than that of the monomers, whereas the amount of 
Aβ recovered in the saline extracts was comparable (Figure 4.7B).  These results 
suggest that Aβ dimers quickly bind to membranes. 
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Figure 4.7. A higher proportion of the injected Aβ dimers are recovered from the 
membrane-bound extracts of the brain homogenates as compared to the injected 
Aβ monomers. 
 
(A) Aβ monomers or dimers that were injected into the hippocampi of wt mice 
were recovered in the TBS and the TBS-Tx extracts.  IP: R1282, WB: 3D6 and 
6E10.  (B) The proportion of Aβ recovered in the TBS-Tx extracts after the 
injection of Aβ dimers was 23 ± 6.4 fold than that of the Aβ monomers, whereas 
the amount of Aβ recovered in the TBS extracts was comparable (1.00 ± 0.136 
fold; average ± S.E.M., N=4 pairs).  WB quantification by ImageJ of N=8 mice 
injected side-by-side with either wt monomers or S26C Aβ dimers. 
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In vivo injection of soluble Aβ dimers (both synthetic and natural (Aβ isolated 
from human AD cortex)) led to their recovery from the membrane-associated 
brain fractions bound to GM1 ganglioside and Prion protein 
Interestingly, synthetic Aβ dimers injected into wt mouse hippocampal ISF 
were not retained as dimers as judged by WB of subsequent saline extracts but 
rather as a 4 kDa Aβ monomer in the TBS-soluble fraction and as a ~5 kDa Aβ 
species in the membrane (TBS-Tx) fraction (Figure 4.7A).  We also found that, in 
contrast to the in vitro setting where synthetic dimers were stable (Figure 4.5B), 
the Aβ dimers injected in vivo into the ISF pool did not retain their dimeric state, 
as measured by the o-ELISA, but were apparently reduced to monomers, as 
evidenced by positive signals in the Aβ1-x ELISA (Figure 4.8A).  As the synthetic 
Aβ S26C dimers are disulfide cross-linked, their reduction to monomers when 
injected in vivo can be explained by the brain providing a reducing environment.  
We next injected into the ISF of wt mice in vivo a natural form of Aβ: dimers 
isolated from the cerebral cortex of typical AD patients (Shankar et al., 2008).  
Even the natural dimers were recovered as monomers from the mouse brain 
homogenates (Figure 4.8B).  The injected natural Aβ was not recovered in the 
TBS-Tx pellet dissolved in 88% formic acid (Figure 4.8C shows the WB of the 
formic acid-treated samples; Figure 4.8D shows that the same method yielded 
ample amount of Aβ of both monomers and dimers from the TBS-Tx pellet of old 
transgenic brain, which has an abundant Aβ monomers and dimers).  This 
suggested that all of the injected material in the wt brain were recovered in TBS  	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Figure 4.8. The Aβ dimers injected in vivo into the ISF are promptly reduced to 
monomers. 
 
(A) The ISF sampled in the first hour from wt mice that were injected with the 
synthetic Aβ S26C dimers failed to yield any detectable signals in the o-ELISA, 
but gave positive signals in the Aβ1-x ELISA.  Both ELISAs can detect low (< 80 
pg/ml) amount of Aβ dimers, but o-ELISA cannot detect Aβ monomers, even at a 
high (70 ng/ml) concentration.  (B) Soluble Aβ dimers derived from human AD 
TBS extract that were injected into the wt mice were recovered as monomers 
from the brain homogenates.  IP: R1282, WB: 3D6 and 6E10.  SM: Starting 
material that was injected into the brain, which contained mostly dimers and 
some monomers.  Synthetic Aβ dimers or monomers were loaded as controls.  
Representative blot of N=5 mice.  (C-D) WB of TBS-Tx pellets after treatment 
with 88% formic acid.  WB: 3D6 and 6E10.  (C) There was no detectable Aβ 
present in the TBS-Tx pellets of wt brains injected with either natural or synthetic 
Aβ.  Entire 2 hemispheres loaded per lane.  (D) Ample amounts of Aβ of both 
monomers and dimers from the TBS-Tx pellet of 19 mo transgenic were eluted 
using the formic acid treatment (<1/16 hemisphere loaded). 	 ﾠ   124 
 
 
Figure 4.8 (Continued). The Aβ dimers injected in vivo into the ISF are promptly 
reduced to monomers. 	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and TBS-Tx extracts. 
To search for endogenous molecules that the in vivo injected Aβ might 
have bound to, we IP’ed the brain extracts for Aβ and blotted for two previously 
reported ligands of human Aβ: GM1 ganglioside (Yanagisawa et al., 1995; Choo-
Smith et al., 1997; Hayashi et al., 2004; Williams et al., 2011) and the cellular 
prior protein (PrP
c) (Laurén et al., 2009; Freir et al., 2011; Kudo et al., 2012).  
Both the injected AD brain-derived Aβ dimers (Figures 4.8B and 4.9A) and the 
synthetic S26C Aβ dimers (Figures 4.7A and 4.9D) which were recovered in the 
membrane-associated brain fraction (TBS-Tx) and migrated as a 5 kDa 
monomeric species were reactive with cholera toxin, which specifically binds to 
GM1 ganglioside (van Heyningen, 1974) (Figure 4.9B: mouse injected with AD 
brain-derived Aβ dimers; Figure 4.9E: mouse injected with synthetic S26C Aβ 
dimers).  Furthermore, we found that the recovered Aβ from the TBS-Tx fraction, 
but not the Aβ from the TBS fraction, was associated with PrP
c (Figure 4.9C: 
mouse injected with AD brain-derived Aβ dimers; Figure 4.9F: mouse injected 
with synthetic S26C Aβ dimers).  We did not observe any co-IP of GM1 
ganglioside or PrP
c with Aβ in brains of wt mice that did not receive Aβ injection 
(Figures 4.9G-I), arguing that the pull-down of the GM1 ganglioside and PrP
c with 
Aβ was not due to non-specific immunoprecipitation.  Importantly, the binding of 
Aβ monomers to GM1 ganglioside (and hence their altered migration at 5 kDa on 
SDS-PAGE) and their association with PrP
c could not be seen when we spiked 
synthetic S26C Aβ dimers ex vivo into post-mortem wt brain homogenates  	 ﾠ   126 
Figure 4.9. The injected Aβ are recovered from the membrane-associated 
fraction as bound to GM1 ganglioside and Prion protein. 
 
(A-C) Human AD brain-derived Aβ dimers were injected in vivo to anesthetized 
wt mice or spiked ex vivo, then the brain extracts were IP’ed for Aβ using the 
R1282 Aβ antibody.  (D-E) Synthetic S26C Aβ dimers were injected in vivo to 
anesthetized wt mice, then the brain extracts or S26C Aβ in buffer alone were 
IP’ed for Aβ using R1282.  (F-I) Brain extracts with or without spiking of the 
synthetic S26C Aβ dimers were IP’ed for Aβ using R1282.  (A, D and G) WB for 
Aβ using 3D6 and 6E10 mouse monoclonal antibodies (against Aβ1-5 and Aβ5-9, 
respectively).  (B, E and H) WB for GM1 ganglioside using cholera toxin.  (C, F 
and I) WB for Prion protein using a mouse monoclonal anti-PrP antibody (the 
ICSM 35 antibody, against aa 93-102 of PrP). 	 ﾠ   127 
 
Figure 4.9 (Continued). The injected Aβ are recovered from the membrane-
associated fraction as bound to GM1 ganglioside and Prion protein. 	 ﾠ   128 
(Figures 4.9G-I), suggesting that the binding of Aβ to endogenous GM1 
ganglioside and PrP
c requires an environment that the intact, living brain 
provides. 
 
The membrane-bound fractions in hAPP transgenic mice contain GM1 
ganglioside- and Prion protein-bound Aβ 
  We’re currently investigating whether we can recover the Aβ-GM1 
ganglioside complex, which may also be associated with PrP
c, in the membrane-
bound fractions of hAPP transgenic mice.  Preliminary results indicate that such a 
complex exists in young, pre-plaque J20 transgenic mice: Aβ in the TBS-Tx 
fraction of a 3 mo transgenic mouse which was pulled down by the R1282 Aβ 
antibody was also reactive for GM1 ganglioside; however, Aβ in the TBS-Tx 
fractions of a 24 mo transgenic mouse which was pulled down by the R1282 Aβ 
was not as reactive for GM1 ganglioside despite having much more Aβ present 
(Figures 4.10A and B).  The endogenous Aβ in the TBS-Tx extract of the 3 mo 
transgenic was also associated with more PrP
c than Aβ in the TBS-Tx extracts of 
the 24 mo transgenic or non-transgenic littermate control (Figure 4.10C).  
Furthermore, a monoclonal antibody that was raised against GM1 ganglioside-
bound Aβ isolated from membrane fractions of human brains with diffuse plaques 
(i.e., the 4396C antibody) (Yanagisawa et al., 1997; Hayashi et al., 2004) 
specifically pulled out an Aβ-immunoreactive band from the 3 mo pre-plaque  	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Figure 4.10. Aβ from the membrane-bound fractions of young hAPP transgenic 
mice are associated with GM1 ganglioside and PrP
c. 
 
(A-C) TBS-Tx extracts of 3 mo transgenic, 20 mo transgenic and 20 mo non-
transgenic littermate control were subjected to IP with the R1282 Aβ antibody.  
The immunoprecipitates were then subjected to SDS-PAGE and blotted for Aβ 
using 3D6 and 6E10 mouse monoclonal antibodies (A), GM1 ganglioside using 
cholera toxin (B), and PrP
c using 6D11 mouse monoclonal antibody (against aa 
93-109 of PrP) (C).   
 
(D-F) TBS-Tx extracts of 3 mo transgenic, 20 mo transgenic and 20 mo non-
transgenic littermate control were subjected to IP with the 4396C antibody (raised 
against GM1 ganglioside-bound human Aβ), then the subsequent 4396C-
immunodepleted supernatant was IP’ed with R1282.  The 4396C and the R1282 
immunoprecipitates were then subjected to SDS-PAGE and blotted for Aβ using 
3D6 and 6E10 monoclonal antibodies (D), GM1 ganglioside using cholera toxin 
(E), and PrP
c using 6D11 monoclonal antibody (F). 
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Figure 4.10 (Continued). Aβ from the membrane-bound fractions of young hAPP 
transgenic mice are associated with GM1 ganglioside and PrP
c. 	 ﾠ   131 
transgenic mouse that migrated ~5 kDa and retained a cusp-like shape similar to 
the shape of the Aβ that was injected into wt mice and subsequently recovered 
from the membrane-bound fractions (Figures 4.9A and D) (Figure 4.10D).  This 5 
kDa Aβ-immunoreactive band was then positively stained for GM1 ganglioside 
(Figure 4.10E) and PrP
c (Figure 4.10F).  When there was an absence of this 
cusp-like structure, as was the case for the plaque-rich old transgenic and the 
non-transgenic, there was no apparent Aβ-bound GM1 ganglioside that migrated 
above the 3 kDa MW marker (Figure 4.10E); accordingly, there was no PrP
c 
(between 28-38 kDa) that was pulled down with the 4396C (Figure 4.10F).  
Importantly, the subsequent R1282 immunoprecipitate of the 4396C-
immuodepleted materials lacked any GM1 ganglioside, despite there still being 
an abundant amount of Aβ left in the material (Figures 4.10D and E), suggesting 
that the 4396C was effectively pulling down a specific GM1 ganglioside-bound 
and PrP
c-associated Aβ complex from the membrane-bound fractions of 3 mo 
transgenic mice.   
 
Aβ dimers may have a higher affinity to lipid membranes 
In a separate set of experiments, I am currently performing surface 
plasmon resonance (SPR) experiments to assess directly whether Aβ dimers and 
monomers have different binding affinities to lipid membranes.  To ensure that I 
am using predominantly the dimeric form of Aβ, I perform non-denaturing SEC 
with S26C Aβ oligomers using the Superdex 75 SEC column < 24 h before 	 ﾠ   132 
running the SPR experiments and use the fractions where the Aβ dimers are 
eluted; I also avoid multiple freeze-thaw cycles to decrease the likelihood of in 
vitro aggregation (O'Nuallain et al., 2010).  To obtain Aβ monomers, I treat the 
Aβ S26C dimers with 3% β-mercaptoethanol (βME) for 10 min at RT, which 
reduces most of the Aβ S26C dimers to monomers (Figure 4.11A).  The 
monomers are treated shortly before they are used and handled in buffer 
containing 0.1% βME to ensure they are kept in a reduced state.  I coat the SPR 
chips with freshly prepared small unilamellar vesicles of brain total lipid extracts 
in regular buffer (50 mM ammonium acetate, pH 8.5) or buffer containing 0.1% 
βME.  First, I confirm uniform lipid coating of the chips by subsequently injecting 
BSA as a control (data not shown).  I then perfuse the oxidized S26C dimers (in 
regular buffer) or the reduced S26C monomers (in buffer containing 0.1% βME).  
Preliminary results indicate that the non-reduced Aβ S26C dimers yielded a 3-
fold enhanced SPR signal (Figure 4.11B) over the reduced Aβ monomers (Figure 
4.11C).  When I perfused the chips with melittin in either buffer as a positive 
control, I observed no significant changes in the response signal (Figures 4.11D 
and E).  The preliminary findings thus suggest that Aβ dimers have an enhanced 
affinity for lipid bilayer membranes than the Aβ monomers do.  Given the recent 
findings of a potential GM1 ganglioside- and PrP
c-bound Aβ complex, it will be 
imperative to test by SPR the role of these two molecules the binding of Aβ to the 
lipid membranes, i.e., to determine whether one or both of these two molecules 
mediate the binding of Aβ to the lipid membrane. 	 ﾠ   133 
Figure 4.11. Aβ dimers may have a ~3-fold enhanced affinity to lipid membranes. 
 
(A) The SEC fraction containing mostly SDS-stable S26C Aβ dimers was treated 
with 3% βME at RT for 5, 10, 15, and 20 min.  WB: 3D6.  (B-E) SPR response 
units, corresponding to the binding of the injected molecules (B-C: S26C Aβ 
dimers at different concentrations; D-E: Melittin at 3 ng/ml).  (B) Dose-dependent 
increase in the binding of the S26C Aβ dimers to the lipid bilayer membrane.  (C) 
A much reduced binding response seen with the reduced Aβ S26C monomers (in 
0.1% βME) to the lipid bilayer membrane.  (D-E) There are no significant 
changes in the response signal with melittin between the non-reduced (no βME) 
and reduced (with 0.1% βME) conditions.  	 ﾠ   134 
 
Figure 4.11 (Continued). Aβ dimers may have a ~3-fold enhanced affinity to lipid 
membranes. 
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Discussion 
  Using three biochemical methods – IP-WB, ELISA specific for Aβ 
oligomers (o-ELISA), and non-denaturing size-exclusion chromatography (SEC) 
– we failed to detect any low-molecular weight (LMW) Aβ oligomers in the 
hippocampal ISF or CSF of the J20 hAPP transgenic mice, regardless of their 
age or plaque deposition.  Using two polyclonal Aβ antibodies that can pull down 
Aβ dimers, if they are present, only Aβ monomers were recovered from the ISF 
and CSF (Figure 4.2).  The o-ELISA also failed to detect any signal for Aβ 
oligomers in all ISF and CSF samples we tested, despite there being ample 
amounts of Aβ present in both samples (Figure 4.3).  Finally, using a combination 
of two non-denaturing methods, the SEC and a sensitive ELISA for Aβ38, Aβ40 
and Aβ42 that detects Aβ dimers and monomers to a comparable degree, we 
failed to gain any evidence that there exist Aβ38, Aβ40, or Aβ42 LMW oligomers in 
the ISF (Figure 4.4).  Hence, we report that there does not exist any LMW Aβ 
oligomers in the aqueous compartments of the brain, i.e., the CSF and the ISF, of 
the hAPP transgenic mice; if a LMW oligomeric unit may exist in the fluid 
compartment, we calculate it to be of a negligible amount (< 0.004% of total Aβ 
present). 
This data reinforces our recent finding using two Aβ o-ELISAs (whose 
specificity for oligomers was extensively validated) that in all 13 human CSF 
samples tested (among which 4 were CSF from individuals clinically diagnosed to 
have AD), we failed to detect any Aβ oligomers (Yang et al., submitted).  	 ﾠ   136 
Although there has been a few reports on Aβ oligomers existing in CSF and 
plasma of humans developing AD (for e.g., (Klyubin et al., 2008; Fukumoto et al., 
2010; Gao et al., 2010; Villemagne et al., 2010), the interpretation of these 
various assays has been difficult due to vague definitions of the precise 
oligomeric unit the assays are detecting and whether one can really exclude the 
detection of Aβ monomers.  However, our results do not necessarily support 
critics’ doubts as to whether LMW Aβ oligomers really exist in vivo (Haass, 2010; 
Benilova et al., 2012); instead, they suggest that the Aβ oligomers may not exist 
in the aqueous biological fluids, but due to their substantial hydrophobicity, they 
may be sequestered away from the extracellular fluid onto membranes and/or 
existing aggregates (plaques). 
To determine whether LMW Aβ oligomers in fact have a shortened half-life 
in the aqueous compartment, we acutely injected exogenous Aβ into brains naïve 
of plaques (i.e., the wt mouse hippocampi) and observed a rapid sequestration of 
the Aβ dimers away from the hippocampal ISF pool: in just one hour, Aβ dimers 
showed ~8.5-fold less recovery when injected into the ISF than did Aβ monomers 
(Figure 4.6).  This was in stark contrast to the in vitro test tube setting, where 
comparable percentages of the starting Aβ monomers and dimers were 
recovered in the microdialysates (Figure 4.5).  This suggested that in vivo, Aβ 
dimers are much more rapidly sequestered away from the aqueous compartment 
because they have an enhanced affinity for a binding platform.  Accordingly, the 
injected Aβ dimers were recovered at a much higher proportion in the 	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membrane-bound pool than in the cytosolic pool (Figure 4.7), suggesting that Aβ 
dimers, compared to monomers, much more quickly bind membranes.  The 
sequestration of the Aβ dimers from the brain ISF happened pretty rapidly (< 1 h) 
in a plaque-naïve brain, arguing against mere aggregation of the Aβ.  We 
suspected whether Aβ dimers, being much more hydrophobic than the 
monomers, could be binding to lipid membranes, and whether the dimers have a 
higher affinity for them.  To this end, we recently began surface plasmon 
resonance to directly measure the affinity of Aβ dimers or monomers to lipid 
bilayer membrane; preliminary results indicate that Aβ dimers may in fact have 
an enhanced affinity to the lipid membrane than do the monomers (Figure 4.11). 
Interestingly, the injected Aβ materials (both the synthetic cross-linked 
dimers and the natural Aβ dimers from human AD cortical tissue) that were 
recovered from the membrane-bound fractions migrated as 5 kDa monomers, 
and the 5 kDa Aβ band was reactive for GM1 ganglioside.  Furthermore, the 
GM1-bound Aβ was found to be associated with PrP
c (Figure 4.9).  Using two 
antibodies – a polyclonal antibody that recognizes all forms of Aβ (the R1282) 
and a monoclonal antibody specifically raised against human GM1-associated Aβ 
(the 4396C) – we also recovered this apparent Aβ/GM1/PrP
c tri-complex from the 
membrane-bound fractions of pre-plaque 3 mo transgenic mice (Figure 4.10). 
The abnormally migrating Aβ monomers on SDS-PAGE (i.e., migrating ~5 
kDa instead of the usual 4 kDa) was reported once earlier: it was found to be 
GM1 ganglioside-bound Aβ monomers (mostly Aβ42) detected in early sucrose 	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gradient fractions of AD brains with diffuse plaques (Yanagisawa et al., 1995).  
As the GM1 ganglioside-bound Aβ monomer was observed only in brains that 
contained diffuse plaques, but not in AD brains that were rich with fibrillar amyloid 
plaques or in non-AD cortices, the authors hypothesized that the GM1 
ganglioside-bound Aβ could be a “seed” for amyloid fibril formation.  Several in 
vitro biophysical studies that followed the Yanagisawa et al. (1995) paper 
supported the view that Aβ, upon binding to GM1 ganglioside on neuronal 
membranes, undergoes a conformational change that confers a higher 
propensity to aggregate, thus acting as an endogenous seed (reviewed in Ariga 
et al., 2008; Yanagisawa, 2011); however, to date, no other group has reported 
seeing such species in vivo from transgenic mouse brain homogenates or human 
AD brains.  Furthermore, we have shown (in Chapters 3 and 4) that the 
hippocampal ISF and CSF of APP transgenic carried an abundant amount (~40% 
of total ISF Aβ) of a 5 kDa Aβ species that was immunoprecipitable by a 
polyclonal Aβ antibody (the AW8); however, we have not been able to determine 
its molecular identity or whether the 5 kDa Aβ species found endogenously in 
these fluid compartments is of similar molecular identity (i.e., GM1 ganglioside-
bound) to that recovered from the membrane-bound brain fractions. 
The PrP
c/Aβ interaction on the other hand has been a recent hotbed of 
controversy ever since Laurén et al. (2009) reported PrP
c as an apparent 
receptor for the synaptotoxic synthetic Aβ42 oligomers (where residues 95-105 of 
PrP
c were mapped out as the primary determinant of binding).  However, Laurén 	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et al.’s findings were soon disputed (Kessels et al., 2010), and since, a series of 
papers have reported data either in support of (Chen et al., 2010; Chung et al., 
2010; Gimbel et al., 2010; Barry et al., 2011; Freir et al., 2011; Resenberger et 
al., 2011; Kudo et al., 2012) or against (Balducci et al., 2010; Calella et al., 2010; 
Kessels et al., 2010; Cissé et al., 2011) a critical role of PrP
c for Aβ to suppress 
cognitive function. 
As Aβ oligomers have also been suggested to increase localization of 
PrP
c to the cell surface (Caetano et al., 2011), it is possible that Aβ targets a 
specific protein receptor, such as the PrP
c or other synaptic components, and 
“overstabilizes” their presence on the cell membrane, thereby inducing 
“pathological signaling platforms” (Renner et al., 2010).  Alternatively, given that 
hydrophobicity is a key feature of Aβ oligomers (Haass and Selkoe, 2007), there 
very well may not be a specific target protein receptor for Aβ.  The hydrophobic 
Aβ oligomers, once released into the extracellular space, may quickly be 
sequestered to certain microdomains on plasma membranes of cells or to certain 
lipid vesicles and exert subtle physicochemical properties of membranes (for e.g., 
by interfering with membrane fluidity, dynamics of membrane lipids and proteins, 
or ion permeability), which may in turn affect various proteins that are expressed 
on the membrane surface. 
In particular, Aβ has been found to bind preferentially to GM1 ganglioside-
containing liposomes that also include sphingomyelin and cholesterol, and upon 
binding, to display rapid fibril formation (McLaurin and Chakrabartty, 1996; Choo-	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Smith and Surewicz, 1997; Kakio et al., 2002; Hayashi et al., 2004).  
Gangliosides are particularly enriched in the nervous system, as compared to 
other cellular membranes, and their localization is thought to be on specific raft-
like domains that are also enriched in cholesterol and sphingomyelin on pre- and 
postsynaptic membranes or on certain lipid vesicles, such as the exosomes 
(where PrP
c is also highly localized) (Hansson et al., 1977; Svennerholm and 
Gottfries, 1994; Sonnino et al., 2007; Théry et al., 2009).  Furthermore, GM1 
ganglioside has recently been found to bind to the C-termini of PrP
c and to be a 
necessary ligand for PrP
c to be anchored on lipid rafts (Sanghera et al., 2011).  
Hence, the physical proximity of GM1 ganglioside and PrP
c on specific raft-like 
domains may explain the association of Aβ to both GM1 and PrP
c in the 
membrane-bound fractions. 
Whether it is the PrP
c or the GM1 ganglioside that acts as the primary 
binding site for Aβ has yet to be investigated.  To this end, we are planning to 
obtain some PrnP null mice to see whether we can still recover the Aβ/GM1/PrP
c 
tri-complex upon Aβ injection.  Mice that lack GM1 gangliosides in their central 
nervous system do exist (mice with disrupted GM2/GD2 synthase); however, the 
amount of GM3 increases accordingly and hence the readout may not be as 
straightforward (Takamiya et al., 1996; Sheikh et al., 1999; Oikawa et al., 2009).  
On the other hand, Aβ’s binding site could require both GM1 ganglioside and 
PrP
c to be in a specific complex.  When we spiked Aβ dimers ex vivo into post-
mortem wt brain extracts, we did not see a binding of the spiked Aβ to either 	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GM1 ganglioside or PrP
c (Figure 4.9), which suggests that the Aβ does not bind 
to any free endogenous GM1 ganglioside or PrP
c, but to a specific complex that 
requires an environment that the intact, living brain provides.  Changing the pH 
(from 7.4 to 6.0, which has been reported to facilitate binding of Aβ to GM1 
ganglioside (McLaurin and Chakrabartty, 1996)), temperature, or incubation 
times did not allow for a complete recapitulation of the binding of injected Aβ to 
endogenous GM1 and PrP
c such as those shown in the in vivo setting (data not 
shown).  Furthermore, preliminary results suggest that the altered migration of 
acutely injected Aβ as a GM1-associated 5 kDa molecule may be time-
dependent, i.e., the longer we wait to sacrifice the mouse after injecting the Aβ, 
the less of an altered migration we observe. 
Interestingly, both the Aβ IP-WBs on the injected mouse brain 
homogenates and the Aβ ELISAs on the ISF samples indicated that the synthetic 
Aβ dimers injected into the ISF no longer existed as a dimer-unit, i.e., they were 
promptly reduced to monomers (Figure 4.8).  This was in contrast to the in vitro 
test tube setting, where the molecular unit of the Aβ dimers and monomers 
remained unperturbed even after 36 h at RT, i.e., Aβ recovered in the 
microdialysate from a starting material that contained mostly monomers stayed 
as monomers, and those from a dimer-containing material stayed as dimers 
(Figure 4.5).  As the synthetic Aβ dimers were disulfide cross-linked, the 
reduction of these dimers to monomers when injected in vivo could be explained 
by the brain providing a reducing environment.  However, we also found that the 	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non-cross-linked Aβ dimers isolated directly from human AD cortical tissue were 
recovered as monomers in the mouse brain homogenates (Figure 4.8).  When 
Aβ dimers were applied onto rat hippocampal neuronal cultures, the Aβ dimers 
(both synthetic and human brain-derived) remained as dimers up to 3 days at 37 
°C (Jin et al., 2011).  One possible explanation for the rapid depolymerization of 
the injected Aβ dimers we observed here could be that in the wt brain, local 
microglia are able to rapidly degrade the injected Aβ dimers into monomers.  We 
are unsure whether the reduction of Aβ dimers to monomers happens first or the 
binding to GM1 ganglioside and/or PrP
c occurs first.  Our current thought is that 
the depolymerization to monomers occurs first, then the monomers bind to GM1 
ganglioside/PrP
c.  Regardless of the exact order of events, the depolymerization 
to monomers and the binding of Aβ to GM1 and PrP
c seem to be a concurrent 
phenomenon, i.e., if we fail to see the spiked Aβ dimers reduced to monomers 
(as was the case for most of the ex vivo spiking experiments (Figures 4.9G-I)), 
we also do not see binding of Aβ to GM1 or PrP
c. 
As to the recovery of the Aβ/GM1/PrP
c tri-complex in young (pre-plaque) 
J20 transgenic mice but not in the old (plaque-rich) transgenic, despite there 
being a substantially higher amount of total Aβ recoverable in the membrane-
bound fraction in the old transgenic, we speculate that a specific pool of Aβ, i.e., 
the Aβ in the extracellular space (the ISF Aβ), binds to the GM1 ganglioside 
and/or PrP
c available on the surface of neuronal membranes and hence form the 
Aβ/GM1/PrP
c tri-complex.  The amount of ISF Aβ in young, pre-plaque transgenic 	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is considerably higher than in old, plaque-rich transgenic: ISF Aβ falls 
significantly (especially the Aβ42) as mice accrue plaques (Chapter 2; Hong et al., 
2011).  The substantial level of steady-state ISF Aβ in the pre-plaque brain, 
where Aβ mostly represents recent products of APP processing (t1/2 ~2 h) (see 
Chapter 2) may therefore lead to a higher amount of Aβ/GM1/PrP
c tri-complex as 
seen in the young, pre-plaque transgenic mice.  In contrast, a plaque-rich brain, 
which contains minimal levels of ISF Aβ, especially the Aβ42, has less amount of 
Aβ available to bind to GM1 and PrP
c, as the Aβ is rapidly sequestered onto 
existing plaques.  The injected Aβ (at the low concentrations of 8-40 nM we used 
here) may in essence mimic the ISF Aβ of young transgenic mice.  This may 
support the hypothesis that GM1 ganglioside-bound Aβ could be a “seed” for 
amyloid fibril formation (Yanagisawa, 2011) and that this formation initially occurs 
on the surface of neuronal membranes (Selkoe, 2011).  (Note, in plaque-rich 
brains, the Aβ recovered in the TBS-Tx fraction may represent not only the 
membrane-bound Aβ, but also the Aβ associated with extracellular plaques that 
were eluted off with the TBS-Tx buffer.) 
In summary, I report in this Chapter three major findings: first, Aβ 
oligomers were undetectable in aqueous brain compartments (i.e., the ISF and 
CSF) of the J20 hAPP transgenic mice; second, the Aβ dimers were rapidly 
sequestered away from the hippocampal ISF pool in vivo and principally 
recovered as 5 kDa Aβ monomers in membrane-associated brain pool; and third, 
both the injected Aβ in wt mice and the endogenous Aβ in young hAPP 	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transgenic mice were recovered from the membrane-associated fraction as 
bound to GM1 ganglioside and Prion protein (PrP
c).  Taken together, these 
results suggest that LMW Aβ oligomers are rapidly sequestered away from the 
ISF and bind to GM1 ganglioside- and PrP
c-enriched lipid membranes, such as 
raft-like microdomains on secreted vesicles or on plasma membranes of cells. 
 
Materials and Methods 
Mice 
J20 line carrying hAPP minigene with FAD mutations KM670/671NL and 
V717F was a kind gift of L. Mucke (Gladstone Institute, UCSF) and was 
maintained on a C57BL6 x DBA2 background (Mucke et al., 2000).  All animal 
procedures were approved by the Harvard Medical School Institutional Animal 
Care and Use Committee.   Mice of either sex were used in all experiments.  
  
In vivo Aβ microdialysis 
Microdialysis was performed as previously described (Cirrito et al., 2003): 
intracerebral guides were inserted following the coordinates for left hippocampal 
placement (bregma -3.1 mm, 2.5 mm lateral to midline, and 1.2 mm below dura 
at 12° angle).  Perfusion buffer (1.5% bovine serum albumin (BSA) in artificial 
CSF (in mM: 1.3 CaCl2, 1.2 MgSO4, 3 KCl, 0.4 KH2PO4, 25 NaHCO3, and 122 
NaCl, pH 7.35)) was perfused using probes with 35 kDa MWCO membranes 
(BR-2, Bioanalytical Systems) at flow rates 0.2-1 μl/min with an infusion syringe 	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pump (Stoelting).  Microdialysates (ISF) were collected using a refrigerated 
fraction collector (Univentor).  Mice were housed in a “Raturn” cage system 
(Bioanalytical Systems), which allows mice to resume normal activities, and were 
subjected to 12 h light/dark cycles. 
 
Mouse brain sample preparation for biochemical analyses 
Brains were homogenized using a mechanical Dounce homogenizer with 
20 strokes at 4000 rpm in ice-cold TBS (20 mM Tris-HCl, 150 mM NaCl, pH 7.4) 
and protease inhibitors at 4:1 TBS volume:brain wet weight.  Homogenate was 
centrifuged for 30 min at 175,000 g in a 4°C TLA100.2 rotor on Beckman TL 100 
(resulting supernatant = “TBS extract”).  Pellet was homogenized in ice-cold TBS 
with 1% Triton-X (TBS-Tx) and protease inhibitors at 4:1 TBS-Tx volume:brain 
wet weight and centrifuged for 30 min at 175,000 g in a 4°C TLA100.2 rotor on 
Beckman TL 100 (resulting supernatant = “TBS-Tx extract”).  The pellet was then 
incubated with 88% formic acid at RT for 2 h.  Resulting supernatant (“FA 
extract”) was diluted 10X with water and lyophilized. 
 
CSF collection from cisterna magna 
  CSF was collected from cisterna magna compartment from anesthetized 
mice as previously described (DeMattos et al., 2002).  Briefly, mouse was deeply 
anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine administered 
intraperitoneally.  Midline incision was made from the top of the skull to the dorsal 	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thorax, followed by a series of excision of muscles and excess tissue from the 
base of the skull to the first vertebrae for proper exposure of the cisterna magna. 
Any residual blood or ISF were rid using cotton swabs.  A puncture to the 
arachnoid membrane covering the cistern was made using the very tip of a 29 G 
½” needle, then very quickly, a gel loading pipet tip was gently applied to collect 
CSF as it exited the compartment. 
 
Immunoprecipitation and Western blot for Aβ 
Buffer alone, synthetic Aβ, ISF, CSF or brain extracts were first pre-
cleared using Protein A (Sigma) alone, then IP’ed using either AW8 Aβ antiserum 
(1:100, gift of D. Walsh, BWH) or R1282 Aβ antiserum (1:75) and Protein A.  
Alternatively, the brain extracts were pre-cleared with Protein G (GE Healthcare) 
alone, then IP’ed using the 4396C monoclonal antibody (gift of K. Yanagisawa, 
NILS, Japan) and Protein G.  For conventional SDS-PAGE, a previously 
described protocol (Walsh et al., 2000) was followed.  Samples were 
electrophoresed using 12% Bis-Tris gel and MES SDS running buffer 
(Invitrogen), transferred onto 0.2-μm nitrocellulose, boiled, then blotted to Aβ 
using a combination of Aβ antibodies as fitting (for e.g., for specific recognition of 
human Aβ, we used a combination of 3D6 (against Aβ1-5, gift of Elan) and 6E10 
(against Aβ5-9, Covance) mouse monoclonal antibodies), to GM1 ganglioside 
using HRP-conjugated cholera toxin (Sigma), or to Prion protein using ICSM 35 
(D-Gen) or 6D11 (Covance) mouse monoclonal antibodies, and detected using 
HRP and ECL Plus, Advanced or Prime WB Detection Reagent (GE Healthcare). 	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Aβ ELISA 
All sandwich ELISAs for Aβ were performed using the MULTI-ARRAY® 
96-well Plate platform (MesoScale Discovery) following the manufacturer’s 
protocol and as described in (Yang et al., submitted).  For Aβ o-ELISA, 3D6 
monoclonal antibody (against Aβ1-5, gift of Elan) was used as capture antibody at 
3 μg/ml and the biotinylated 3D6 was used as detection antibody at 100 ng/ml 
with SULFO-TAG
TM Streptavidin (MesoScale Discovery).  For Aβ1-x ELISA, the 
266 monoclonal antibody (against Aβ16-23, gift of Elan) was used as capture 
antibody at 3 μg/ml and the biotinylated 3D6 was used as detection antibody at 
100 ng/ml with SULFO-TAG
TM Streptavidin (MesoScale Discovery).  For 6E10 Aβ 
Triplex ELISA, we used the MSD® 96-well MULTI-SPOT® Human (6E10) Abeta 
Triplex Assay, following the manufacturer’s protocol and as described in (Hong et 
al., 2011).  The 6E10 Aβ Triplex ELISA uses MULTI-SPOT® microplates pre-
coated with antibodies specific to the C-termini of Aβ38, Aβ40, and Aβ42 and 
detected with SULFO-TAG
TM-labeled 6E10 antibody. 
 
Size-exclusion chromatography 
ISF sampled at 0.4 μl/min (250 μl), synthetic Aβ (2 ng) or 3D6 IP’ed 
material of TBS extract of human AD brain were eluted at 0.5 ml/min from a 
Superdex 75 10/300GL column (GE Healthcare) with 50 mM ammonium acetate, 
pH 8.5.  Resulting 1-ml fractions were lyophilized, reconstituted in LDS sample 
buffer and heated at 65 °C for 10 min.  Samples were subjected to WB using 3D6  	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(to Aβ1-5, gift of Elan) and the ECL Plus WB Detection Reagent (GE Healthcare). 
 
Preparation of Aβ isolated from AD cortex 
  Aβ from TBS extract of human AD cortical tissue was prepared as 
previously described (Shankar et al., 2008; Yang et al., submitted).  Briefly, 
frozen temporal or frontal cortex samples were dissected then homogenized as 
described above for mouse brain sample preparation.  The TBS extract was then 
IP’ed with 3D6 antibody and the Aβ immunoprecipitate was eluted off a Superdex 
75 SEC column in 50 mM ammonium acetate, pH 8.5.  The SEC elution profile 
for Aβ was verified by SDS-PAGE.  The corresponding fractions where Aβ 
dimers were eluted were used for the injection studies. 	 ﾠ
 
Test tube model of microdialysis for crossover efficiency 
For the initial test tube microdialysis (Figure 4.1), buffer (1.5% BSA in 
artificial CSF) was perfused at 0.2 μl/min through human CSF spiked with 
synthetic Aβ40 (251 nM) using the BR-2 35 kDa MWCO microdialysis membrane. 
Samples were then IP’ed using AW8 polyclonal antibody to Aβ.  Precipitates 
were subjected to SDS-PAGE and Western blotted using monoclonal antibodies 
6E10 (to Aβ3-8, Covance) and 2G3 (to Aβ33-40, gift of Elan).  For the crossover 
studies of dimers versus monomers (Figure 4.5), we first performed microdialysis 
at 0.4 μl/min with differing starting concentrations of either wt Aβ1-40 monomers 
(MesoScale Discovery) or S26C Aβ1-40 dimers (gift of D. Walsh, BWH).  The 	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amount of Aβ recovered in the microdialysates was then assessed by Aβ1-x 
ELISA, then the % starting material that crossed over the microdialysis 
membrane was plotted against the respective starting concentrations.  The 
crossover efficiency (i.e., the % Aβ that was in the test tube as the starting 
material now recovered in the microdialysates) increased in a non-linear fashion 
with increasing concentrations of the starting material.  The crossover efficiency 
of the Aβ dimers was calculated to be comparable to that of the Aβ monomers 
when enhanced 5-fold, i.e., Aβ dimers at 40 nM and Aβ monomers at 8 nM.  To 
test this, test tubes containing S26C dimers at 40 nM or wt monomers at 8 nM 
were microdialyzed side by side at 3 different rates, 0.1, 0.4 and 1.0 μl/min, and 
the resulting microdialysates were assessed for levels of Aβ using the Aβ1-x 
ELISA.  The quality of the Aβ in the starting materials in the test tubes and their 
corresponding microdialysates were also checked by IP-WB. 
 
Interpolated zero-flow method 
The in vitro percent recovery was calculated as previously described 
(Cirrito et al., 2003; Hong et al., 2011).  Microdialysis was performed from starting 
materials that contained either 8 nM Aβ1-40 monomers or 40 nM Aβ1-40 S26C 
dimers in perfusion buffer (1.5% BSA in artificial CSF), while varying the 
perfusion rates (PR): 1.0, 0.7, 0.4, and 0.1 μl/min.  Aβ levels were measured 
using the Aβ1-x ELISA and the values obtained at each PR were plotted versus 
the PR.  The 100% recovery (i.e., the theoretical maximal amount of 	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exchangeable ISF Aβ species occurring at a zero PR) was calculated by 
extrapolating back the curve to a zero-flow rate.  Then, for each PR, percent 
recovery was determined by calculating how much % Aβ was captured as  
compared to the theoretical [Aβ] at zero PR. 
 
Half-life studies of Aβ in ISF in vivo 
3 μl of either 8 nM Aβ1-40 monomers (MesoScale Discovery) or 40 nM Aβ1-
40 S26C dimers (gift of D. Walsh, BWH) was injected through a combination 
infusion cannula and microdialysis probe (IBR-2, Bioanalytical Systems) at 0.2 
μl/min.  ISF was collected hourly at 0.4 μl/min, paused during the injection, then 
restarted 1 min after injection.  The resulting ISF microdialysates were then 
analyzed by Aβ1-x ELISA or sent to the Yale Center for Clinical Investigation for 
measurements of lactate, pyruvate, glycerol, and glucose. 
 
Intracortical injection of Aβ 
For intracortical injection, a previously described protocol (Spires et al., 
2005) was modified.  Briefly, anesthetized mouse was placed in a stereotaxic 
equipment and using the same coordinates as described above for the guide 
cannula placement into the left hippocampus, 320 pg Aβ (corresponding to 1-2 μl 
vol.) was injected at 0.5 μl/min via a Hamilton syringe.  Immediately (< 1 min) 
upon injection, mice were sacrificed and brains were harvested for biochemical 
analysis.  	 ﾠ   151 
Surface plasmon resonance 
  SPR was performed with modified protocols from (Bartels et al., 2011) and  
(Hou et al., 2010).   Briefly, SPR was performed at 20 °C on a BIACORE 3000 
apparatus using the L1 sensor chip (Biacore AB).  The running buffer was 50 mM 
ammonium acetate, pH 8.5.  SUVs were prepared by sonicating brain total lipid 
extract (chloroform:methanol extract from bovine brain tissue; Avanti) and 300 μl 
SUVs were applied onto the sensor chip surface at a flow rate of 10 μl/min until 
equilibrium was achieved (~1 h).  For regeneration buffers, either 5% ethanol or 
300 mM sodium chloride was used.  All injections were performed at 10 μl/min 
with 50 μl sample volume.  
 
Statistical analysis 
Data was analyzed using PRISM (Graphpad Software) for one-way or two-
way analysis of variance (ANOVA) followed by Bonferroni post-hoc test if means 
were significantly different by ANOVA, or Student’s t test, as appropriate. 
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       After decades of investigative focus on amyloid plaques, a hallmark of 
Alzheimer’s disease (AD), findings in the past ten years have led to a conceptual 
shift.  Accumulating evidence suggests that the insoluble amyloid fibrils that 
comprise plaques may not directly confer neurotoxicity, but that they sequester 
the soluble oligomeric forms of the amyloid β-peptide (Aβ) that potently alter 
synaptic structure and function.  Recognition of Aβ oligomers as highly bioactive 
assemblies has furthered interest in detecting and analyzing soluble forms of the 
peptide for mechanistic, diagnostic and therapeutic purposes.  Currently, virtually 
all treatments under development are focused on decreasing or neutralizing Aβ.  
Moreover, a reduced CSF level of Aβ42 in subjects with incipient or very early AD 
is one of the most promising biomarkers.  However, despite the therapeutic and 
diagnostic focus on the dyshomeostasis of Aβ, we still lack insight into the in vivo 
economy of Aβ in the brain.  Thus, my thesis work focused on understanding the 
dynamics of Aβ in a living brain during the development of AD-type pathology.  
The first half of my thesis aimed at gaining insight into the dyhomeostasis of Aβ 
as plaques accrue in brain parenchyma.  The second half of my thesis focused 
on deciphering the fate of Aβ once it is released into the extracellular space.  
In order to gain insight into the dynamics of Aβ that remains diffusible in 
the extracellular space in vivo, I sampled by microdialysis the hippocampal 
interstitial fluid (ISF) of awake and behaving hAPP transgenic mice.  First, I found 
that the Aβ species that remained soluble, diffusible, and of < 35 kDa molecular 
weight (MW) in the ISF in vivo (termed ISF Aβ herein) were composed of Aβ38, 	 ﾠ 160 
Aβ39, Aβ40, and Aβ42 (relative abundance: Aβ40 >> Aβ38, Aβ42 >> Aβ39).  
Interestingly, the ISF Aβ contained species of two distinct MWs: 4 kDa 
(corresponding to the MW of Aβ monomers; ~60% of ISF Aβ) and a novel 5 kDa 
species (~40% of ISF Aβ).  Acute inhibition of γ-secretase in young transgenic 
mice led to a rapid fall of the ISF Aβ captured in microdialysates (t1/2 of fall ~2 h), 
showing that most of the ISF Aβ sampled by microdialysis represented newly 
synthesized APP cleavage products.   
Second, in order to understand the dyshomeostasis of Aβ during 
development of AD-type pathology, I sampled ISF of hAPP transgenic mice from 
three age groups: before (3 mo), during (12 mo), and after (24 mo) plaque 
deposition.  I found that Aβ levels in the most soluble compartment (the ISF) 
declined significantly as mice underwent progressive parenchymal deposition of 
Aβ (from 1.2 nM [ISF Aβ] in pre-plaque 3 mo to 0.5 nM [ISF Aβ] in plaque-rich 24 
mo).  Among the ISF Aβ peptides measured, Aβ42 decreased the most; in accord, 
Aβ42 rose the most in the brain parenchyma, in keeping with its documented 
primary role in oligomerization and plaque formation.  Using the interpolated 
zero-flow method of microdialysis, I observed similar % recovery of 
microdialyzable Aβ at both 3 mo and 24 mo transgenic, which indicated that the 
age-dependent decrease in ISF Aβ was not due to technical issues with the 
microdialysis system.  Furthermore, neither the lactate-to-pyruvate ratio (an 
established marker of the redox state of cells) nor the level of glycerol (an integral 
component of cellular membranes for which changes in ISF levels may reflect 	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degradation of membranes) in the ISF changed significantly between 3 mo and 
24 mo in the APP transgenic mice, suggesting that the decrease in ISF Aβ was 
not associated with altered intermediary metabolism or perturbation of cell 
membrane integrity.  The levels of full-length APP and their C-terminal fragments 
generated by α- and β-secretases were constant between 3 mo and 24 mo, 
indicating that the fall in ISF Aβ was not likely due to a decrease of cellular 
production of Aβ.  Hence, I obtained no evidence that decreased neuronal 
activity, decreased Aβ production, or altered spontaneous behavior (eating, 
exploring, grooming, etc.) in the mice explains the drop in soluble ISF Aβ as mice 
accrue amyloid deposits.   
Rather, the decrease in steady-state ISF Aβ occurred simultaneously with 
rises of insoluble Aβ in the brain parenchyma (i.e., Aβ obtained in the SDS- and 
formic acid-extractable pools of brain homogenates).  In order to mimic new Aβ 
production and monitor its fate, I administered soluble radiolabeled Aβ at 
physiological concentrations directly into the ISF.  In plaque-rich (24-27 mo 
transgenic) mice, the acutely injected radiolabeled Aβ became rapidly less 
diffusible and more associated with the loosely membrane-bound (i.e., saline-
extractable) pool, as compared to the radiolabeled Aβ injected into the ISF of 
plaque-free (3-7 mo transgenic) mice.  The distinct disposition of the radiolabeled 
Aβ in plaque-rich vs. plaque-free mice suggested that in plaque-rich mice, 
cerebral amyloid deposits rapidly sequester newly released Aβ, thereby 
accounting for the lower steady-state level of Aβ in the ISF.  Taken together, the 	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studies of the steady-state ISF Aβ and the fate of radiolabeled Aβ before vs. after 
plaque initiation provide, for the first time, in vivo evidence from controlled animal 
experiments for the hypothesis that soluble Aβ42 in human CSF falls because it is 
sequestered into insoluble parenchymal deposits as AD develops.   
The association of Aβ with the insoluble deposits may not be irreversible, 
however, because when I acutely inhibited γ-secretase in vivo in plaque-rich 
mice, this failed to lower ISF Aβ42 (whereas ISF Aβ38 and Aβ40 fell rapidly (t1/2 
~1.9 h and ~2.3 h, respectively)).  As Aβ42 is the species reported to accumulate 
much more into insoluble plaques than Aβ38 and Aβ40 in both AD patients and 
APP transgenic mice, this result suggests that most of the soluble Aβ42 peptide 
that populates the ISF in plaque-rich mice is not derived primarily from new Aβ 
biosynthesis but rather from the large reservoir of Aβ42 deposited in the brain 
parenchyma.  This concept is consistent with earlier reports that amyloid plaques 
in APP transgenic mice appear to act as a local reservoir of “loosely-associated” 
Aβ that can diffuse from plaques.  Hence, whereas the ISF of young, plaque-free 
mice acts as a reservoir for mainly the acute cellular production of Aβ, ISF in 
plaque-rich mice seems to be a reservoir for both new Aβ production and Aβ that 
diffuses off of membrane- and plaque-bound deposits.   
The above results (along with some biochemical characterization of saline-
extractable brain Aβ suggesting that aqueous extracts do not contain the truly 
diffusible Aβ species in vivo as thought heretofore) were published in the Journal 
of Neuroscience on November 2, 2011. 	 ﾠ 163 
Finally, I showed that Aβ dimers, which are known to be potent synaptic 
neurotoxins, are undetectable in the aqueous compartments of the central 
nervous system, i.e., the brain ISF and the cerebrospinal fluid (CSF), as they are 
rapidly sequestered away from the aqueous pool to lipid membranes, where they 
bind to GM1 ganglioside and/or Prion protein.  One interesting observation made 
in my earlier work was that in ISF from more than 25 hAPP transgenic mice, Aβ 
dimers were not detected by the immunoprecipitation (IP)-Western blotting (WB) 
technique, regardless of the age of mice or their extent of plaque deposition (i.e., 
even when dimers can be found in the saline extracts of their brain 
homogenates).  I found this particularly interesting, as Aβ dimers are currently 
thought to be the earliest oligomeric assembly that exerts synaptotoxic effects.  
Using a test tube version of microdialysis, I verified that Aβ dimers (~8 kDa MW) 
indeed crossed over the 35 kDa MW cutoff membrane that I use for in vivo brain 
microdialysis.  Therefore, I wanted to explore whether Aβ dimers cannot exist as 
free entities in the ISF; rather, due to their increased hydrophobicity, the dimers 
bind to membranes, pre-existing aggregates or other potential binding partners 
much more rapidly than monomers do.  This could explain why dimers, but not 
monomers, are thought to be the earliest synaptotoxic assembly forms of Aβ. 
I first confirmed that Aβ dimers were indeed undetectable in the brain fluid 
compartments using young hAPP transgenic mice, which should contain 
abundant levels of soluble Aβ.  To ensure that the apparent lack of oligomers in 
ISF samples was not simply due to ineffective passage of the ~8 kDa dimers and 	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any other LMW oligomers across the 35 kDa MWCO membrane, I also collected 
CSF from the cisterna magna.  Using three biochemical methods, IP-WB, an Aβ 
oligomer-specific ELISA, and a non-denaturing size-exclusion chromatography 
(SEC), I failed to observe any Aβ oligomers in the hippocampal ISF or CSF from 
hAPP transgenic mice. 
Next, I used in vitro (test tube) microdialysis to establish conditions in 
which dimers and monomers have similar % crossover efficiency.  I found that at 
a five-fold higher concentration as that of monomers, dimers crossed over the 
microdialysis membrane with similar efficiency as the monomers.  I verified that 
the Aβ recovered in the microdialysates indeed reflected their starting material 
throughout the time of my analysis; i.e., the microdialysate recovered from 
starting material that contained mostly dimers was in fact principally dimers and 
stayed as such, and those recovered from monomer-containing material stayed 
as monomers.  Having established conditions where comparable % Aβ crossover 
efficiencies could be achieved in vitro, I next examined the half-life of acutely 
administered synthetic dimers vs. monomers in hippocampal ISF in vivo.  I 
injected synthetic Aβ of human sequence into the ISF of wild-type (wt) mice to 
distinguish between the acutely administered human Aβ and endogenously 
secreted mouse Aβ.  I found that acutely administered dimers were much more 
rapidly sequestered away from the hippocampal ISF pool in vivo: in just one hour, 
Aβ dimers showed ~8.5-fold less recovery when injected into the ISF than did Aβ 
monomers.  Accordingly, the injected Aβ dimers were recovered at higher 	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proportions in the membrane-bound pool than in the cytosolic pool, suggesting 
that Aβ dimers (versus monomers) quickly bind membranes.  When I spiked the 
dimers into TBS extracts of wt mice ex vivo and performed SEC using a 
Superdex 75 SEC column, I observed an immediate shift of its elution profile from 
the dimer (~ 8 kDa) fractions to the void volume fractions (i.e., > 70 kDa).  Dimers 
spiked into buffer alone eluted at the expected dimer position, arguing against 
mere aggregation of the Aβ.  Thus, I suspected whether Aβ could be binding to 
lipid membranes, and whether the dimers have a higher affinity for them.  As a 
direct in vitro measurement of binding affinities, I recently began surface plasmon 
resonance experiments on chips coated with lipid bilayer membranes.  
Preliminary results indicate that Aβ dimers may in fact have an enhanced affinity 
to the lipid membrane than do the monomers; however, the experiments need to 
be repeated. 
Interestingly, the injected Aβ (both the synthetic Aβ dimers and the natural 
Aβ dimers isolated from human AD cortical tissue) were now recovered as 
monomers.  Furthermore, the Aβ recovered in the membrane-bound fractions 
were found to be tightly associated to endogenous GM1 ganglioside (and hence 
migrating ~5 kDa) and Prion protein.  I found that the endogenous Aβ in the 
membrane-bound fractions of young hAPP transgenic mice were also tightly 
bound to GM1 ganglioside and that these GM1 ganglioside-bound Aβ were 
associated with Prion protein.  Further experiments will be necessary to 
determine which of these two molecules, the GM1 ganglioside and Prion protein, 	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acts the primary binding site that mediates Aβ’s notorious synaptotoxic offense 
and which may be the accomplice.  
In summary, my studies show that upon plaque accumulation, the 
dynamics of Aβ are altered, and that Aβ dimers, and probably higher oligomers, 
do not exist in the aqueous brain compartments but instead are rapidly 
sequestered away from the ISF and bind to GM1 ganglioside- and Prion protein-
enriched lipid membranes.    
Appendix 1 
 
Disrupting the in vivo economy of amyloid β in an intact living brain of APP 
transgenic mouse using antibodies against the amyloid β-peptide 
 
 
 
 
 
 
 
 
Contributions to this Appendix: 
Experiments were designed by Soyon Hong and Dennis Selkoe.  ELISAs and 
Western blotting experiments were performed by Beth Ostaszewski and Soyon 
Hong.  All other experiments were performed by Soyon Hong.   168 
Introduction 
  A project I have started but suspended at this time relates to the question 
of how two antibodies against β-amyloid (Aβ) that are currently in Phase 3 
clinical trials alter Aβ equilibrium in an intact living brain.  One antibody is against 
the free N-terminus of Aβ (the 3D6 antibody) and the second antibody is against 
the mid-region of Aβ (the 266 antibody); both are delivered to patients with 
Alzheimer’s disease (AD) by passive intravenous infusion.  Initially, I injected 
intraperitoneally each of these antibodies into pre-plaque (3 mo) or plaque-rich 
(24 mo) APP transgenic (tg) mice and asked whether the quantity and quality of 
the most soluble Aβ species in the interstitial fluid (ISF) (sampled by 
microdialysis) changed before vs. after the antibody injection.   
Currently, there are more than 13 active clinical immunotherapy trials in 
patients with mild to moderate AD aimed at lowering the total Aβ burden in the 
central nervous system (CNS) (Lemere and Masliah, 2010).  Multiple passive 
immunotherapy studies using mouse models of AD have successfully shown that 
anti-Aβ antibodies promote plaque clearance in the CNS and subsequent 
neuronal and behavioral rescue (for e.g., Schenk et al., 1999; Bard et al., 2000; 
DeMattos et al., 2001; Dodart et al., 2002; Brendza et al., 2005).  There are three 
proposed mechanisms behind passive immunization: direct resolution, microglial-
cell mediated, and peripheral sink hypothesis (Solomon et al., 1996; Bard et al., 
2000; Demattos et al., 2002; Weiner and Frenkel, 2006).  3D6 (directed against 
1-5 of Aβ) is among the most effective antibodies studied, especially in binding   169 
and triggering the clearance of plaques (Bard et al., 2003).  Fc-mediated 
microglial phagocytosis of Aβ, together with the direct resolution against the Aβ 
fibrils, has been suggested as the primary mechanism for the 3D6 antibody-
mediated plaque clearance.  The 266 antibody (directed against 16-23 of Aβ) has 
been found to effectively induce behavioral improvements in 11 mo to 24 mo 
PDAPP tg mice, but without lowering the Aβ plaque burden in the brain.  
Interestingly, a single dose of 266 antibody effectively reversed learning 
impairments in the 12 mo PDAPP mice in a time period as short as 24 h (Dodart 
et al., 2002).  As Aβ-266 antibody complexes were found in both CSF and 
plasma but the total Aβ plaque burden seemed unperturbed (even in the 
subchronic weekly treated mice for up to 6 months), the primary mechanism 
suggested for the 266 antibody was the peripheral sink, i.e., the 266 antibody 
sequestered the free Aβ in the plasma and thereby shifted the Aβ equilibrium, 
continuously pulling the Aβ from the CNS (Demattos et al., 2002; Dodart et al., 
2002). 
Here, we hypothesize that the 3D6 antibody primarily binds aggregated Aβ, 
i.e., Aβ deposited onto the brain parenchyma, and works to dissolve the plaques, 
ultimately leading to an altered dynamics in the CNS.  We therefore hypothesize 
to observe a short initial fall in the ISF Aβ levels (as the 3D6 antibody may at first 
directly sequester the available Aβ1-x species in the ISF pool), then a prolonged 
rise (as over time, the 3D6 antibody may directly resolve the aggregated Aβ 
fibrils, hence releasing more Aβ into the ISF).  On the other hand, the 266   170 
antibody may only sequester the immediately available soluble pool, i.e., the ISF, 
but may not be able to dissolve the plaques directly (as the epitope for 266, the 
mid-region of Aβ, may be hidden in fibrils). 
The specific questions we aim to address here are: (1) what are the acute 
effects that an anti-Aβ antibody administration has on steady-state brain ISF Aβ?  
To this end, we aim to monitor pre- and post-injection ISF Aβ levels and measure 
other non-Aβ analytes present in the ISF; (2) how does the presence of plaques 
influence such effects?  To this end, we will use two ages of the J20 tg mice: ~3 
mo which are virtually free of plaques, and ~24 mo which are plaque-rich (see 
Chapter 2); (3) how specific are the effects to the 3D6 or 266 antibody?  To this 
end, we will administer mice with vehicle alone or IgG isotype control.  In addition, 
we may use a different monoclonal anti-Aβ antibody that recognizes a distinct 
epitope from 3D6 and 266 (for e.g., antibodies directed against the C-termini of 
Aβ, the 2G3 (against Aβ31-40) or 21F12 (against Aβ33-42)); and (4) can we gain 
insight into the main mechanism(s) at play?  To understand whether the increase 
or decrease of ISF Aβ is due to an alternate source other than manipulation of 
the acute APP processing process (i.e., Aβ production), we will treat mice with 
Compound E, a potent γ-secretase inhibitor which decreases ISF Aβ levels with 
tt/2 ~2 h (see Chapter 2).  To see whether direct resolution is at play, we could 
attempt in vitro microdialysis using different brain pools (TBS or SDS extracts).  
We will also perform immunohistochemistry against CD-45, Iba-1, or GFAP to 
see the effect a single dose injection may have on microglial and astrocytic   171 
activation.  Finally, we can also measure Aβ levels in blood before and after 
injection to see to what extent Aβ levels in plasma are altered and how these 
levels correlate with the brain ISF Aβ levels. 
 
Results and Discussion 
Levels of ISF Aβ were monitored for 72 hours before injection of the 
antibody.  It took ~12 hours for the levels of ISF Aβ to stabilize after initiation of 
microdialysis, but then ISF Aβ stayed stable (Figure A1.1).  Therefore, in all 
experiments, we waited 36-48 hours after microdialysis was initiated in the mice 
and confirmed that their ISF levels were stable for at least 24 hours before 
injecting the antibodies.   
  Next, pre-plaque (3-4 mo tg) mice were given intraperitoneal injections of 
the 3D6 antibody at 5 mg/kg and their Aβ levels in ISF were monitored until day 8 
post injection using the 6E10 Aβ triplex ELISA.  Within 48 hours of injection 
(injection performed at day 0), the levels of all three peptides, i.e., Aβ38, Aβ40 and 
Aβ42, rose rapidly to a two-fold and continued to slightly increase until day 4 post 
injection, upon which the enhanced levels seemed to stabilize (Figure A1.2A).  
Interestingly, the degree to which Aβ levels rose was the least for Aβ42, as 
compared to Aβ38 and Aβ40.  To see whether these effects were distinct in the 
presence of plaques, the 3D6 antibody was administered to plaque-rich (26-28 
mo tg) mice and their ISF levels were collected before and after the 3D6 injection.  
Similar to the observation made in pre-plaque mice, the levels of Aβ38 and Aβ40   172 
 
 
Figure A1.1. There is little fluctuation in the levels of ISF Aβ from 12
th hour 
onwards after microdialysis is initiated. 
 
A representative figure showing the levels of ISF Aβ immediately following 
microdialysis, as measured by the 6E10 Aβ triplex ELISA. 
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rose steadily until day 4 post injection, albeit more slowly than the rate at which 
these two peptides rose in the pre-plaque brain (Figure A1.2B).  The peptides 
then seemed to either stabilize or rise slightly.  Interestingly, Aβ42 peptide 
behaved exceptionally in the plaque-rich mice: Aβ42 barely rose until day 8 
following the 3D6 administration (Figure A1.2B).  We measured the ISF Aβ levels 
with another ELISA, which uses antibodies that recognize different epitopes of 
Aβ (the 266/3D6B or more commonly known as the Aβ1-x ELISA), and confirmed 
that the readout by the Aβ1-x ELISA was comparable to the readout given by the 
6E10 Aβ triplex ELISA (Figure A1.3).  By IP-WB, we did not see any significant 
changes in the molecular composition of ISF Aβ collected between days 4 and 5 
of 3D6 administration, i.e., the ISF Aβ seemed to have similar degrees of both 4 
and 5 kDa Aβ-immunoreactive species (as pulled out by the AW8 Aβ antisera) 
(Figure A1.4) as the ISF Aβ from mice that did not receive an antibody injection 
(see Chapter 2).  Likewise, we saw similar levels of increase in Aβ38, Aβ40 and 
Aβ42 in SEC fractions that correspond to monomers and the 5 kDa species (data 
not shown).  The rise of ISF Aβ we observed in the microdialysates was not due 
to IgG interfering with the ELISA itself, as (1) IgGs are not expected to cross over 
the 35 kDa MWCO membrane and therefore will be absent in the 
microdialysates; and (2) even if they may cross over into the microdialysate, the 
IgG may interfere with the ELISA by reducing the total Aβ reading (and not by 
increasing it) (Figure A1.5A).  To determine whether the increase of ISF Aβ was 
due to increased APP processing (i.e., increased Aβ production), we    174 
  
Figure A1.2. A single injection of the 3D6 antibody leads to prolonged increased 
levels of ISF Aβ in both plaque-free (3 mo) and plaque-rich (26-28 mo) J20 tg 
mice, with exception for Aβ42 in the plaque-rich mice. 
 
ISF Aβ levels in (A) pre-plaque 3-4 mo tg (N=3 mice) and (B) plaque-rich 26-28 
mo tg (N=3 mice) before and after 3D6 intraperitoneal administration.    175 
 
Figure A1.3. Levels of Aβ1-x rise in the ISF of mice injected with the 3D6 antibody.  
 
A representative figure showing the ISF Aβ levels in a 3 mo tg after 3D6 antibody 
injection.  Black line: Aβ1-x levels, as read by the 266/3D6B ELISA; blue, red and 
green lines: Aβx-38, Aβx-40 and Aβx-42 levels, respectively, as read by the 6E10 Aβ 
triplex ELISA. 
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Figure A1.4. ISF Aβ is separated to 4 kDa and 5 kDa species by SDS-PAGE. 
 
500 μl of perfusion buffer (PB) and 500 μl of ISF collected on days 4 and 5 post-
3D6 injection were IP’ed with AW8 (1:100) and subjected to denaturing SDS-
PAGE.  Synthetic Aβ40 were loaded as control.  WB: 6E10, 2G3 and 21F12. 
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Figure A1.5. IgGs and 1,2-propanediol may interfere with the 6E10 Aβ triplex 
ELISA.  
Different amounts of (A) IgG2b or (B) 1,2-propanediol were spiked directly into the 
ELISA wells to determine whether they interfere with the ELISA antibodies and 
induce an artifactual increase in the Aβ levels obtained by the ELISA.   178 
 
Figure A1.6. Compound E injection fails to bring the ISF Aβ levels completely 
down. 
ISF levels from a 3 mo J20 tg, as measured by the 6E10 Aβ triplex ELISA.  Day 
0: 3D6 injection (5 mg/kg).  Day 7: Compound E injection (10 mg/kg).   179 
intraperitoneally injected Compound E (5-10 mg/kg) into the 3D6-injected mice.  
We saw that the Compound E injection decreased the ISF Aβ levels to only 
~50% (Figure A1.6) (instead of the nearly complete (> 80%) decrease observed 
in non-3D6-injected young tg mice (see Chapter 2)), which implies that the 
increased levels of ISF Aβ post 3D6 administration is not due to increased Aβ 
production by cells, but rather due to a manipulation of an alternative source 
(decreased degradation of Aβ and/or dissolution of pre-existing Aβ aggregates).  
There seemed to have been a reset in the equilibrium between the Aβ pools that 
exist in ISF and brain parenchyma to give rise to an altered steady-state level. 
  To see whether the rise in the ISF Aβ levels were mediated by the 
antibody, we injected vehicle alone (which was 1,2-propanediol, a vehicle also 
used for the Compound E injection studies) and observed a rise in all three Aβ 
peptides in the ISF of both pre-plaque (Figure A1.7A) and plaque-rich (Figure 
A1.7B) mice; this rise was even more substantial than the rise from ISF of mice 
injected with 3D6 antibody (Figure A1.7: bold line).  Although the vehicle injection 
experiment was done only in N=1 mouse each for pre-plaque and plaque-rich 
group, and the rise of the ISF Aβ levels upon antibody injection did not seem to 
be an artifact of 1,2-propanediol (as high amounts of 1,2-propanediol may lead to 
an artifactual decrease in Aβ ELISA values, not to an increase) (Figure A1.5B), it 
was clear that vehicle alone mediated a rise similar to what we observed with the 
3D6 antibody.  This result therefore called into question whether the rise in ISF 
Aβ we had upon 3D6 antibody administration was indeed mediated by the    180 
 
Figure A1.7. Vehicle alone (1,2-propanediol) induces an enhanced rise in levels 
of ISF Aβ in both pre-plaque and plaque-rich mice.  
ISF levels from a 3 mo and a 26 mo J20 tg were monitored for 6 days post 
injection of vehicle at day 0 (1,2-propanediol:PBS 1:1).  Vehicle alone induced a 
rise in the levels of all three Aβ38, Aβ40 and Aβ42 peptides in the 3 mo tg and Aβ38 
and Aβ40 in the 24 mo tg (and to some degree, Aβ42). 
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antibody. 
Next, we repeated the 3D6 antibody injection with PBS as vehicle, and 
compared the effects of the 3D6 on ISF Aβ with mock (no injection) or vehicle 
(PBS) injection (Figure A1.8A shows results in young tg (pre-plaque) and Figure 
A1.8B shows results in old tg (plaque-rich)).  Although there was N=1 mouse for 
each group, it was evident that it would be challenging to distinguish antibody-
mediated results above PBS injection or mock alone.  We therefore determined 
that the current experimental paradigm would not allow for a clear interpretation 
of results, especially as only a single injection was given per mouse and it has 
been reported that a minute fraction (~0.4%) of the antibody crosses over the 
blood brain barrier (BBB) into the CNS.  In previous Aβ antibody infusion studies 
with 3D6 antibody where effective plaque clearance in the brain parenchyma was 
noted, the hAPP tg mice received weekly treatments for at least 6 weeks to 6 
months.  Therefore, a single intraperitoneal administration of the antibody may 
not be sufficient to observe a significant change in the CNS Aβ equilibrium.  
Hence, I want to restart this project by directly injecting the antibodies into the 
hippocampal ISF through the injection cannula attached to the microdialysis 
probe, mimicking antibody that has already crossed the BBB.  I also want to 
utilize a larger (100 kDa) MW cutoff microdialysis membrane.  The question I will 
be asking then will thus be a more straightforward one: how does the Aβ 
antibody affect the Aβ equilibrium in an intact living brain either devoid of (3 mo 
tg) or enriched with (24 mo tg) amyloid plaques?  Monitoring the ISF Aβ in this    182 
 
Figure A1.8. ISF Aβ levels upon PBS, mock, or antibody injection. 
ISF Aβ levels were monitored up to 48 hours after PBS or 3D6 in pre-plaque 
young mice (A) or after PBS, 3D6, 266 or mock (no) injection in plaque-rich old 
mice (N=1 mouse per group). 
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way may give insight into the overall equilibrium maintained between the different 
Aβ pools in the brain and how the antibodies may alter this; e.g., by dissolution of 
amyloid fibrils or by direct sequestration of the soluble species.  The results may 
help clarify the underlying mechanism of the current passive anti-Aβ 
immunotherapy on trials. 
 
Materials and Methods 
Two age groups of J20 tg mice, pre-plaque (3-4 mo) and plaque-rich (20-28 
mo), were used in this study.  The APP genotype was verified twice by PCR of 
genomic DNA.  ISF was sampled at 0.4 μl/min with perfusate composed of 1.5% 
BSA in artificial cerebrospinal fluid (see Chapter 2 for composition and details in 
material and methods).  Microdialysis was initiated in the tg mice at least 36 
hours before the Aβ antibody was injected.  The basal steady-state levels of Aβ 
in the ISF were verified using the 6E10 Aβ triplex ELISA, which captures Aβ 
according to their C-termini (i.e., Aβ38, Aβ40 and Aβ42) and detects using the 
6E10 antibody (directed against Aβ5-9) (MesoScale Discovery).  36-48 hours after 
surgery and initiation of microdialysis, 3D6 antibody (IgG2b; gift of Elan), 266 
antibody (IgG1; gift of Elan), 21F12 antibody (IgG2a; gift of Elan), or IgG isotype 
control (from R&D Systems and Abcam) was administered once to the tg mice by 
intraperitoneal injection.  The ISF microdialysates were collected hourly before 
and after antibody injection and the levels of Aβ were measured using the 6E10 
triplex Aβ ELISA.  The ISF were also analyzed for Aβ by immunoprecipitation   184 
(IP)-Western blotting (WB), where Aβ antisera (AW8, gift of D. Walsh, BWH) was 
used for IP and the 6E10, 2G3 and 21F12 anti-Aβ antibodies were used for WB.  
Some ISF microdialysates were pooled, run on a size-exclusion chromatography 
(SEC) Superdex 75 HR 10/30 column, and were eluted at 0.4 ml/min in 50 mM 
ammonium acetate, pH 8.5.  The subsequent 1-ml fractions were promptly 
lyophilized, then assayed for Aβ38, Aβ40 and Aβ42 using the 6E10 Aβ triplex 
ELISA. 
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Appendix 2 
 
Co-immunoprecipitation studies using saline extracts of Alzheimer’s 
disease human brains do not show a specific binding of Aβ to 
apolipoprotein E or apolipoprotein J over GAPDH or β-tubulin 
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Introduction 
  The β-amyloid peptide (Aβ) in saline (TBS) extracts of human brains of 
Alzheimer’s disease (huAD) and hAPP transgenic (J20) mice appears to be a > 
500 kDa complex in non-denaturing conditions (see Chapter 3) (Shankar et al., 
2008; Hong et al., 2011).  We wondered whether the Aβ is in a complex with 
specific proteins.  We decided to take a candidate-based approach: we wanted to 
see whether the two proteins that have been shown to bind Aβ, the 
Apolipoprotein E (ApoE) (Näslund et al., 1995) and Apolipoprotein J (ApoJ), 
which is also known as clusterin (Ghiso et al., 1993), are solely responsible for 
mediating the Aβ to run as a > 500 kDa.  First, we checked whether endogenous 
ApoE and ApoJ from huAD TBS extract are co-eluted in the void volume fractions 
where the soluble Aβ is eluted.  Next, we used co-immuoprecipitation (co-IP) 
methods to verify whether Aβ in the huAD TBS extract is specifically bound to 
ApoE and ApoJ.	 ﾠ
 
Results and Discussion 
First, we performed non-denaturing size-exclusion chromatography (SEC) 
by loading the TBS extract from huAD brain homogenate onto a Superdex 200 
SEC column.  Fractions were eluted at 0.5 ml/min in 50 mM ammonium acetate, 
pH 8.5.  The fractions that correspond to the void volume fractions (> 500 kDa) 
were immediately lyophilized upon elution.  The fractions were then straight-	 ﾠ 188 
loaded onto denaturing SDS-PAGE, and subsequently Western blotted for Aβ, 
ApoE, and ApoJ (Figure A2.1).  Figure A2.1A shows the SEC elution profile of 
synthetic Aβ off the column and Figure A2.1B shows the elution profile of soluble 
Aβ from huAD TBS extract.  The SEC elution profile of the human AD brain-
derived soluble Aβ is distinct from the elution profile of the synthetic Aβ (red 
arrows indicate the fractions where synthetic Aβ were eluted using this column).  
Next, we blotted the fractions for ApoE (Figure A2.1C: red arrow indicates where 
the ApoE is expected to run; boxed areas are where Aβ immunoreactivity was 
the strongest on this blot) and ApoJ (Figure A2.1D; red arrow indicates where the 
ApoJ is expected to run).  Therefore, endogenous ApoE and ApoJ from huAD 
brain TBS extracts were co-eluted with Aβ in the void volume fractions of 
Superdex 200 SEC column. 
Next, we performed co-IP experiments to see whether ApoE and ApoJ are 
specifically bound to Aβ.  TBS extracts of huAD brain were IP’ed for Aβ using 
R1282 antiserum, then the immunoprecipitates were washed and loaded onto 
denaturing SDS-PAGE.  The R1282 antibody brought down ApoE in a 
concentration-dependent manner, whereas the pre-immune sera failed to do so 
(Figures A2.2A and B).  Furthermore, the R1282 antibody failed to pull down any 
ApoE in human brain extracts that had little or no Aβ (an AD brain that contained 
minute amount of Aβ and a non-AD control brain that carried undetectable levels 
of Aβ) (Figures A2.2C and D).  ApoJ was also brought down with Aβ, in an 
apparent Aβ-specific and concentration-dependent manner (Figures A2.2E and 	 ﾠ 189 
 
Figure A2.1. Endogenous ApoE and ApoJ in huAD TBS extracts are co-eluted 
with Aβ in the void volume fractions of Superdex 200 SEC column. 
(A) SEC elution profile of synthetic Aβ.  WB: 3D6.  (B-D) SEC elution profiles of 
(B) Aβ (WB: 3D6), (C) ApoE, and (D) ApoJ from huAD brain TBS extract. 	 ﾠ 190 
Figure A2.2. ApoE and ApoJ are co-immunoprecipitated with Aβ from the huAD 
TBS extracts. 
(A-B) The R1282 Aβ antisera brought down ApoE, whereas the pre-immune sera 
failed to do so.  (A) ApoE WB; (B) Aβ WB. 
(C-D) The R1282 Aβ antisera pulled out little ApoE from TBS extacts of an AD 
brain that did not have much Aβ and a non-AD control human brain.  (C) ApoE 
WB; (D) Aβ WB.  Red arrows indicate ApoE-immunoreactive band and green 
arrows indicate Aβ-immunoreactive bands. 
(E-F) Likewise, the R1282 Aβ antisera brought down ApoJ, whereas the pre-
immune sera failed to do so.  (E) ApoJ WB; (F) Aβ WB.  Red arrows indicate 
ApoJ-immunoreactive band and green arrows indicate Aβ-immunoreactive bands. 	 ﾠ 191 
 
Figure A2.2 (Continued). ApoE and ApoJ are co-immunoprecipitated with Aβ 
from the huAD TBS extracts. 	 ﾠ 192 
 
Figure A2.3. Pulling down for ApoE and ApoJ also brings down Aβ. 
IP’ing huAD TBS extract for ApoE (A) or ApoJ (B) brought down Aβ.  Synthetic 
Aβ loaded as control.  Aβ WB (6E10, 2G3 and 21F12). 
 
 
 
 
 	 ﾠ 193 
   
Figure A2.4. GAPDH is also co-immunoprecipitated with Aβ.  
(A) IP’ing for GAPDH also brought down Aβ.  Aβ WB (6E10, 2G3 and 21F12).  D: 
Aβ dimers, M: Aβ monomers. (B) R1282 Aβ antisera pulled down GAPDH (right 
WB), albeit less efficiently than it did ApoE (left WB).  Arrows point to ApoE and 
GAPDH. 
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Figure A2.5. GAPDH and β-tubulin are also eluted together with ApoE, ApoJ and 
Aβ in the void volume fractions of the Superdex 75 SEC column. 
The R1282 Aβ immunoprecipitate was eluted using Superdex 75 SEC column, 
and the void volume fractions (corresponding to fraction numbers 8-10 shown 
above) were blotted for ApoE, ApoJ, Aβ, β-tubulin, and GAPDH. 
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F).  We performed reverse co-IP studies and confirmed that immunoprecipitating 
for ApoE or ApoJ also brought down Aβ (Figure A2.3). 
To confirm whether the apparent interaction of ApoE and ApoJ with Aβ 
were specific for the two apolipoproteins, we pulled down for GAPDH in the huAD 
TBS extract and also checked for presence of GAPDH in the R1282 Aβ antisera 
pull-down.  We saw that IP’ing for GAPDH in the huAD TBS extract also brought 
down Aβ; in accord, IP’ing for Aβ brought down GAPDH (Figure A2.4).  Next, we 
attempted to clean the SEC fractions by first IP’ing the huAD TBS extract for Aβ, 
then loading the Aβ immunoprecipitate onto the SEC column (i.e., IP/SEC).  We 
found that the Aβ, ApoE and ApoJ still co-eluted in the void volume IP/SEC 
fractions; however, so did GAPDH and β-tubulin (Figure A2.5). 
 
Conclusion 
We first obtained promising co-IP data that ApoE and ApoJ may exist in a 
complex with Aβ in the saline extract of huAD brain homogenate.  However, we 
failed to see a significantly enhanced specificity in the apparent interaction 
between Aβ and the reported chaperon molecules, the ApoE and ApoJ, over 
what we considered to be negative control molecules, i.e., the GAPDH and β-
tubulin.  Instead, the saline-extractable Aβ may exist as a > 500 kDa molecule 
(Chapter 3) due to an artifactual globule formed during the homogenization 
process and/or unspecific hydrophobic binding to proteins or lipid molecules.  In 	 ﾠ 196 
conclusion, we found no evidence for a specific interaction of Aβ to ApoE and 
ApoJ in the saline extracts of human AD brain homogenate. 
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Appendix 3 
 
Soluble amyloid β oligomers and their potential on in vitro microglial 
activation 
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Introduction 
Soluble Aβ dimers and trimers are currently thought to act as the smallest 
oligomeric unit to exert synapto- and neurotoxic effects, whereas the Aβ 
monomers are thought to be an innocuous species.  Although there has been 
numerous studies in the past that helps us gain insight into the complex 
relationship between the β-amyloid protein (Aβ) and microglia, most of these 
studies have utilized synthetic source for Aβ, rather than natural sources (for e.g., 
Aβ from cell-culture media or Aβ isolated from human AD cortical tissue).  
Furthermore, how soluble low molecular weight (LMW) Aβ oligomers affect 
microglia and how this effect may differ from monomers still needs to be 
investigated.  To gain insight into this, I used a cell culture line of microglia (the 
N9 cells) and soluble Aβ dimers and monomers isolated either from cell-culture 
media or from human AD cortical tissue. 
 
Microglia 
Microglia are the resident macrophages in the central nervous system 
(CNS) (Adames et al., 1995).  Composing about 10% of the CNS population, the 
main function of microglia is to protect the CNS against various injuries (Streit 
and Kincaid-Colton, 1995).  In the healthy adult brain, microglia are said to be 
“resting”, characterized by a ramified and highly branched morphology, that is, a 
small cell body with fine, elaborated processes.  Microglia in the resting state   200 
have a very low surface antigenic profile (van Rossum and Hanisch, 2004), but 
display rapid dynamics of fine processes, constantly sampling the CNS 
environment (Chung et al., 1999; Davalos et al., 2005; Nimmerjahn et al., 2005).  
Upon CNS injury, microglia transform into an “activated” state, followed by the 
“phagocytic” state, where microglia clear cellular debris (Streit and Kincaid-Colton, 
1995).  The hallmarks of microglial activation are increased surface antigen 
expression, proliferation, migration to the site of injury, and release of various 
immuno- and neuromodulatory factors, chemokines, pro- and anti-inflammatory 
cytokines, and growth factors (Hanisch, 2002; van Rossum and Hanisch, 2004). 
Microglial activation is considered a double-edged sword.  There is the 
neuroprotective side: substances released from damaged tissue trigger microglial 
activation with an attempt to restore the CNS environment.  Microglia release 
growth factors, anti-inflammatory molecules, and neuroprotective cytokines to 
restore tissue homeostasis (Hanisch, 2002; Streit, 2002).  However, sustained 
microglial activation can turn around to exacerbate the situation.  Microglia 
release proinflammatory cytokines, such as TNF-α, and other cytotoxic and 
neurotoxic substances such as nitric oxide, glutamate and proteases.  Thus, the 
neurotoxicity mediated by activated microglia may lead to a “secondary CNS 
injury” (Wyss-Coray et al., 2002; van Rossum and Hanisch, 2004).  These 
detrimental consequences of chronic microglial activation have posed microglia 
as a principal culprit in the pathogenesis of many acute and chronic neurological 
diseases (Carson, 2002; Wyss-Coray et al., 2002; Weydt and Moller, 2005).  The   201 
detailed mechanisms underlying the shift from neuroprotective effects of 
microglial activation to its detrimental consequences are under study. 
 
Relationship between microglia and Aβ 
Consistently observed phenomena in the brains of AD patients are the 
prominent activation of inflammatory processes and the innate immune response 
(Akiyama et al., 2000; Wyss-Coray et al., 2002).  Activation of inflammatory 
pathways in very early stages of the disease may be beneficiary to limit the 
disease progression (Wyss-Coray et al., 2002; El Khoury et al., 2007).  Activated 
microglia may play an important role in clearing Aβ in vivo by binding and/or 
releasing proteases to degrade the Aβ assemblies (Bard et al., 2000; Rogers et 
al., 2002; Nicoll et al., 2003; Akiyama and McGeer, 2004).  Very recent dynamic 
confocal microscopy indicates that within 1-2 days after Aβ plaques form, 
microglia are activated (Meyer-Luehmann et al., 2008).  Despite numerous 
studies in the past showing effects of soluble and fibrillar Aβ on microglia (Floden 
and Combs, 2006) and microglial uptake and degradation of soluble and fibrillar 
Aβ (Chung et al., 1999), the important question of whether there are differential 
effects of Aβ dimers vs. monomers on microglia still needs to be investigated, 
especially in light of the recent establishment of soluble low-n Aβ oligomers as 
the earliest potent synaptotoxins (McLean et al., 1999; Klyubin et al., 2008; 
Shankar et al., 2008a; Li et al., 2009; Mc Donald et al., 2010; O'Nuallain et al.,   202 
2010; Jin et al., 2011; Li et al., 2011).  How do microglia affect the local pool of 
soluble Aβ?  Do microglia react to the synaptotoxic soluble Aβ oligomers (but not 
to the apparently innocuous monomers) before amyloid plaques build up and 
neuronal cell death is observed?  Interestingly, cell-secreted, soluble low n 
oligomers, but not monomers, are resistant to degradation by the microglial-
released protease, insulin-degrading enzyme (IDE) (Qiu et al., 1997).  Does the 
inability of IDE to degrade dimers and trimers lead to extracellular accumulation 
of the synaptotoxic Aβ oligomeric species?  Answers to these questions will 
provide important insights into the interplay between the various Aβ assemblies 
and microglia. 
Furthermore, microglial activation has been suggested to be a necessary 
mediator for Aβ’s ability to inhibit long-term potentiation (LTP) (Wang et al., 2004).  
Upon application of minocycline, a potent (however, widely nonspecific) inhibitor 
of microglial activation, Aβ no longer inhibited the NMDAR-dependent LTP 
induction.  The notorious role of Aβ as the prime synaptotoxic offender has been 
extensively researched (see Chapter 1).  Previously thought to be neuronal 
events, such as synaptogenesis, modulation of synaptic functions and synaptic 
pruning, are now being found to include glia as active players (Slezak and 
Pfrieger, 2003; Tremblay et al., 2011).  What role, if any, does microglia play in 
Aβ mediating its synaptotoxic effects? 
An attractive candidate to mediate neuron-glia interaction is the glial-
secreted tumor necrosis factor-alpha (TNF-α).  Several reports have suggested   203 
that TNF-α may influence synaptic function (Tancredi et al., 1992; Cunningham 
et al., 1996; Albensi and Mattson, 2000), synapse maturation (Beattie et al., 
2002), and synaptic scaling (Stellwagen and Malenka, 2006).  Soluble Aβ has 
been found to bind potently to TNF type I receptor (TNFRI) (Li et al., 2004), and 
activated microglia and astrocytes are the major sources of TNF-α in the CNS 
(Hanisch, 2002).  However, whether glial-released TNF-α mediates the inhibitory 
effect of Aβ in NMDAR-dependent LTP induction has yet to be revealed.  Other 
candidates that might mediate the interplay between Aβ and microglia in synaptic 
function are the immune proteins in the CNS that have recently been found to 
play important roles in regulating synaptic function, in particular, C1q (Fonseca, 
2004; Stevens et al., 2007) and the major histocompatibility complex class I 
(MHC-I) (Huh et al., 2000; Goddard et al., 2007).  It will be interesting to see 
whether Aβ regulates the expression of these molecules and/or the secretion of 
these molecules impacts Aβ production and accumulation, thereby inducing 
alterations in synaptic function. 
 
Results 
Here, we used a cell culture line of microglia (the N9 cells) to determine 
whether the soluble Aβ dimers affect microglia in vitro differently than the 
monomers do.  The Aβ monomers and oligomers were from two sources: a 
conditioned media of Chinese hamster ovary (CHO) cells that have mutated   204 
human APP (the APP V717F) stably transfected in them and thus secrete an 
abundant amount of Aβ species (the 7PA2 cells) (Podlisny et al., 1998; Walsh et 
al., 2000) and the saline extracts of AD human brain homogenates (the AD TBS 
ext), which has been found to carry an ample amount of Aβ monomers and 
dimers (Shankar et al., 2008b).  The 7PA2 cells were conditioned for 48 hours in 
DMEM, upon which the conditioned media (termed 7PA2CM herein) was 
collected and concentrated.  Non-transfected CHO-cells were also conditioned in 
the same manner as negative control (termed CHO-CM).  For the AD TBS ext, 
grey matter from a frozen cortical tissue from an AD human patient was isolated 
from the white matter, then homogenized in TBS buffer 1:4 brain tissue 
weight:TBS volume.  Then, the homogenate was ultracentrifugated at 75,000 g 
for 30 min at 4 °C.  The supernatant (termed the AD TBS ext) was then either 
loaded onto a Superdex 75 column or immunoprecipitated for Aβ using a 
monoclonal anti-Aβ antibody 3D6 or polyclonal anti-Aβ antibody AW8.  The 
concentrated 7PA2CM, AD TBS ext, or the Aβ immunoprecipitate (IP) of AD TBS 
ext were loaded onto the Superdex 75 SEC column and materials were eluted off 
the column by non-denaturing size exclusion chromatography (SEC) at 0.5 
ml/min in 50 mM ammonium acetate, pH 8.5.  The resulting SEC fractions were 
promptly lyophilized upon fractionation.  The separation of the Aβ monomers 
from the LMW oligomers (i.e., dimers and trimers) were identified by Western 
blotting.  The fractions which were identified to be enriched with Aβ monomers 
(termed monomer fraction) or dimers (termed dimer fraction) (Figure A3.1) were   205 
then brought up in macrophage serum free media (MSFM) and applied onto the 
N9 microglia cells (kind gift of J. El Khoury, MGH).   
The N9 microglia cells were passaged in DMEM with 10% serum, then plated 
onto a 96-well poly-D-lysine-coated plate at 5,000 cells per well.  The plated cells 
were serum-starved for 24 h, then treated with either the Aβ monomer or dimer 
fraction (Figure A3.2: treated with fractions from the 7PA2CM; Figure A3.3: 
treated with SEC fractions from two different huAD brains (void volume fraction, 
dimer fraction or monomer fraction); and Figure A3.4: treated with Aβ dimers 
isolated by IP/SEC method from huAD TBS ext).  Lipopolysaccharide (LPS) with 
interferon-γ (IFNγ) were applied at 100 ng/ml and 10 U/ml, respectively, as 
positive controls, and the fractions from the conditioned media of the non-
transfected CHO cells that correspond to the dimer-containing fractions in 
7PA2CM were used as negative controls.  24 hours upon application of the 
different fractions, the activation properties of the N9 cells were determined by 
measuring the number of metabolically active cells (using the WST-1 assay), 
cytotoxicity (using the lactate dehydrogenase (LDH) assay), and nitric oxide (NO) 
secretion (using the Griess assay). 
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Figure A3.1.  Separation of soluble Aβ monomers and dimers from human AD by 
SEC. 
 
(A) Human AD TBS ext. was straight-loaded onto the Superdex 75 SEC column.  
The material that eluted at the void volume of the SEC column carried Aβ that 
separated into Aβ dimers and monomers by denaturing SDS-PAGE.  The dimer 
fraction contained mostly Aβ species that ran as dimers on SDS-PAGE and the 
monomer fraction contained mostly Aβ species that ran as monomers on SDS-
PAGE.  (B) Human AD TBS ext. was IP’ed with 3D6 anti-Aβ antibody and the 
immunoprecipitated was straight-loaded onto the Superdex 75 SEC column.  WB: 
2G3 and 21F12 antibodies (directed against Aβ31-40 and Aβ33-42, respectively; gift 
of Elan, plc.).  D: Aβ Dimers, M: Aβ Monomers.   207 
 
Figure A3.2. Aβ oligomers from 7PA2 cells reduced number of metabolically 
active cells, whereas Aβ monomers appeared to induce cell proliferation. 
 
The N9 cells were treated for 24 hours with fractions that contain mostly Aβ low n 
oligomers or mostly Aβ monomers from 7PA2CM at two doses (1X 
corresponding to 1-ml fraction, 0.1X corresponding to 0.1-ml fraction).  As a 
negative control, the SEC fraction from CHO-CM that corresponds to the dimer 
fraction of 7PA2CM was also applied onto the N9 cells.  24 hours later, the 
number of metabolically active cells was quantified using the WST-1 assay.  Aβ 
oligomers from 7PA2 cells reduced the number of metabolically active cells, 
whereas Aβ monomers appeared to induce cell proliferation.  N=2 experiments 
(in triplicates per experiment). 
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Figure A3.3. Soluble Aβ dimers from two human AD brains induce microglial 
proliferation and LDH release. 
 
The N9 cells were treated with Aβ dimer-containing fraction (dimer fxn), Aβ 
monomer-containing (monomer fxn), and the SEC fraction that eluted in the void 
volume which contained mostly Aβ dimers and monomers (void volume fxn).  24 
hours later, the number of metabolically active cells was quantified using the 
WST-1 assay and LDH release was measured in the conditioned media of the 
treated cells.  The cell proliferative effect and the stimulated LDH release were 
greatest and most consistent in the treatment with “free-floating” Aβ dimers, i.e., 
the dimer fxn, despite there being very little Aβ present (see Figure A3.1).  
Interestingly, Aβ monomers and dimers from the void volume fraction also 
induced cell proliferation, albeit in a much less concentration than the “free-
floating” dimers.  N=3 experiments for huAD TBS ext. #1; N=1 experiment for 
huAD TBS ext. #2; triplicates per experiment. 
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Figure A3.3 (Continued). Soluble Aβ dimers from two human AD brains induce 
microglial proliferation and LDH release. 
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Figure A3.4. Soluble Aβ dimers isolated from human AD brain by IP/SEC induce 
microglial activation and this effect is exacerbated when cells are primed with 
IFNγ. 
Only the Aβ dimers (isolated using IP/SEC) induced cell proliferative effect (A) 
and LDH release (C) from the N9 cells, whereas the monomers did not.  
Interestingly, they did not induce nitrite release (E), unless co-stimulated with 
IFNγ (F).  The Aβ monomers failed to induce any effect, unless cells were 
already primed with IFNγ.  N=2 experiments (in triplicates per experiment).
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Figure A3.5. Human AD brain-derived soluble Aβ dimers induce cell proliferation 
and several cytokines, and these effects are abolished upon Aβ immunodepletion. 
N9 cells treated for 24 hours with Aβ dimers from huAD TBS ext. (IP/SEC; IP’ed 
with AW8; ~5 pM) were quantified using the WST-1 and their conditioned media 
were assayed for various cytokines using the MesoScale 7-plex cytokine ELISA.  
Both the proliferative effect and induction of certain cytokines were abolished 
upon Aβ-immunodepletion (using the AW7 antibody).  The secretion of IL-12 
seem to be non Aβ-specific, and to some degree, IL-6 as well.  N=1 experiment. 
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Discussion 
In summary, the preliminary experiments suggest the following: (1) Aβ low 
n oligomers from 7PA2CM affect cell viability, whereas Aβ monomers induce cell 
proliferation; (2) soluble Aβ dimers alone induce microglial proliferation and LDH 
release, whereas monomers do not, and the proliferative effect is abolished upon 
Aβ-immunodepletion; and (3) the soluble Aβ by themselves do not induce nitrite 
release, unless primed with IFN-γ.  Furthermore, several cytokines also seem to 
be induced specifically with the soluble Aβ dimers derived from human AD brain 
(note, these are results from only one experiment).  We have attempted to repeat 
the findings multiple times with the human brain AD material; however, we have 
failed to do so.  One likely explanation for the failure to repeat the above findings 
is the heterogeneous level of purity of the Aβ dimers obtained with the IP/SEC 
technique from the huAD brains (with the additive variability coming from the 
human brain materials themselves) (Figure A3.6 shows silver stains of the 5 
different preparations and Table A3.1 summarizes the experimental results 
obtained from some of these preparations).  Another likely explanation is the 
contamination of the samples with endotoxin, which are known to robustly induce 
microglial activity (Weinstein et al., 2005), and therefore endotoxin could be 
masking the effects of Aβ in the fractions.  A removal of endotoxin contamination 
or attempt at its neutralization (for e..g, with polymyxin B) in the fractions may be 
necessary. 
In conclusion, to date, I was unable to repeat the preliminary findings.    213 
Nonetheless, I think the question, i.e., “Do microglia react different to natural Aβ 
dimers versus monomers at physiological concentrations?” is still an interesting 
one that remains unanswered in the AD field (especially as the field is limited in 
obtaining natural Aβ).  However, before the question can be pursued in an in vitro 
setting such as that attempted here, a considerable amount of work should be 
focused in obtaining relatively pure, homogenous and endotoxin-free Aβ samples 
from the human brain homogenates.  Even then, data obtained should be 
carefully evaluated in the most rigorous manner, as microglia are responsive to 
many agents that may be present in post-mortem tissue. 
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Figure A3.6. Heterogeneity in the IP/SEC fractions prepared from 5 different 
human brain materials (#1-5) shown by silver stain (A-F). 
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Table A3.1. Heterogeneity in the experimental results obtained from different 
IP/SEC fractions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IP/SEC 
Prep 
WST-1 results  # 
experiments 
Prep #2  No difference between monomer and dimer 
fractions 
2 
Prep #3  Inconsistent   4 
Prep #4  No difference between monomers and dimers   2   216 
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Appendix 4 
 
Development of an electrophoretic system for a better separation 
of proteins with molecular masses of 3-14 kDa 
 
 
 
 
 
 
 
 
Contributions to this Appendix: 
Experiments were designed by John Maggio, Dennis Selkoe and Soyon Hong.  
All experiments were performed by Soyon Hong. 	 ﾠ 221 
Aim:  To create an electrophoretic system for a better separation of proteins with 
molecular masses of 3-14 kDa while retaining a high resolving power. 
 
Variables considered/tested: 
(1) Gel composition: Tricine, Bis-Tris  
(2) Detergent: 2% LiDS, 2% AOT, 2% SDS  
(3) Running buffer: 0.1% SDS MES, 0.25% SDS MES, 0.1% AOT 
(4) % Acrylamide: 4-12, 12, 16, 20 
(5) % Cross-linker: 3.3, 5, 6 
(6) Gel length: Mini-gel, 20 cm 
(7) Gel thickness: 0.75, 1 mm 
(8) 10% “Spacer” gel: Considerably sharpens the bands for proteins and 
peptides of 1-5 kDa (Schägger, 2006) 
(9) 10% glycine in separating gel: Increased the density of solutions and 
facilitate gel casting, but had no obvious effect on protein separation. 
(10)  Urea 6M: For unknown reasons, urea seems to alter SDS-binding to 
proteins and while reducing the electrophoretic mobility of proteins in 
general, it enhances the resolution of very small proteins (to the peptide 
level) (Klafki et al., 1996). 
 
Results: 
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Figure A4.1. Migration table of the 3-14 kDa molecular weight markers in the 
different gels tested, in relation to the 3 kDa (1.0). 
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Figure A4.2. Separation of Aβ dimers and trimers, in relation to the monomers 
(1.0). 
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Figure A4.3. Gel composition for the 20-cm long 16% Tricine gel with 1-cm 
spacer gel, which provides optimal separation of Aβ monomers and dimers. 
 
   
Figure A4.4. Optimal separation of Aβ by the 20-cm 16% Tricine gel.  It also 
resolves Aβ monomer peptides, the Aβ40 and Aβ42 from the longer Aβ species.  
WB: 6E10.  D: Aβ Dimers, M: Aβ Monomers.  
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Figure A4.5. The powerful separation of the gel allowed a better distinction 
between the different APP cleavage products in the conditioned media of the 
7PA2 cells. 
(A) Antibodies used in the immunoprecipitation (IP) panel study.  
(B, C) The different Aβ peptides present in the conditioned media of 7PA2 cells 
as recognized by the respective antibodies.  WB: 6E10.	 ﾠ 226 
 
Figure A4.6. The heterogeneous pattern as recognized by the respective 
antibodies in the IP panel. 
 
 
Figure A4.7. The same materials in the IP panel as Figure A4.5 now run on a 
mini 12% Bis-Tris gel (Invitrogen Novex). 
 
 
 	 ﾠ 227 
Conclusion 
The 20-cm long 16% tricine gel with 1-cm spacer gel provided optimal resolution 
between Aβ monomers and low n oligomers; furthermore, it allowed separation 
between the Aβ monomer peptides available.  This gel may be a useful tool in 
studying the heterogeneity of APP processing, as shown in Figure A4.5, where it 
allowed for a better distinction between the different Aβ peptides present (as 
compared to Figure A4.7). 
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ThepathogenesisofAlzheimer’sdiseaseischaracterized byaggregation
of the amyloid-  protein (A ) into neurotoxic plaques. Recent in vivo
studieshavesuggestedthenon-proteolyticclearanceofA viareceptor-
mediated transport across the blood–brain barrier (BBB). The aim of
this study was to investigate the role of P-glycoprotein (Pgp) and the
low-density lipoprotein receptor-related protein (LRP) in A  efflux
acrosstheBBB.WedevelopedaninvitroBBB-likemodelusingMadin–
Darby Canine Kidney (MDCK) cells seeded on filters separating apical
(blood) and basolateral (brain) compartments. MDCK cells were
stably transfected with Pgp or mLRP4, an LRP mini-receptor. When
compared to empty vector-transfected cells, MDCK-Pgp cells did not
transcytose radiolabeled A  in the basolateral-to-apical direction.
MDCK-mLRP4 cells were found to endocytose and degrade, but not
to trasncytose intact radiolabeled A . These results implicate LRP
as a mediator of A  degradation, but indicate that overexpression of
LRP or Pgp alone is insufficient for non-proteolytic transcytosis of
intact A .
© 2008 Elsevier Inc. All rights reserved.
Keywords: Alzheimer’s disease; Amyloid-  protein; Blood–brain barrier;
Low-densitylipoproteinreceptor-relatedprotein;MDCKcells;P-glycoprotein
Introduction
Alzheimer’s disease (AD) is the most common cause of de-
mentia, with over 30 million people affected world-wide. A key
neuropathological lesion in AD, the neuritic plaque, consists of
extracellular deposits of the amyloid-  protein (A ). Accumula-
tion of A  is believed to initiate AD when there is an imbalance
between its production and clearance, leading to its aggregation
into oligomers and neuritic plaques (Hardy and Selkoe, 2002).
Research into therapeutic avenues to lower cerebral A  levels
has largely centered on decreasing its production by inhibiting the
proteases that generate A  (Selkoe and Schenk, 2003), increasing
its clearance through immunotherapy (Weiner and Frenkel, 2006),
or promoting its degradation by proteases such as insulin-de-
grading enzyme and neprilysin (Tanzi et al., 2004). In addition,
non-proteolytic clearance by receptor-mediated transport of A 
out of the CNS has been investigated as another potential me-
chanism for decreasing cerebral A  load. Two pathways for A 
transport out of the CNS exist: bulk flow (Silverberg et al., 2003)
of interstitial fluid (ISF) into the blood via the cerebrospinal
fluid (CSF), and transcytosis of A  across the blood–brain barrier
(BBB). It has been reported that CSF-mediated bulk flow accounts
for no more than 10–15% of non-proteolytic transport of A  out
of the CNS in vivo (Shibata et al., 2000), leaving the BBB as the
main route of efflux. The BBB is distinct from other cell barriers
by its increased tight junction density, lower rates of non-selective
pinocytosis, lack of fenestrations, and unique cell surface recep-
tor expression profile (Rubin and Staddon, 1999). A few such
receptors for A  transport have been described (Zlokovic, 2004).
Low-density lipoprotein receptor-related protein (LRP) is a
~600 kDa multi-ligand cell surface receptor that is highly ex-
pressed in brain and contains four extracellular ligand-binding
domains (designated I–IV). Over 30 different ligands for LRP have
been reported and include the classes: lipoproteins, coagulation
factors, growth factors, extracellular matrix proteins, chaperones,
and bacterial/viral proteins. The majority of LRP ligands bind to
domains II and IV with equal affinity (Cam and Bu, 2006).
Investigation into LRP’s role in AD was stimulated by genetic
evidence linking the LRP gene to late-onset AD (Kang et al.,
1997). Zlokovic and colleagues first reported LRP’s effects on A 
efflux, showing that the in vivo clearance of radiolabeled A 
peptides injected into the brains of mice was inhibited by co-
injection with the endogenous inhibitor receptor-associated peptide
(RAP) and by an anti-LRP antibody (Shibata et al., 2000). In vivo
studies of LRP’s potential for effluxing A  are promising, but they
do not identify the biochemical mechanism of the apparent trans-
cytosis of intact A  across the endothelial cells of the BBB.
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doi:10.1016/j.nbd.2007.12.005Moreover, as a member of the LDL receptor family, LRP is
primarily an endocytic receptor and is not generally known to
transcytose its ligands, most of which are degraded in lysosomes
after endocytosis (Krieger and Herz, 1994).
P-glycoprotein (Pgp) is a 170 kDa single-transmembrane
protein known for its role in resistance to chemotherapeutic drugs
(Sharom, 1997). In vivo work has shown that PGP-null mice clear
microinjected [
125I]A  out of the CNS at half the rate of wt mice
and that A  increases within brain ISF after treatment with a
Pgp inhibitor (Cirrito et al., 2005). As with LRP, the mechanism
of Pgp-mediated A  efflux is unknown and has not been studied
in controlled culture models of the BBB. All known substrates of
Pgp are small molecules and cytosolic, whereas A  is a peptide
and is not known to exist in the cytosol. While in vivo work
has thus generated much excitement with regard to the poten-
tial of LRP and Pgp to efflux cortical A , elucidating the mole-
cular mechanisms of these effects through well-controlled in vitro
models should help to promote rational therapeutic design.
Madin–Darby canine kidney (MDCK) cells are routinely used
as a model of polarized protein sorting and trafficking (Irvine
et al., 1999), and have been used previously to investigate po-
larization of amyloid-  precursor protein (APP) and its proteolytic
products, A  and the secreted ectodomain, APPs (Haass et al.,
1994). An in vitro model of a polarized epithelial barrier ha-
ving tight intercellular junctions can be created by plating MDCK
cells onto a porous polycarbonate filter, separating apical (AP)
and basolateral (BL) compartments of medium, representing the
brain and blood compartments, respectively, of a BBB-like bar-
rier. MDCK monolayers plated in this manner have been used to
investigate transcytosis of cell-surface proteins (Brandli et al.,
1990), as well as antibody-antigen complexes (Hunziker and
Mellman, 1989). MDCK monolayers have been used to simulate
transport across the BBB (Garberg et al., 2005; Gumbleton and
Audus, 2001). Despite its epithelial origin, this polarized, im-
mortalized and impermeable system provides a manipulable
model for investigating the effects of Pgp and LRP on A  BBB
transport.
Materials and methods
Cell culture
MDCK wt cells (ATCC, Manassas, VA) were grown in DMEM
with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100  g/ml
streptomycin and 20 mM HEPES buffer. MDCK cells stably
transfected with Pgp (MDCK-Pgp) or empty vector (MDCK-
Parental) were the generous gift of Dr. P. Borst (Bakos et al., 1998).
MDCK-Pgp cells were grown in the same media as MDCK wt
cells and replaced with frozen stocks after one month of passage.
MDCK cells stably transfected with mLRP4 (MDCK-mLRP4),
an LRP-minireceptor which contains the native C-terminus and
transmembrane domain, a N-terminal hemagglutinin (HA) tag, but
only one (IV) of its four ligand-binding domains (Obermoeller-
McCormick et al., 2001), were the generous gift of Dr. M. Marzolo
(Marzolo et al., 2003). MDCK-mLRP4 cells were grown in the
same media as MDCK cells, with the addition of 200  g/ml G418.
An immortalized human brain endothelial cell line, HCMEC/D3
(Weksler et al., 2005), was generously provided by Dr. B. Weksler,
and grown in EGM-2 endothelial cell media (Lonza Group, Basel,
Switzerland) on dishes coated with 50  g/ml rat tail collagen I
(BD Biosciences, Franklin Lakes, NJ).
In vitro transwell MDCK model
MDCK cells were plated onto 6.5 mm diameter Transwell
filters (Corning Life Sciences, Acton, MA) with 0.4  m pores at a
seeding density of 1 10
5 cells per filter. Media was changed daily,
with 100  l in the apical (AP) compartment and 600  l in the
basolateral (BL) compartment. Trans-epithelial electrical resistance
(TEER) was measured using an EVOM epithelial volt-ohmmeter
with STX2 electrodes (World Precision Instruments, Sarasota, FL).
Background resistance across a non-seeded filter was subtracted
from the TEER measurements. Models were used for A  transport
experiments on day 5. [
125I]A 40,[
14C]Inulin or [
3H]Verapamil
(GE Healthcare Bio-sciences, Piscataway, NJ) were added to the
media in the BL side of the Transwell filters at concentrations
of 1 nM, 0.5  Ci/ml and 1  Ci/ml, respectively. For inhibition of
Pgp, 25  g/ml RU-486 (Biomol International, Plymouth Meeting,
PA) was added to AP and BL media immediately before trans-
port experiments. At each timepoint, 10  l samples of AP and BL
medias were counted on a Cobra II Auto-Gamma scintillation
counter (Packard Biosciences, Shelton, CT) for
125I, or on a
Beckman-Coulter LS6500 scintillation counter (Beckman-Coulter,
Fullerton, CA) for
14C or
3H. To determine the amount of intact
radiolabeled peptide, 50  l of 15% trichloroacetic acid was added
to a 50  l sample of media and centrifuged at 10,000 g for 10 min.
Supernatant (degraded peptide) and pellet (intact peptide) were
counted separately for [
125I].
Transport of each compound across the monolayers was cal-
culated as the percentage of the total counts per minute that were
detected in the AP compartment. For A  transport, to control for
paracellular leak in each Transwell monolayer, both [
14C]inulin
and [
125I]A  were added to BL compartments, and an A  clearance
quotient (A  CQ) was calculated as below:
Ah CQ  
125I
  
AP= 125I
  
AP   125I
  
BL
  
14C
  
AP= 14C
  
AP   14C
  
BL
  
Polarized cell surface biotinylation and gel electrophoresis
MDCK wt or MDCK-mLRP4 cells were plated onto 24 mm
diameter Transwell filters with 0.4  m pores at a seeding density of
1 10
6 cells per filter and grown for five days with 1.5 ml AP and
2.5 ml BL media. Monolayers were washed on both sides with cold
PBS with Ca
2+ and Mg
2+ (PBS
++) four times. EZ-link Sulfo-NHS-
SS-biotin (Pierce Biotechnology, Rockford, IL) was dissolved to
1 mg/ml in cold HBSS and 1 ml was added to either AP or BL
compartments. One ml PBS
++ was added to the non-biotinylated
side. Monolayers were rocked for 1 h at 4 °C, and 50  l quenching
solution (Pierce) was added to the biotinylated side. Cells were
scraped and lysed in 1% NP40 lysis buffer with protease inhibi-
tors. After normalizing for total protein concentrations using a
bicinchoninic assay (Pierce), the cell lysate was precipitated with
1 ml immobilized NeutrAvidin gel (Pierce) per 3 mg total protein
overnight with mixing at 4 °C. Immobilized Neutravidin gel was
centrifuged at 2500 g for 2 min. Biotinylated proteins were eluted
with SDS-PAGE sample buffer with 50 mM DTT.
Samples were electrophoresed on an 8% Tris–Glycine gel
(Invitrogen, Carlsbad, CA) and immunoblotted with 3F10 rat mo-
noclonal anti-HA antibody (Roche, Basel, Switzerland) for detec-
tion of mLRP2, or C219 monoclonal mouse anti-Pgp antibody (ID
Labs, London, Ontario).
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For detection of LRP, HCMEC/D3, HUVEC, MDCK wt and
MDCK-mLRP4 cells were cultured to 80% confluency on 150-mm
plates. Cells were washed three times with cold PBS with Ca
2+ and
Mg
2+, and were lysed in 300  l of 1% Triton X-100 (Sigma) lysis
buffer with 1 mM PMSF and protease inhibitors (Roche). Total
proteinwasquantifiedusingbicinchoninicacidproteinassay(Pierce).
20  g of cell lysates were boiled at 100 °C for 5 min in a 4x lithium
dodecyl sulfate (LDS) sample buffer containing 50 mM DTT, then
were electrophoresed at 200 Von a 9-well 4–12% Bis–Tris gel for
35 min in a MES SDS running buffer (Invitrogen). Proteins were
transferred onto 0.2  m nitrocellulose membranes, probed with
MMMM, a rabbit polyclonalanti-LRPtailantibody (kindly provided
by Dr. G. Bu), and detected using the LiCor Odyssey Infrared
Imaging System.
For immunoprecipitation of LRP, lysates of HCMEC/D3 cells
from 150-mm plates were prepared in 1 ml non-denaturing lysis
buffer (20 mM Tris HCl pH 8 containing 137 mM NaCl, 10%
glycerol, 1% Nonidet P-40 (NP-40) and2 mM EDTA)with protease
inhibitors (Roche). 300  l of lysate was pre-cleared with 20  l
protein A-coupled sepharose (PAS) beads (Sigma) and 20  l protein
G-coupled agarose (PGA) beads (Roche) for 1 h under rotary
agitation at 4 °C. Non-specifically bound proteins to beads were
removed by centrifugation and supernatants were incubated with
5A6, an anti-LRP light-chain mouse monoclonal antibody (Calbio-
chem) and 15  l each of PAS and PGA beads at 4 °C under rotary
agitationovernight.Beadswerethencentrifugedandwashedinlysis
buffer three times. After the final wash, pellet was boiled at 100 °C
for 5 min in 2X LDS sample buffer containing 50 mM DTT
(Invitrogen) to denature and reduce the protein, and to separate it
from the beads. The samples were centrifuged, and supernatants
were electrophoresed to detect LRP via WB as described above.
FACS-based A  endocytosis assay
HCMEC/D3, MDCK wt or MDCK-mLRP4 cells were plated
onto 6-well dishes at a seeding density of 1 10
5 cells per well and
allowed to grow overnight. 500 nM RAP (Oxford Biomedical
Research, Oxford, MI) was added to inhibit LRP activity in some
wells. At this concentration, RAP is most selective for inhibition of
LRP, while minimizing cross-inhibition of receptors in the same
family, VLDL-R and LDL-R (Holtzman, personal communication).
100 nM fluorescently-labeled HiLyte Fluor 555-A 1–40 or HiLyte
Fluor 488-A 1–42 (AnaSpec, San Jose, CA) were added at various
timepoints,andcellswerewashedtwicewithPBSandthenremoved
from the plate using 0.25% trypsin/EDTA solution. Cells were
centrifuged at 800 g for 5 min, and resuspended in 100  l PBS with
10% BSA. Five  l 7-amino-actinomycin D (7-AAD; BD Bios-
ciences) was added for 10 min prior to analysis to control for cell
viability. 1 10
5 cells from each sample were analyzed for fluo-
rescence on a BD FACSCalibur machine (BD Biosciences). Un-
stained cells without any exposure to fluorescently-labeled A  were
used as a control for background fluorescence, and A  uptake was
quantified as the percentage of non-7-AAD-containing cells in each
sample above the background level of fluorescence.
Radioactivity-based A  endocytosis assay
HCMEC/D3, MDCK wt or MDCK-mLRP4 cells were plated as
in the FACS-based assay above. 1 nM [
125I]A  was added to each
well at various timepoints, and cells were removed as in the FACS-
based assay. Cell pellets were lysed in 100  l of 1% NP40 lysis
buffer with protease inhibitors. 10  l samples of the lysate were
analyzed for [
125I] counts, and 50  l was precipitated with 50  l
TCA as described above for analysis of peptide degradation.
Statistical analysis
Data was analyzed using a one-way ANOVAwith Tukey’s post
hoc comparison or a two-way ANOVA with Bonferroni post hoc
comparison, where appropriate. Calculated comparisons of pb0.05
were considered significant.
Results
Assessment of Transwell MDCK model of the BBB
In order to simulate the integrity of the BBB, an in vitro model
must demonstrate adequate tight junction formation as well as
impermeability to macromolecules. To assess the former, the trans-
epithelial electrical resistance (TEER) of Transwell MDCK
monolayers was measured daily after plating, reaching an average
of 85.8±0.60  *cm
2 (mean±SD; n=22) after 5 days (Fig. 1A). As
with most in vitro BBB models, this value falls far short of
Fig. 1. BBB-like characteristics of the MDCK Transwell model. A, Trans-
epithelialelectricalresistance.TEERincreasesdailywithmonolayergrowth.
Data are mean±SEM (n=22 independent Transwell filters). B, [
14C]Inulin
and [
125I]A  permeabilities. Both radiolabeled compounds freely diffuse
across non-seeded Transwell filters such that half of the BL-added CPM are
found in the AP compartment by 12 h. In contrast, less than 3% of each
moleculeisabletocrossMDCKmonolayersafter48h.Datashownaremean±
SD (n=3 at each time point).
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2 (mean±
SD;n=40)(CroneandOlesen,1982),butitisgreaterthanachievedin
most endothelial cell in vitro models (Garberg et al., 2005). TEER of
MDCK cells transfected with Pgp or mLRP4 was not significantly
different from that of MDCK wt cells (data not shown).
The inert polysaccharide, inulin (1.7 kDa) is routinely used as a
control for paracellular leak in models of epithelial and endothelial
barriers given its lack of active, receptor-mediated transport. [
14C]
Inulin was added to the BL side of MDCK cell-seeded and non-
seeded control Transwell filters, and radioactivity of media on both
sides was counted at 2, 6, 12, 24 and 48 h. At 48 h, MDCK cell-
seeded BBB models remained quite impermeable to inulin, with
only 2.3% of [
14C]inulin counts crossing to the AP compartment
compared to 50.3% that freely diffuses across non-seeded filters
(Fig. 1B). To determine the ability of MDCK wt cells to transport
A , the same experiment was performed with [
125I]A 40, with
2.7% crossing MDCK cell-seeded filters compared to 49.1% ac-
ross non-seeded controls (Fig. 1B). The high TEER values and
low [
14C]inulin permeability across MDCK wt cells indicates that
MDCK Transwell monolayers provide a BBB-like model with low
paracellular leak for the investigation of macromolecular transport.
Furthermore, because permeability of MDCK wt monolayers to
inulin and A  was similar, these cells represent a manipulable
model in which transfection with LRP, Pgp, or other potential A 
transporters can be shown to promote A  transport across the BBB,
elucidating its mechanism.
Fig. 2. Pgp upregulation does not promote A  transcytosis. A, Western blot of Pgp from whole cell lysatses of MDCK-Pgp and MDCK-Parental cells showing
increased Pgp expression the former. B, Transport of [
3H]verapamil across MDCK-Pgp and MDCK-Parental Transwell monolayers. MDCK-Pgp cells express
functionalPgp as evidenced by increased BL-to-AP transport of [
3H]verapamil across their monolayers comparedto that of MDCK-Parental cells (pb0.001at 2,
6 and 24 h). RU-486, a pharmacological Pgp inhibitor, eliminated this difference when added to MDCK-Pgp monolayers (pb0.001 at 2, 6 and 24 h).
C, Transport of [
125I]A  across MDCK-Pgp and MDCK-Parental monolayers. MDCK-Pgp monolayers do not exhibit greater BL-to-AP transport of [
125I]A 
than MDCK-Parental monolayers. (pN0.05 at each timepoint). D, A  clearance quotient, which controls for paracellular leak by dividing A  transport by inulin
transport, is not significantly different between MDCK-Pgp and MDCK-Parental monolayers (pN0.05 at each timepoint). Data shown are mean±SEM (n=3 at
each time point).
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Expression of Pgp by MDCK-Pgp cells was verified by Western
blotting. Pgp expression was significantly greater in the MDCK-
Pgp cell line, although some expression was seen in the empty
vector-transfected (MDCK-Parental) line (Fig. 2A). This was like-
ly due to cross-reacting endogenous expression of canine ABC-
family transporters including Pgp, as seen previously (Lalloo et al.,
2004).
Verapamil, a known substrate for Pgp that is preferentially
effluxed across the BBB by this transporter, was used to determine
functional expression of Pgp in the cells. [
3H]Verapamil was added
to the BL compartment of Transwell filters of MDCK-Pgp and
MDCK-Parental monolayers. After 6 h, 60.0% of [
3H]verapamil
had been transported to the AP compartment of MDCK-Pgp mo-
nolayers, as compared with 47.4% for MDCK-Parental mono-
layers. When RU-486, a pharmacological inhibitor of Pgp, was
added to MDCK-Pgp monolayers, the 6 h transport was rescued to
Fig. 3. mLRP4 expression promotes A  uptake and intracellular degradation, but not transcytosis. A, Western blot of mLRP4 in whole cell lysates, and in
apically and basolaterally biotinylated of MDCK-mLRP4 cells on Transwell filters after precipitation with immobilized neutravidin. MDCK-mLRP4 cells
expressboth matureandimmatureformsof theminireceptoron theBLsurface,but onlythe immature,unprocessedformonthe APsurface.B, Transport of[
125I]
A  across MDCK-mLRP4 and MDCK wt monolayers. MDCK-mLRP4 monolayers exhibit greater BL-to-AP transport of [
125I] counts than MDCK wt
monolayers (pb0.05 at 12 h, pb0.001 at 24 and 48 h). C, A  clearance quotient is significantly higher for MDCK-mLRP4 than for MDCK wt monolayers
(pb0.05 at 12 h, pb0.001 at 24 and 48 h). D, TCA precipitation of BL media. MDCK-mLRP4 monolayers degraded significantly more of the [
125I]A  that was
added to the BL compartment than MDCK wt monolayers (pb0.001 at 48 h), accounting for the increased transport of [
125I] counts seen in (B) and (C). E, TCA
precipitation of AP media. 48 h after adding 1 nM [
125I]A  to the BL compartments, nearly all [
125I] counts that crossed MDCK-mLRP4 or MDCK wt
monolayers were due to degraded peptide fragments. Data shown are mean±SEM (n=3 at each time point). Error bars in D and E are present, but too small to be
seen.
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results indicate functional expression of Pgp in the MDCK-Pgp cell
line. The high background level of [
3H]verapamil transport in
MDCK-Parental cells and after RU-486 treatment of MDCK-Pgp
cells is presumably due to passive paracellular and transcellular leak
ofthesmallmolecule,aswellastoactivityofotherendogenousABC-
family transporters, many of which are not inhibited by RU-486.
To determine the ability of Pgp to transcytose A , 1 nm [
125I]A 
was added to the BL compartment of MDCK-Pgp and MDCK-
Parental control Transwell monolayers. After 48 h, there was very
little transport of [
125I] counts from the BL to AP compartment in
both the MDCK-Pgp and MDCK-Parental monolayers (0.56% vs
0.47%, pN0.05) (Fig. 2C). There was also no significant difference
in the A  clearance quotient (Fig. 2D), indicating that all of the
apically-localized A  was due to paracellular leak and that up-
regulation of Pgp alone is insufficient to promote A  transcytosis
across this in vitro BBB model.
MDCK–mLRP4 BBB models
MDCK cells stably expressing the LRP minireceptor, mLRP4, or
non-transfected controls (MDCK wt) were plated on Transwell filters.
To determine expression and polarity of mLRP4, the AP and BL sides
of the monolayers were biotinylated separately, and plasma membrane
proteins were precipitated with neutravidin and analyzed by Western
blotting.LRP and itsminireceptors are known to be cleaved by furin to
yield the mature, functional version of the receptor (Obermoeller-
McCormick et al., 2001). Both immature and mature forms were
expressedon the BLsurface ofourTranswellBBB model,butonlythe
immature form was expressed on the AP surface (Fig. 3A).
Fig. 4. LRP mediates A  endocytosis and intracellular degradation. A, [
125I] CPM in MDCK-mLRP4 and MDCK wt cell lysates after 24 h exposure to 1 nM
[
125I]A . Significantly more[
125I]A was endocytosed byMDCK-mLRP4cells thanbyMDCK wt cells (pb0.01).B, TCAprecipitationof MDCK-mLRP4and
MDCK wt cell lysates after 24 h exposure to 1 nM [
125I]A . Significantly more intracellular degradation occurred in MDCK-mLRP4 cells than in MDCK wt
cells (pb0.01). C, Western blot of LRP light chain in whole cell lysates (20  g total protein) of HCMEC/D3, HUVEC, MDCK wt, and MDCK-mLRP4 cells.
D, Western blot of MMMM-immunoprecipitated LRPlight chain fromHCMEC/D3 cell lysates (100 g total protein), andnon-precipitated LRP light chainfrom
whole cell lysates (20  g total protein) of MDCK-mLRP4 and MDCK wt cells. E, [
125I] CPM in HCMEC/D3 endothelial cell lysates after 24 h of exposure to
1 nM [
125I]A  in the presence or absence of 500 nM RAP. [
125I]A  endocytosis was significantly inhibited by inhibition of LRP activity by RAP (pb0.01).
F, TCA precipitation of HCMEC/D3 cell lysates after 24 h exposure to 1 nM [
125I]A  in the presence or absence of 500 nM RAP. [
125I]A  degradation was
significantly inhibited by RAP (pb0.01) Data are mean±SEM (n=3).
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125I]A 
was added to the BL compartment of MDCK-mLRP4 and MDCK
wt Transwell monolayers. After 48 h, 11.8% of total [
125I] counts in
MDCK-mLRP4 Transwell monolayers were found in the AP com-
partment, compared to 4.0% in MDCK wt monolayers (Fig. 3B).
The A  clearance quotient was significantly higher for MDCK-
mLRP4 monolayers than for MDCK wt monolayers (Fig. 3C),
indicating a selective transport of [
125I]A . However, when AP and
BL media were precipitated with TCA to quantify the intact A 
peptide,wefoundthat81.9%ofthe[
125I]A intheBLcompartment
of MDCK wt monolayers at 48 h was still intact, whereas only 9.6%
remained intact at 48 h in the BL compartment of the MDCK-
mLRP4monolayers (Fig.3D). Inthe APcompartments, virtually all
of the [
125I] counts that reached this compartment represented
degraded peptide in both the MDCK wt and MDCK-mLRP4 mo-
nolayers (Fig. 3E), suggesting that only fragments of A  efficiently
cross the in vitro barrier from the BL to AP side. These findings
suggestthattheoverexpressionofLRPontheBLplasmamembrane
promotes A  degradation, but alone is insufficient to promote the
transcytosis of the intact peptide, as would be required for non-
proteolytic efflux of A  across the barrier.
LRP-mediated A  endocytosis and degradation
The reported role of LRP for all studied ligands besides A  is to
bind, endocytose and facilitate their degradation. In accord with
these data, expressing mLRP4 on the BL plasma membrane in
our MDCK monolayer resulted in no LRP-mediated transport of
intact [
125I]A , but rather transport of [
125I]-bearing cleaved peptide
fragments. To directly address this process, MDCK wt and MDCK-
mLRP4 cells were grown in conventional cultures and exposed to
1 nM [
125I]A . At 24 h, the cells were washed to remove surface
peptide, lysed and samples of the lysate counted for internalized
[
125I]. We found that [
125I]A  uptake was markedly greater in
MDCK-mLRP4 than MDCK wt cells (1543 vs 166 CPM; Fig. 4A).
Samples of the lysate (Fig. 4B) were then precipitated with TCA to
determine the percentage of intact A . In MDCK-mLRP4 cultures,
significantly more intracellular A  had been degraded by 24 h
compared with MDCK wt cultures (74.7 vs 7.1%) (Fig. 4B).
While the MDCK monolayer presents a polarized, impermeable
and manipulablesystem forthe investigation of LRP’seffectson A 
transcytosis, it is not of endothelial origin. To determine the effects
of LRP on A  endocytosis and degradation in an endothelial cell
culture, immortalized HCMEC/D3 cells, which are of human brain
endothelial origin, were used in a similar experiment. First, we
determined LRP expression in HCMEC/D3 cells, as well in the
positive controls human umbilical vein endothelial cells (HUVEC)
and MDCK-mLRP4 cells by western blotting with MMMM rabbit
polyclonal anti-LRP light chain antibody. A faint 85 kDa band was
seenintheHCMEC/D3lane(Fig.4C),consistentwithexpressionof
the LRP light chain. This expression was verified by immunopre-
cipitation ofthe LRPlight chain withMMMM, and western blotting
with 5AG, a mouse monoclonal anti-LRP light chain (Fig. 4D).
HCMEC/D3 cells were incubated with 1 nM [
125I]A  in the
presence or absence of 500 nM RAP to inhibit endogenous LRP
activity.[
125I]A uptake (33vs737 CPM)(Fig.4E) anddegradation
(2.3 vs 44.2%) (Fig. 4F) were decreased in the presence of RAP.
As with primary endothelial cells and other immortalized endothe-
lial lines, when these cells were seeded onto Transwell filters, they
failed to achieve adequate TEER or inulin impermeability to allow
investigation of A  transcytosis (data not shown).
Theoretically, a radiolabel could alter the physiologic function
or activity of a peptide. To further confirm the ability of LRP to
promote A  endocytosis by using a different label on the peptide,
fluorescently-labeled A  was added to MDCK-mLRP4 and MDCK
wt cells in culture at various time points, and the fluorescent cells
that had endocytosed A  were counted using FACS. As with the
radiolabeled A , the uptake of HiLyte Fluor 555-A 1–40 was time-
dependent and significantly greater with MDCK-mLRP4 cells than
with MDCK wt cells (42.7% vs 8.41% at 24 h) (Fig. 5A). Addition
of RAP significantly decreased A  uptake by MDCK-mLRP4 cells
down to 29.5% at 24 h (Fig. 5A). Similar results were obtained for
uptake of fluorescently-labeled A 42 (data not shown).
Finally, HCMEC/D3 cells were used in the same FACS-based
A  uptake assay. Their A 40 uptake was also time-dependent and
significantly inhibited by RAP (Fig. 5B).
Discussion
As the A  hypothesis has gained increasing acceptance as the
apparent mechanism of AD pathogenesis, investigation surround-
ing potential strategies to chronically decrease cortical A  levels
has intensified. Of several such approaches, the non-proteolytic
clearance of A  by efflux across the BBB is perhaps the least
studied, and the biochemical basis for this phenomenon is unclear.
The promising in vivo work identifying Pgp and LRP as potential
A  efflux pumps needs to be followed up using controlled in vitro
Fig. 5. FACS-basedanalysisoffluorescently-labeledA 40uptake.A,MDCK-
mLRP4 cells exhibit greater time-dependent uptake of fluorescent A  than do
MDCK WT cells. This effect of LRP activity was partially reversed by the
additionof500nMRAP.B,HCMEC/D3cellsalsoexhibittime-dependentA 
uptake that is inhibited by co-administering 500 nM RAP. 1 10
5 cells from
each cell population were counted.
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transport of A  across cell barriers by these proteins.
The MDCK in vitro model we principally used here, while of
epithelial rather than endothelial origin, is a useful tool for the mecha-
nistic investigation of potential A  transporters across tight monolayer
barriers. These cells readily form monolayers that are polarized and
impermeable to macromolecules—two properties that are vital to in-
vestigation of A  transcytosis, and that have not been readily repro-
ducedinmanyendothelialBBBmodels.Furthermore,MDCKcellscan
betransfectedwithPgp,LRPminireceptors,orothergeneproductsthat
may be implicated in the process of A  efflux across the BBB.
Inourstudy,MDCKcellsstablyoverexpressingPgpdidnotexhibit
any increased transport of [
125I]A  across their monolayers when
comparedwithMDCKcellstransfectedwithemptyvectorandcultured
identically. Although they functionally expressed Pgp, as evidenced by
the efficient efflux of [
3H]verapamil that was inhibited by RU-486, the
upregulationofPgpalonewasnotsufficienttopromoteA transcytosis
as has been suggested by in vivo experiments in which Pgp-null mice
clear CNS-injected A  at a lower rate than did wt mice, and in which
administration of a Pgp inhibitor increased A  levels in the brain ISF
within hours (Cirrito et al., 2005). Because Pgp is a transporter whose
ligandsarealmostexclusivelysmallmolecules(nopeptidesubstratesof
Pgp have been identified), it is not surprising that the pump itself is
unable to transport a 4 kDa peptide such as A . It is possible that Pgp
functions in conjunction with another transporter or requires an as-yet-
unidentified cofactor for A  transcytosis such that its inhibition or
deletion in vivo inhibited A  clearance and increased cortical A  levels
but its upregulation failed to promote A  efflux in our cellular model.
In our MDCK-mLRP4 model, LRP activity led to the uptake and
degradation of [
125I]A  from the BL compartment, but not to trans-
cytosisoftheintactpeptideinitsintactform,ashasbeensuggestedby
the results of in vivo experiments (Shibata et al., 2000). As with Pgp,
the effects of LRP seen in our study are more congruent with its
accepted biological mechanism—as an endocytic receptor that
usually leads to degradation of its ligands. Any role it may have in
transcytosing intact A  across the BBB, as in the case with Pgp, may
requireaco-transporter,oradownstreammolecule.Nevertheless,our
resultsclearlyimplicateLRPasameansofpromotingA degradation
and help to explain the apparent relationship between down-
regulation of LRP and progression of AD pathology in humans
(Deane et al., 2004). Although it has been shown that complexes of
A  and its binding partner  2-macroglobulin can be endocytosed by
LRP(Kangetal.,2000),wedemonstratetheabilityofLRPtonotonly
endocytose,butalsoleadtothedegradationofthepathologicpeptide.
There currently exists a disconnect between the accepted bio-
logical mechanisms of Pgp and LRP, with which our in vitro
experiments are consistent, and the in vivo findings regarding LRP-
and Pgp-mediated A  efflux across the BBB in rodents. More in
vitro workon these two transporters and others that mayserve asco-
transporters in A  efflux may help to reconcile these differences. A
compelling in vitro BBB model is invaluable to such efforts. While
currentendothelialmonolayersystemsneedtobeimprovedtocreate
more impermeable and physiologic BBB models, the MDCK
Transwell model described here is an impermeable, polarized and
biochemically readily manipulable system for such invenstigations.
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SUMMARY
InAlzheimer’sdisease(AD),theimpairmentofdeclar-
ative memory coincides with the accumulation of
extracellularamyloid-bprotein(Ab)andintraneuronal
tau aggregates. Dementia severity correlates with
decreased synapse density in hippocampus and
cortex.Althoughnumerousstudiesshowthatsoluble
Ab oligomers inhibit hippocampal long-term potenti-
ation, their role in long-term synaptic depression
(LTD) remains unclear. Here, we report that soluble
Ab oligomers from several sources (synthetic, cell
culture, human brain extracts) facilitated electrically
evoked LTD in the CA1 region. Ab-enhanced LTD
was mediated by mGluR or NMDAR activity. Both
forms of LTD were prevented by an extracellular
glutamate scavenger system. Ab-facilitated LTD
was mimicked by the glutamate reuptake inhibitor
TBOA, including a shared dependence on extracel-
lular calcium levels and activation of PP2B and
GSK-3 signaling. In accord, synaptic glutamate
uptake was signiﬁcantly decreased by soluble Ab.
We conclude that soluble Ab oligomers perturb
synaptic plasticity by altering glutamate recycling at
the synapse and promoting synapse depression.
INTRODUCTION
Alzheimer’s disease (AD), the most common neurodegenerative
disorder, is characterized by progressive memory and cognitive
impairment and cerebral accumulation of extracellular amyloid
plaques and intraneuronal neuroﬁbrillary tangles. Although the
speciﬁc molecular initiators of AD remain unknown in most
patients, extensive research suggests that the amyloid b protein
(Ab) plays an early and essential pathogenic role. Of note,
dementia severity in AD correlates more strongly with cortical
levels of soluble Ab species than with insoluble amyloid plaque
burden (Lue et al., 1999; McLean et al., 1999). Experimentally,
soluble Ab oligomers have been speciﬁcally shown to block
hippocampal long-term potentiation (LTP), an electrophysiolog-
ical correlate of learning and memory (e.g., Lambert et al., 1998;
Walsh et al., 2002; Wang et al., 2002; Townsend et al., 2006;
Shankaret al.,2008). Inaccord, impairmentof synaptic plasticity
can be detected in vivo before the formation of insoluble Ab
deposits in APP transgenic mouse models (e.g., Hsia et al.,
1999; Mucke et al., 2000). Synthetic Ab aggregates have been
reported to inhibit N-methyl-D-aspartate receptor (NMDAR)-
dependent LTP, but not NMDAR-independent LTP (Chen et al.,
2002; Wang et al., 2004a; but see Raymond et al., 2003). This
ﬁnding is consistent with evidence that Ab can affect surface
expression of NMDARs (Snyder et al., 2005; Dewachter et al.,
2009) and may increase (Molna ´r et al., 2004; Wu et al., 1995)
or decrease (Chen et al., 2002; Raymond et al., 2003) NMDAR
conductance.
A principal neuropathological ﬁnding in AD subjects is cortical
atrophy associated with degeneration of neurites, decreased
dendritic spine density, and frank neuronal loss (Terry et al.,
1991; Knobloch and Mansuy, 2008). Anatomical studies in
normal rodents suggest that the induction of LTP is associated
with spine formation and increased spine volume, whereas the
induction of long-term synaptic depression (LTD) results in
decreased spine volume and spine elimination (Matsuzaki et al.,
2004; Na ¨gerl et al., 2004; Zhou et al., 2004; Bastrikova et al.,
2008). Similar to LTP, the induction of LTD in the CA1 region of
hippocampus requires activation of NMDAR and/or metabo-
tropic glutamate receptors (mGluR), depending on the stimula-
tion protocol and recording conditions (Kemp and Bashir,
2001; Anwyl, 2006; Citri and Malenka, 2008). Mechanistically,
synapse potentiation versus depression may ultimately depend
on alterations in cytosolic Ca
2+ concentration and the differential
activation of certain kinases and phosphatases, including p38
mitogen-activated protein kinase (MAPK) and calcineurin
(protein phosphatase 2B [PP2B]) (reviewed in Kemp and Bashir,
2001; Citri and Malenka, 2008).
Although numerous reports describe the effects of soluble Ab
species on LTP, only a few studies have examined LTD induc-
tion, and they have yielded inconsistent results. For example,
synthetic Ab peptides were reported to facilitate LTD induction
in an NMDAR-dependent manner in vivo (Kim et al., 2001),
whereasotherstudiesfoundnoeffectonLTDinslices(Raymond
et al., 2003; Wang et al., 2002, 2004a). We recently extracted
buffer-soluble Ab directly from the brains of typical AD patients
and showed that this extract, which contains soluble Ab dimers
and trimers, facilitated LTD induction in the CA1 region of mouse
hippocampus by an mGluR-dependent mechanism (Shankar
et al., 2008). Given that both NMDAR and mGluR activation
have been implicated in the effects of Ab on LTD, we asked
788 Neuron 62, 788–801, June 25, 2009 ª2009 Elsevier Inc.whether glutamate clearance mechanisms are perturbed by Ab.
In addition to affecting synaptic plasticity, excitotoxic effects of
glutamate are believed to contribute to progressive neuronal
loss in AD (Pomara et al., 1992; Harkany et al., 2000). Further-
more, gene expression and protein levels of excitatory amino
acid transporters (EAAT1 and EAAT2) are altered in the hippo-
campus and frontal cortex of AD subjects (Jacob et al., 2007).
Here, we provide evidence that small, soluble Ab assemblies
from several sources enhance synaptic depression through
amechanisminvolvingaltered glutamateuptake athippocampal
synapses. Our results have both mechanistic and therapeutic
implications for the initiation of hippocampal synaptic failure in
AD and in more subtle forms of age-related Ab accumulation.
AB
D C
F E
Figure 1. Soluble Ab Facilitates Long-Term
Depression in the CA1 Region of Hippo-
campal Slices
(A) Western blot of the three sources of soluble Ab
used for LTD experiments in this study. All three
contain an SDS-stable band at 8 kDa, and this
has been conﬁrmed previously as an Ab dimer
by mass spectrometry (Shankar et al., 2008).
7PA2 CM also contains a higher, apparent trimer
species. CHO- CM is devoid of these human Ab
species, as expected, and serves as a negative
control throughout these studies. All samples
were immunoprecipitated with polyclonal Ab anti-
body AW8 and blotted with combined Ab mono-
clonal antibodies 2G3 (Ab40) and 21F12 (Ab42).
SEC: fractions rich in oligomers (left) or monomers
(right) separated by SEC of 7PA2 CM.
(B) A train of 300 single pulses at 1 Hz (5 min; small
graybar)didnotinduceLTDinacutemousehippo-
campal slices in the presence of CHO- CM (blue
squares, n = 6) but induced a signiﬁcant LTD in
the presence of 7PA2 CM (red circles, n = 7).
(C–F) A standard LTD protocol of 900 single
pulses at 1 Hz (15 min; long gray bar) was applied
to slices treated with 7PA2 CM (C), synthetic
Ab1-42 (D), AD brain TBS extract (E), or SEC frac-
tions from 7PA2 CM (F). All are not signiﬁcantly
different from their respective controls.
Insets in (B)–(F) represent typical ﬁeld excitatory
postsynaptic potentials (fEPSPs) recorded before
(light) and 50 min after (dark) LFS. Horizontal cali-
bration bar, 10 ms; vertical bar, 0.5 mV.
RESULTS
Soluble Human Ab from Several
Sources Facilitates Hippocampal
LTD
Small, soluble Ab assemblies have been
obtained from a variety of sources,
including synthetic peptides, cell culture
medium, and human brain extracts
(Lambertetal.,1998;Podlisnyetal.,1995;
McLeanetal.,1999;Shankaretal.,2008).
A common feature among the soluble Ab
preparations used in the current study is
the presence of low-n assembly forms,
i.e., Ab oligomers that are slightly larger than the monomer but
muchsmallerthanamyloidﬁbrils. Whenexamined ondenaturing
gels, these oligomers run principally as SDS-stable dimers and
trimers (Figure 1A). We recently reported that soluble oligomers
extracteddirectlyfromhuman(AD)cortexfacilitateLTDinduction
through activation of mGluR when a subthreshold (300 pulses,
1 Hz) stimulation is applied to hippocampal slices (Shankar
et al., 2008). To investigate the mechanisms underlying the
enhancement of LTD by soluble human Ab, we ﬁrst used cell-
secreted Ab species obtained from a CHO cell line that stably
expresses hAPP with the V717F amyloidogenic AD mutation
(7PA2 cells). These cells release readily detectable levels of
monomeric and oligomeric Ab species into the medium in the
Neuron
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et al., 2002). In accord with our recent work using soluble Ab
extracted from human cortex, we found that 7PA2 CM (but not
the CM of untransfected [CHO-] cells) facilitated the induction
of hippocampal LTD following a subthreshold, low-frequency
stimulus(LFS)(300pulsesat1Hz)thatotherwisedoesnotinduce
LTD (79.7% ± 2.4%, n = 6, versus 93.4% ± 4.2%, n = 7, of base-
line fEPSP slope; p < 0.05) (Figure 1B). We next sought to estab-
lish the effects of soluble Ab on the expression of LTD using
a standard LTD-inducing protocol known to be NMDAR depen-
dent (Kemp and Bashir, 2001), namely, 900 pulses at 1 Hz. This
formofLTDwas equallyinduciblein slicesperfused with artiﬁcial
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Figure 2. Soluble Ab Enhances Hippo-
campal LTD through mGluR or NMDAR,
Depending on the Stimulation Protocol
(A) LTD induced by the 300-pulse protocol (gray
bar) in the presence of 7PA2 CM was blocked
upon coadministration of the nonselective group
I/II mGluR antagonist, MCPG (500 mM, red circles,
n = 6), but not the NMDAR antagonist, AP5 (50 mM,
black squares, n = 5). Horizontal colored bars
represent the corresponding means ± SEMs from
data shown in Figure 1B.
(B) LTD induced by the 900-pulse protocol (gray
bar) is independent of mGluR activation. Horizontal
colored bars represent the corresponding means ±
SEMs from data shown in Figure 1C.
(C) The 900-pulse LTD induced in slices in CHO-
CM was blocked by coadministering the NMDAR
antagonist, AP5 (50 mM, black squares, n = 8),
whereas LTD in slices in 7PA2 CM was unaltered
(red circles, n = 6). Horizontal colored bars from
data in Figure 1C.
(D) 900-pulse LTD in Ab monomer-treated slices
was blocked upon coperfusing AP5 (50 mM, black
squares, n = 5), whereas the LTD in oligomer-
treatedsliceswasnot(redcircles,n=6).Horizontal
colored bars represent the corresponding means ±
SEMs from Figure 1F.
(E) 7PA2 CM enhanced LTD was blocked by treat-
ment with D-AP5 at 100 mM (n = 5). Horizontal
colored bars represent the corresponding means ±
SEMs from Figure 2C.
(F) Dose-response curves of LTD blockade by AP5
in either CHO- CM (black squares) or 7PA2 CM
(red circles). Data are means ± SEMs.
Insets in (A)–(E) represent typical fEPSPs recorded
before (light) and 50 min after (dark) the LFS. Hori-
zontal calibration bar, 10 ms; vertical bar, 0.5 mV.
cerebrospinal ﬂuid (ACSF) supplemented
with 7PA2 CM or CHO- CM (73.6% ±
2.6%, n = 9, versus 77.1% ± 2.1%, n = 9;
p > 0.05) (Figure 1C). Similar results were
observedusingsyntheticAb1-42(Figure1D),
soluble extracts of human AD cortex con-
taining Ab oligomers (Figure 1E), or size-
exclusion chromatography (SEC) fractions
of 7PA2 CM enriched in either oligomers
or monomers (Figures 1A, right panel, and
Figure 1F). These data are consistent with
previous reports that synthetic Ab does not signiﬁcantly change
the magnitude of NMDAR-dependent (i.e., 900-pulse) LTD
achievedinvitro (Raymond etal., 2003; Wang etal.,2002, 2004a).
To probe the mechanism of Ab-facilitated LTD, we used the
nonselective group I/II mGluR antagonist MCPG (500 mM) and
the NMDAR antagonist AP5 (50 mM). In agreement with our
previous ﬁnding using soluble Ab from AD cortex (Shankar
et al., 2008), the facilitation of 300-pulse LTD by 7PA2 CM was
dependent on activation of mGluR but not NMDAR, as the LTD
was MCPG sensitive and AP5 resistant (93.2% ± 6.1%, n = 6,
versus 80.4% ± 4.8%, n = 5; p < 0.05) (Figure 2A). Unlike the
300-pulse LTD, 900-pulse LTD induced in the presence of
Neuron
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versus 73.6% ± 2.6%, n = 9; p > 0.05) (Figure 2B). Interestingly,
50 mM AP5 fully blocked 900-pulse LTD in slices exposed to
CHO- CM but had no signiﬁcant effect on the 900-pulse LTD in
slices exposed to the Ab-rich 7PA2 CM (100.6% ± 1.4%, n = 8,
versus75.4%±3.4%,n=6;p<0.01)(Figure2C).ThisAP5resis-
tance noted with 7PA2 CM was also observed with soluble
synthetic Ab1-42 (see Figure S1A available online) and soluble
extracts of AD cortex containing Ab oligomers (Supp. Figure 1B;
data quantiﬁed in Supp. Figure 1C). Furthermore, application of
SEC fractions of 7PA2 CM revealed that the induction of AP5-
resistant900-pulse LTDwasspeciﬁc toAboligomers,notmono-
mers (Figures 2D and S1C). These results using three distinct
sources of soluble low-n oligomers suggest that the LTD facili-
tated by Ab oligomers is mechanistically different from conven-
tional NMDAR-dependent LTD that is sensitive to 50 mM AP5.
Becausethe900-LFSprotocolforinducingLTDintheCA1region
is well known to be NMDAR dependent (see Kemp and Bashir,
2001, and all control data in Figures 2C, 2D, and S1C), the resis-
tance to AP5 of the LTD induced in the presence of the various
soluble Ab preparations was unexpected. It has been reported
that synthetic Ab can increase NMDAR activity by acting as an
agonist or coagonist of NMDARs (Cowburn et al., 1997) and
increasing NMDA conductance (Wu et al., 1995). Consequently,
50 mM AP5 may not have been sufﬁcient to completely block an
enhanced NMDAR activation mediated by Ab oligomers. When
we used a more potent isoform of AP5, D-AP5, and increased
the concentration to 100 mM, the soluble Ab-facilitated LTD was
now signiﬁcantly prevented (96.5% ± 3.4%, n = 5) (Figure 2E).
Indeed, the block of Ab-facilitated LTD was dependent on AP5
dose (Figure 2F). Rescuing LTD expression in the presence of
7PA2 CM required much higher AP5 concentrations than those
needed to rescue LTD in the presence of CHO- CM (IC50: 17.4
versus 72.5 mM; p <0.001), supporting the conclusion that active
NMDARs are involved in LTD facilitation by soluble Ab.
An Extracellular Glutamate Scavenger Restores Soluble
Ab-Enhanced LTD to Normal Levels
BecauseAboligomersenhancedLTDthroughactivationofgluta-
mate receptors, we asked whether this activity of soluble Ab was
dependentonextracellularglutamateconcentration.Tothisend,
we used an enzymatic glutamate scavenger system (glutamic-
pyruvic transaminase [GPT] + pyruvate) to reduce extracellular
glutamate levels (Overstreet et al., 1997; Min et al., 1998). Expo-
sureofhippocampalslicestoGPTalone(5units/ml)hadnoeffect
on baseline synaptic activity (data not shown). GPT + pyruvate
(2 mM) treatment 15 min prior to the application of CHO- CM or
7PA2 CM affected neither baseline activity nor the magnitude
of LTD induced by 900-LFS (CHO-: 82.6% ± 2.1%, n = 5; 7PA2:
81.8% ± 4.5%, n = 5) (Figure 3A); however, the LTD induced in
the presence of Ab and GPT could now be blocked by 50 mM
AP5 (95.1% ± 3.6%, n = 5) (Figure 3B). This result suggests that
elevated extracellular glutamate concentrations contribute to
the enhancement of LTD by soluble Ab. Similarly, treatment
AB C
DE
Figure 3. Selective Metabolism of Extracel-
lular Glutamate Prevents Soluble Ab-Facili-
tated LTD
(A) A glutamate scavenger system (glutamic pyr-
uvic transaminase [GPT, 5 unit/ml] + pyruvate
[2 mM]) has no signiﬁcant effect on the fEPSP
baseline and 900-pulse LTD in CHO- or 7PA2 CM
treated slices. Horizontal colored bars represent
the corresponding means ± SEMs from Figure 1C.
Insetsin(A)–(C) represent typical fEPSPsrecorded
before(light)and50minafter(dark)LFS;horizontal
calibration bar, 10 ms; vertical bar, 0.5 mV.
(B) 900-pulse LTD (gray bar) was blocked by AP5
(50 mM) in slices exposed to GPT + pyruvate for
15 min prior to 7PA2 CM (n = 6). Red horizontal
bar shows the LTD resistant to the same dose of
AP5 in the absence of exposure to scavengers.
(C) 300-pulse LTD (gray bar) was signiﬁcantly pre-
vented by coadministering glutamate scavengers
with the 7PA2 CM. Horizontal colored bars repre-
sent the corresponding means ± SEMs from
Figure 1B.
(D) Paired-pulse facilitation in slices exposed to
7PA2 CM, CHO- CM, or 7PA2 CM + AP5 (50 mM)
measured before (white)or 30 min after (gray) add-
ing these media or else measured 50 min after
(black) a 900-pulse induction of LTD. At right are
typical traces of these ﬁeld recordings from the
7PA2 group.
(E) Similar paired-pulse facilitation recorded by
whole-cell voltage clamping at 70 mV in CA1
pyramid cells before and 30 min after 7PA2 CM
exposure. At right are typical traces. Data are
means ± SEMs.
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LTD (94.4% ± 2.8%, n = 5) (Figure 3C). We conclude that the
enhancement of LTD by soluble Ab in both mGluR-dependent
and NMDAR-dependent conditions involves elevated extracel-
lular glutamate levels.
Paired-pulse facilitation (PPF) reveals whether alterations of
synaptic transmission are presynaptic. To assess whether
soluble Ab oligomers increase extracellular glutamate levels by
affecting presynaptic release probability, we measured PPF in
slicesexposedtoCHO-CM,7PA2CM,or7PA2CM+AP5(50mM)
at baseline, 30 min after these exposures, and then 50 min after
a 900-pulse LTD induction. PPF was not signiﬁcantly different
between these three conditions (Figure 3D). To establish further
that soluble Ab does not alter presynaptic release, we performed
whole-cellrecordingsofpyramidalcellsandfoundthatPPFratios
before and 30 minafter 7PA2 CM exposure were notsigniﬁcantly
different (Figure 3E). The experiments described so far suggest
that the facilitation of LTD by soluble oligomeric Ab involves
elevated levels of extracellular glutamate, but not by altering
presynaptic release probability.
A1 A2 A3
B1 B2 C1 C2
D1 D2
Figure 4. Soluble Ab Oligomers Alter NMDAR-Medi-
ated EPSCs in Whole-Cell Voltage-Clamp Recordings
(A1) Isolated AMPA-EPSC and NMDA-EPSC were recorded
from 70 mV and +45 mV holding potentials, respectively,
plus pharmacological blockers. Black traces, CHO- CM
treated cells; gray traces, 7PA2 CM treated cells. (A2)
Summary data for CHO- CM (black) and 7PA2 CM (gray)
groups and for pretreatment with cyclothiazide (CTZ, 100 mM)
prior to 7PA2 CM (white). (A3) NMDA/AMPA EPSC ratios are
different in CHO- CM and 7PA2 CM.
(B1) Typical traces from CA1 pyramidal cells held at 70 mV
(black), isolated NMDA-EPSC in low Mg
2+ with NBQX (10 mM)
and bicuculline (20 mM) at 70 mV (gray), and full blockage
of the NMDA current by AP5 (50 mM) (light gray). (B2)
Summary data for the isolated NMDA-EPSC before (pre)
and 20–30 min after 7PA2 CM exposure. Peak amplitudes
(gray) and total charge transfers (black) are expressed as
means ± SEMs.
(C1) The selective NR2B inhibitor, ifenprodil (3 mM), modestly
reduces NMDA charge transfers in control but markedly
reduces it in 7PA2 CM. (C2) 7PA2 CM signiﬁcantly increases
the extrasynaptic response when synaptic NMDAR are ﬁrst
blocked by MK-801.
(D) NMDA-mediated EPSC kinetic analysis: (D1) representa-
tive scaled traces before (black) versus after (gray) 7PA2 CM
exposure; (D2) summary data of rise time plotted versus
decay time before (pre) and after (post)7PA2 CM exposure.
Data are means ± SEMs.
The Ab-Mediated Increase in Synaptic
Glutamate Concentration Alters Properties
of Excitatory Transmission
We next sought to determine more precisely the
basisofsolubleAb-mediatedalterationsinglutama-
tergic transmission through whole-cell recordings.
AMPAR-mediated currents (AMPA-EPSC) and
NMDAR-mediatedcurrents(NMDA-EPSC)werere-
corded from pyramidal neurons in slices treated
with CHO- CM or 7PA2 CM (Figure 4A1). Both
currents were signiﬁcantly reduced by the soluble Ab-rich 7PA2
CM compared to the CHO- CM (AMPA 67% ± 4%, n = 18, p <
0.001;NMDA79%±3%,n=13,p<0.01)(Figure4A2).Thisresult
was unexpected, as the increased extracellular glutamate
concentrations observed above should increase AMPA and/or
NMDA currents. However, the result could be explained if the
Ab-mediated rise in glutamate levels leads to receptor desensiti-
zation. To address this possibility, we applied a well-character-
ized inhibitor of AMPAR desensitization, cyclothiazide (CTZ,
100 mM), to the slices before exposure to 7PA2 CM; the AMPA
EPSC was no longer signiﬁcantly decreased (CHO- CM: 115 ±
14 pA versus 7PA2 CM + CTZ: 96 ± 3 pA, n = 10; p > 0.05)
(Figure4A2).Interestingly,we observed spikingactivity escaping
voltageclampin6/10cellsrecordedinthe7PA2CM+CTZcondi-
tion (Figures S2A and S2B) but not in the CTZ-only condition
(three cells; data not shown), further suggesting alterations in
excitatory transmission due to supraphysiologic levels of extra-
cellular glutamate in the presence of soluble Ab. To assess
whether AMPAR desensitization is involved in the induction of
LTDbysolubleAb,CTZwasappliedtobrainslices,and900-pulse
Neuron
Soluble Ab Enhances Long-Term Depression
792 Neuron 62, 788–801, June 25, 2009 ª2009 Elsevier Inc.LTD was induced; the LTDs were not signiﬁcantly different in
CHO- versus 7PA2 CM (Figure S2C), suggesting that AMPAR
desensitization is not required for the LTD induction.
To preserve the neuronal glutamate uptake expected under
normalphysiologicalfunction,werepeatedthesingle-cellrecord-
ings at 70 mV rather than at positive potentials (Grewer and
Rauen, 2005). NMDA-EPSC was isolated in low Mg
2+ (0.1 mM)
and with pharmacological blockade of AMPAR (with NBQX,
10 mM) and GABA-R (with BIC, 20 mM) (Figure 4B1). Under these
conditions, the NMDAR-EPSC was again found to be decreased
by 7PA2 CM (78% ± 3%, n = 10; p < 0.01) (Figure 4B2). The
NMDA-EPSC reduction could be due to NMDAR desensitization
in the presence of increased extracellular glutamate levels (Sar-
antis et al., 1993). To better understand the NMDA current
changes, we quantiﬁed charge transfers, calculated as the area
under the curve of the NMDA-EPSC. In contrast to the reduction
inpeakamplitude,thetotalchargetransferwasnotdecreasedby
the Ab-rich 7PA2 CM (96% ± 2% of pretreatment values, n = 11;
p > 0.05) (Figure 4B2). Because NR2B receptors have a 2- to
3-fold higher sensitivity for glutamate than do NR2A receptors
(Kutsuwada et al., 1992), we asked whether NR2B receptors
played the principal role in the Ab-mediated effect on NMDA
currents.Theselective NR2Breceptor inhibitor,ifenprodil (3 mM),
modestly inhibited the NMDA-EPSC total charge transfer under
control (CHO- CM) conditions (81% ± 2%, n = 8) (Figure 4C1).
However, ifenprodil strongly and signiﬁcantly inhibited the
NMDA-EPSCchargetransferinthepresenceof7PA2CM(55%±
2%,n=9;p<0.05)(Figure4C1),suggestingenhancedactivation
ofNR2B-subunit-containingNMDAreceptors.TheNR2Bsubunit
is considered to be predominantly present in extrasynaptic
NMDA receptors (Tovar and Westbrook, 1999). We selectively
blocked synaptic NMDAR with MK-801, an irreversible, use-
dependent NMDA channel blocker, washed it out, and perfused
with7PA2CMundertheaboveNMDA-EPSCisolatingconditions.
TheNMDA-EPSCsweremarkedlyincreased(202%±10%ofthe
CHO- CM level, n = 5; p < 0.01) (Figure 4C2). Taken together, the
above results suggest that soluble Ab oligomers increase NR2B-
mediatedNMDARactivityandenhanceextrasynapticresponses.
Spillover of increased extracellular glutamate remained as the
most parsimonious explanation for the relative increases in
NMDAcurrents,activationofNR2Breceptors,andextrasynaptic
responses in the presence of Ab oligomers. To further support
this interpretation, we analyzed the NMDA EPSC kinetics, i.e.,
the 10%–90% rise time and the decay time constant. While the
peak amplitude decreased slightly after 7PA2 CM treatment,
the rise time (16 ms versus 20 ms for pre- versus postexposure;
p < 0.05) and decay time (100 ms versus 109 ms for pre- versus
postexposure; p<0.05) were signiﬁcantly prolonged (Figure 4D),
suggesting increased diffusion distance and dwelling times, i.e.,
that neurotransmitter spillover is enhanced upon exposure to
soluble Ab oligomers.
Soluble Ab Enhances LTD through Inhibition
of Glutamate Uptake
Our ﬁndings above that soluble Ab-enhanced LTD may activate
a larger population of NMDARs can be considered in terms of
Ab interrupting glutamate reuptake (Harkany et al., 2000; Gu
et al., 2004). To investigate this possibility, we examined the
effects of a well-characterized glutamate uptake inhibitor,
TBOA. Soluble Ab extracted from AD brain or present in 7PA2
CM (Figure 1B) facilitates LTD in CA1 after a 300-LFS protocol,
whereas this low stimulus induces weak or no LTD in control-
treated slices. To test whether inhibiting glutamate uptake itself
facilitates LTD, the 300-LFS protocol was applied after a 30 min
TBOAtreatment(15mM).Closelysimilartoourresultswithsoluble
Ab treatment in this 300-LFS mode (Figure 1B), we found that
TBOA alone induced LTD in an NMDAR-independent but
mGluR-dependent manner (TBOA alone: 74% ± 4.5%, n = 5;
TBOA + AP5: 78.1% ± 3.5%, n = 5; TBOA + MCPG: 91% ±
4.6%, n = 6) (Figure 5A). Similar to the 900-pulse LTD induced in
the presence of soluble Ab (Figure 2), the 900-pulse LTD induced
inthepresenceofTBOAwasalsoresistantto50mMAP5butwas
preventedby100mMD-AP5(TBOA:73.5%±3.4%,n=5;TBOA+
AP5: 76.9% ± 5.6%, n = 5; TBOA + D-AP5: 94.2% ± 2.8%, n = 5;
p < 0.01 compared to TBOA + AP5) (Figure 5B).
To assess whether TBOA-enhanced LTD has mechanistic
similarity with soluble Ab, we recorded the TBOA-induced LTD
in a repetitive 900-LFS paradigm to saturate the LTD response,
then washed out the TBOA and replaced it with 7PA2 CM
(Figure 5C). When 900-LFS was then performed, there was no
further increase in LTD (96.1% ± 9.1% of renormalized baseline
measured 40 min after LFS, n = 5; p > 0.05) (Figures 5C and 5D).
This occlusion experiment suggests that these two forms of LTD
share similar mechanisms. Interestingly, if we ﬁrst applied 7PA2
CM and saturated the LTD, then the usual dose (15 mM) of TBOA
signiﬁcantly reduced baseline neurotransmission (to 78% of the
renormalizedbaselineat30min)(FigureS3A),andthiseffectwas
similar to that of a higher dose of TBOA alone (50 mM) on the
baseline (81% at 30 min) (Figure S3B). The latter results further
substantiate a shared mechanism between TBOA and soluble
Ab on perturbation of neurotransmission. We also examined
DHK (500 mM), an inhibitor of glial glutamate transporter (GLT-1),
but the 900-pulse LTD observed in the presence of this agent
was largely prevented by the standard 50 mM AP5 dose
(89.2% ± 3.2%, n = 6, versus 77.5% ± 2.9%, n = 6, p < 0.05,
Figure S3C), suggesting speciﬁcity for neuronal, not glial, gluta-
mate transporters in the enhancement of the 900-pulse LTD.
The effects of soluble Ab in inhibiting HFS-induced LTP have
been well established using several types of Ab preparations,
and we conﬁrmed this here using soluble Ab-rich 7PA2 CM
(CHO- CM: 144.7% ± 5.4%, n = 7, versus 7PA2 CM: 108.1% ±
6.6%, n = 7; p < 0.001) (Figure 5E). TBOA similarly inhibited
HFS-induced LTP (vehicle: 151.3% ± 4.8%, n = 6, versus
TBOA:112.2%±3.1%,n=6;p<0.001)(Figure5F).Theseresults
support our conclusion that the effects of soluble Ab on synaptic
plasticity mimic those observed with the blockade of neuronal
glutamate uptake.
To assess directly whether soluble Ab inhibits glutamate
uptakeasalloftheabovedatasuggest,wemeasuredtheuptake
of radiolabeled glutamate by isolated synaptosomes (see Exper-
imental Procedures). As a positive control, TBOA decreased
glutamate uptake in the synaptosomal preparation in a dose-
dependent manner (IC50 = 73.9 mM) (Figure 5G). Synthetic Ab1-42
signiﬁcantly decreased glutamate uptake into synaptosomes
(69% ± 6% of vehicle treatment, n = 15; p < 0.01), similar to the
effects of TBOA (41% ± 4% at 50 mM, n = 5; p < 0.01)
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hypothesis that soluble Ab impairs neuronal glutamate uptake
and can thereby increase extracellular glutamate concentration
and subsequent NMDAR activation.
Extracellular Calcium Inﬂux, Not Intracellular Stores,
Contributes to Soluble Ab-Facilitated LTD
To assess whether alterations in calcium inﬂux through NMDARs
mediate the facilitation of LTD by soluble Ab, the ACSF calcium
concentration was reduced to 0.5 mM prior to the application of
soluble Ab and 900-LFS to the brain slices. This reduction of
extracellular calcium concentration prevented LTD induction in
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Figure 5. Soluble Ab-Enhanced LTD In-
volves Impaired Glutamate Reuptake
(A)LTDwasinducedby300pulses(graybar)when
just the glutamate uptake inhibitor, TBOA (15 mM),
was perfused (black squares, n = 5). This TBOA-
mediated LTD was prevented by mGluR antago-
nist MCPG (500 mM, blue triangles, n = 6) but
not by NMDAR antagonist AP5 (50 mM, red circles,
n = 6).
Insets in (A)–(F) represent fEPSPs recorded before
(light) and 50 min after (dark) either LFS (in A–C)
or HFS (in E and F). Horizontal calibration bars,
10 ms; vertical bars, 0.5 mV.
(B)A 900-pulse LTD facilitatedby TBOA wasresis-
tant to a standard dose of AP5 (50 mM, red circles,
n = 6), but it could be blocked by D-AP5 (100 mM,
blue triangles, n = 6).
(C) Saturation of 900-pulse LTD occurring in the
presence of TBOA (black horizontal bar) occludes
further LTD in the presence of 7PA2 CM (red hori-
zontal bar).
(D) Summary data from occlusion experiments as
in (C): left bar, evoked fEPSP was renormalized
tobaseline values(i.e., point 3inC)before addition
of 7PA2 CM tothe perfusate and an additional LFS
(right bar).
(E) LTP induced by high-frequency stimulation
(HFS) was prevented in slices in 7PA2 CM (red
circles) but unaffected in slices in CHO- CM (black
squares).
(F) HFS-induced LTP was similarly prevented by
TBOA.
(G) Dose-dependent inhibition of glutamate up-
take by TBOA in hippocampal synaptosomes.
(H) Pretreatment with soluble synthetic Ab1-42
impaired glutamate uptake in hippocampal synap-
tosomes in a fashion similar to TBOA treatment at
50 mM. Data are means ± SEMs as percentage of
vehicle alone; **p < 0.01.
the presence of either 7PA2 or CHO- CM
(Figure 6A). To test whether extracellular
calcium is required for the NMDAR-medi-
ated enhancement of LTD by soluble Ab,
we applied 50 mM AP5 and varied the
extracellular Ca
2+ concentration between
0.5 mM and 6 mM (Figure 6A). The LTD
induced by 900-LFS in the presence of
AP5 + CHO- CM was fully blocked when
the Ca
2+ concentration was 1 mM or 2.5 mM, and only a small
AP5-resistant LTD (86.4% ± 4.5%, n = 6) occurred at the highest
Ca
2+ concentration (6 mM). In contrast, LTD induced in presence
of 7PA2 CM was signiﬁcantly prevented by 50 mM AP5 at low
(1mM) Ca
2+ concentration(7PA2CM:80%± 4.2%, n = 5, versus
7PA2CM+ AP5: 93.2%±3.4%, n =6;p<0.05)butnotatnormal
(2.5mM:75.4%±3.4%,n=6)orhigh(6mM:70.4%±3.4%,n=5)
Ca
2+ concentrations. These results indicate that Ab-enhanced
LTD is dependent on extracellular calcium concentration.
To assess whether intracellular calcium stores also regulate
Ab-mediatedLTD,astheyhavebeenreportedtodoforAbneuro-
toxicity (Demuro et al., 2005), we tested two compounds that
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2+ stores, ryanodine and
U73122. Although ryanodine (20 mM) and U73122 (10 mM) each
prevented 900-LFS LTD induction in slices treated with CHO-
CM, they did not alter the LTD facilitation by 7PA2 CM (87% ±
2.7%, n = 5, versus 76% ± 3.2%, n = 5, for ryanodine, p < 0.05)
(Figure 6B) (96.2% ± 3.4%, n = 4, versus 74.6% ± 4.6%, n = 6,
for U73122, p < 0.01) (Figure 6C). This suggests that soluble
Ab-facilitated LTD requires extracellular calcium inﬂux but not
intracellular calcium release.
Activation of Calcineurin and GSK-3, but Not p38 MAPK,
Is Required for Ab-Mediated LTD
When cytosolic calcium reaches critical concentrations, certain
LTD-related signaling pathways are activated (Kemp and Bashir,
2001). For example, NMDAR-dependent LTD in the CA1 region
recruits calcineurin (PP2B) and p38 MAPK cascades (Mulkey
et al., 1994; Bolshakov et al., 2000; Li et al., 2006). We examined
these two signaling pathways using their respective inhibitors,
FK506 (20 mM) and SB203580 (5 mM). Whereas blocking p38
MAPK activation with SB203580 prevented conventional 900-
pulse LTD induction (i.e., in CHO- CM), it did not signiﬁcantly
affect the LTD induced in the presence of soluble Ab-rich 7PA2
CM (94.6% ± 2.5%, n = 7, versus 73.9% ± 4%, n = 6; p < 0.01)
(Figure 6D). In contrast, PP2B function was required for LTD
induced both in the absence and presence of soluble Ab
(Figure 6E). Glycogen synthase kinase-3 (GSK3)-mediated
signaling was recently reported to play an important role in
LFS-induced LTD (Peineau et al., 2007), and it has also been
implicatedinAb-mediatedneurotoxicityinculturedhippocampal
slices(Nassifetal.,2007).Accordingly, wetreatedslices withthe
GSK-3b inhibitor, SB415286 (10 mM), for 30 min prior to applying
either CHO- CM or 7PA2 CM and then performed 900-LFS. LTD
could not be induced in either condition (94.3% ± 4.7%, n = 6,
versus 98.4% ± 2.6%, n= 6) (Figure 6F), suggesting that GSK-3b
activity is required for both conventional and soluble Ab-medi-
atedLTD.Tofurtherverifythatglutamateuptakeinhibitionshares
similar mechanisms with soluble Ab as regards LTD induction,
ryanodine,SB203580,andFK506wereeachappliedtotheslices
prior to treatment with TBOA. Entirely consistent with the results
for Ab-mediated LTD, both intracellular Ca
2+ release and p38
MAPK activation were not required for the TBOA-mediated LTD,
whereas PP2B activity was (Figures 6G–6I).
To provide furtherinformation about thereceptor mechanisms
of LTD facilitation by soluble Ab, we took advantage of Ras-
guanine nucleotide-releasing factor 1 (Ras-GRF1) knockout
mice, which are deﬁcient in the ability to mount an LTD response
(Li et al., 2006). Ras-GRF proteins are best known for their ability
to activate Ras/Erk through their CDC25-GEF domains and acti-
vatetheRac/p38cascadethroughtheirDH-GEFdomains,which
act as calcium sensors for different classes of NMDARs and
drive the activation of distinct MAP kinase family members. As
expected, hippocampal slices from these Ras-GRF1
/ mice
did not express LTD when 900-LFS was administered in the
presence of CHO- CM. In contrast, LTD was elicited in the pres-
ence of the oligomer-rich 7PA2 CM (99.4% ± 2.9%, n = 6, versus
75.1%±2.9%,n=7;p<0.01)(FigureS4A).ThissolubleAb-facil-
itated LTD in the Ras-GRF1
/ mice was not blocked by 500 mM
MCPG (Figure S4B) nor by 50 mM AP5 (Figure S4C), but it was
signiﬁcantly decreased by 100 mM AP5 (91.6% ± 3.1%, n = 5,
p < 0.05) (Figure S4C). Furthermore, the p38 MAPK inhibitor
(SB203508) had no effect on the Ab-facilitated LTD (80.2% ±
4.8%, n = 5) (data not shown), whereas pretreatment with either
the calcineurin inhibitor (FK506) or the GSK-3b inhibitor
(SB415286) signiﬁcantly prevented the LTD associated with
7PA2CM(95.6%±4.8%,n=6,and88.4%±4.7%,n=6,respec-
tively)(FigureS4D).Therefore,solubleAbbypassedthenonfunc-
tional LTD induction pathway in Ras-GRF1
/ mice, a pathway
that is normally sensitive to 50 mM AP5 in wild-type mice.
DISCUSSION
Given the mounting evidence that soluble Ab oligomers mediate
synaptic impairment in AD, elucidating the precise molecular
pathways by which this occurs has important implications for
treating and preventing the disease. Here, we demonstrate
that soluble Ab oligomers facilitate LTD in the hippocampus
through a mechanism that appears to involve the inhibition of
glutamate uptake. With a weak (300-pulse) LFS, Ab-mediated
LTD was prevented by MCPG but not AP5, and with a conven-
tional (900-pulse) LFS, the LTD was prevented only by a high
(100 mM), not a standard (50 mM), dose of AP5. Extracellular
glutamate scavengers effectively prevented Ab-enhanced LTD.
Mechanistically, soluble Ab oligomers caused glutamate spill-
over, and their ability to facilitate LTD required an inﬂux of extra-
cellular calcium but did not detectably require Ca
2+ release from
intracellular stores. Once Ca
2+ enters the neuron, it is known to
trigger PP2B and GSK3 signaling pathways, and we implicated
these in the Ab-facilitated LTD induction.
Importantly, Ab facilitation of LTD was closely mimicked by
pharmacologically inhibiting neuronal (but not glial) glutamate
uptake, consistent with the rescue of Ab-LTD by the glutamate
scavenger. In accord, we found that Ab signiﬁcantly impaired
glutamate uptake by synaptosomes, suggesting that Ab facili-
tates LTD in part by altering synaptic glutamate recycling. These
results support the hypothesis that excess synaptic glutamate
caused by Ab mechanistically alters LTD induction in hippo-
campus. It should be emphasized that the effects of soluble Ab
we describe in this study are attributable to soluble oligomers
(Figure 1A), as no larger assemblies (protoﬁbrils, ﬁbrils) were
present, and SEC-isolated oligomers but not monomers
conferred theeffectsonLTD(Figure2D).Asummarymechanism
incorporating all of our ﬁndings is proposed in Figure 7.
We focused on the NMDAR-dependent induction of LTD, a
widelyusedprotocolforLTDstudies.Therehavebeencontradic-
tory ﬁndings among the few studies of the effects of Ab on LTD
(Kim et al., 2001; Wang et al., 2002; Raymond et al., 2003; Wang
et al., 2004a). Hsieh et al. (2006) showed that Ab secreted by
neurons in hippocampal slices transfected with mutant human
APP could induce LTD via an mGluR-dependent mechanism
involving AMPAR internalization. Moreover, Chang et al. (2006)
reported that aged APP/Presenilin-1 double knockin mice having
reduced AMPAR mEPSCs were resistant to LTD induction, sug-
gesting a ﬂoor effect for synapse depression following prolonged
exposure to Ab. Our new data indicate that soluble Ab oligomers
can induce hippocampal LTD, although the mechanisms do not
follow canonical p38 MAPK pathways.
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Figure 6. LTD Facilitated by Soluble Ab or TBOA Share Similar Signaling Pathways
(A) Conventional LTD (in CHO- CM, black squares) and Ab-enhanced LTD (in 7PA2 CM, red circles) induced by the 900-pulse LFS in the presence of AP5 (50 mM)
were plotted as a function of increasing extracellular calcium concentrations in the perfusate. Light blue area represents the LTD obtained in the CHO- CM alone
(without AP5). Data are means ± SEMs.
(B) Ryanodine (20 mM) given 30 min prior to 900 pulses partially blocked the LTD in CHO CM (black squares, n = 5) but produced no block of the 7PA2-facilitated
LTD (red circles, n = 6).
(C) U73122 (10 mM) (applied 45 min prior to 900 pulses) fully blocked LTD in the presence of CHO- CM (black squares, n = 6) but had no effect in the presence of
7PA2 CM (red circles, n = 6).
(D) 900-pulse LTD was blocked by p38 MAPK inhibitor, SB203580 (5 mM), in CHO- CM (black squares, n = 7) but not in 7PA2 CM (red circles, n = 7).
(E) Calcineurin inhibitor, FK-506 (20 mM) perfused 40 min prior to 900 pulses prevented LTD in both CHO- CM (black squares, n = 5) and 7PA2 CM (red circles,
n = 6).
(F)GSK-3binhibitor,SB415286(10mM)perfused60minpriorto900pulsespreventedLTDinbothCHO-CM(blacksquares,n=6)and7PA2CM(redcircles,n=7).
(G) LTD enhanced by TBOA (15 mM) was likewise resistant to ryanodine (n = 5).
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currents in rat dentate gyrus (Wu et al., 1995) or enhance
NMDA response in the hippocampus after a 15 min exposure
in vivo (Molna ´r et al., 2004). Our current results show that soluble
Ab oligomers depressed AMPAR currents (Figures 4A and 4B),
but this was likely due to desensitization. Earlier work has sug-
gested that NR2B-containing NMDARs play a major role in
normal LTD induction (Liu et al., 2004), although some recent
evidence is not in agreement (Morishita et al., 2007). Our study
suggests that soluble Ab oligomers can signiﬁcantly increase
NR2B receptor activation, as demonstrated by an increased
ifenprodil-sensitive component of the NMDAR-EPSC following
exposure to soluble Ab. NR2B receptors are speciﬁcally coupled
to SynGAP (Kim et al., 2005), and their activation would thus
inhibit the Ras-Erk signaling pathway known to be required for
LTP, instead favoring LTD induction. Although some studies
have colocalized Ab with NMDAR at synapses (Dewachter
et al., 2009; Lacor et al., 2007), it remains unclear whether these
are a direct target of the peptide, and other studies have sug-
gested Ab interactions with voltage-dependent calcium chan-
nels (VDCCs) (Ueda et al., 1997), mGluRs (Wang et al., 2004b),
nicotinic receptors (Dineley et al., 2001; Snyder et al., 2005), or
insulin receptors (Townsend et al., 2007), all of which could
modulate NMDAR activity. It remains plausible that the hydro-
phobic Ab oligomers actually interact with lipid and/or protein
targets upstream of these various receptors, perturbing their
function secondarily.
Extrasynaptic glutamate spillover is a phenomenon that has
been implicated in cross-talk among hippocampal synapses
(Asztely et al., 1997; Min et al., 1998; Scimemi et al., 2004). Inhibi-
tion of glutamate uptake at the synapse (e.g., by soluble Ab)c a n
signiﬁcantly increase the extracellular glutamate concentration
andtherebyenhanceglutamatespillovertoneighboringsynapses.
Electrophysiologically, NMDA currents will be increased and
their rise and decay time courses signiﬁcantly prolonged, due to
the increased distance between the glutamate release site and
the target receptors. In addition, extrasynaptic NMDAR activity
willbeincreasedbysynapticglutamateaccumulation.Ourpresent
resultsdonotfullymeetthesecriteria,aswefoundthatsolubleAb
depressed peak NMDAR currents. We hypothesize that Ab oligo-
mers depress NMDA currents as a result of desensitization of the
receptors. It is of related interest that several glutamate uptake
(H) TBOA-enhanced LTD was prevented by the calcineurin inhibitor (FK 506, black circles, n = 5) but not by the p38 MAPK inhibitor (SB203580, red diamonds,
n = 5).
(I) Summary data for actions of the signaling pathway modulators on Ab- and TBOA-enhanced LTD. The horizontal gray bar represents mean LTD in TBOA alone
(Figure 5B), and the horizontal light orange bar represents mean LTD in 7PA2 CM alone (Figure 1C). Data are means ± SEMs.
Figure 7. Schematic of the Principal Pathways Implicated by This Study in Conventional LTD and in LTD Facilitated by Soluble Ab Oligomers
(Left panel) Conventional LTD requires NMDAR-mediated inﬂux of extracellular calcium and liberation of intracellular calcium stores. This ultimately activates
PP2B, GSK-3b, or p38 MAPK signaling pathways that induce LTD. (Right panel) Soluble Ab oligomers lead to activation of more NMDAR, leading to extracellular
calcium inﬂux and activation of PP2B and GSK-3b pathways to facilitate LTD. Our data suggest that Ab oligomers decrease glutamate uptake by neuronal trans-
porters (red x’s), resulting in the enhanced activation of NMDARs and thus facilitation of LTD-inducing pathways.
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et al., 1993; Maki et al., 1994; Asztely et al., 1997), as we show
for soluble Ab oligomers here. Thus, Ab-mediated decreases in
glutamate uptake and consequent accumulation of extracellular
glutamate could induceNMDAR desensitization and/oractivation
of presynaptic mGluRs, thereby reducing the peak amplitudes of
the NMDA currents.
Glutamate excitotoxicity has been hypothesized to have a role
in AD pathogenesis. Dysfunction of glutamate transporters has
been implicated in this pathway (Masliah et al., 1996; Jacob
et al., 2007). Synthetic Ab has been shown to inhibit glutamate
uptake in cultured astrocytes (Harris et al., 1996; Harkany
et al., 2000; but see Ikegaya et al., 2002) and oocytes (Gu
et al., 2004). Extracellular glutamate concentration is tightly
controlled in the brain by a family of membrane transporters,
predominantly expressed by perisynaptic astrocytes (Danbolt,
2001). Their role is to regulate the glutamate released at
synapses and to prevent spillover of the transmitter to extrasy-
naptic receptors. Our results showing that soluble Ab facilitates
LTD through both mGluR (300-LFS protocol) and NMDAR (900-
LFS protocol) pathways is supported by our concomitant ﬁnding
that a common upstream element, the glutamate transporter, is
also regulated by soluble Ab. In vivo microdialysis recently re-
vealed that microinjection of the soluble Ab-rich 7PA2 CM can
signiﬁcantly increase the interstitial ﬂuid levels of glutamate—
but not GABA or aspartate—in hippocampus (O’Shea et al.,
2008). Inhibition of glutamate uptake by TBOA has been shown
to increase spontaneous epileptiform discharges, and this
increased excitability can be blocked by AP5 (Campbell and Ha-
blitz, 2004). Interestingly, Ab has also been found to signiﬁcantly
increase spontaneous nonconvulsive seizure activity in cortical
and hippocampal networks in APP-transgenic mice (Palop
et al., 2007). The precise mechanism by which soluble Ab oligo-
mers interfere with glutamate transporters at the synapse
remains to be determined. Given the numerous distinct recep-
tors and channel proteins reported to be altered by Ab to date,
we speculate that the hydrophobic Ab oligomers bind principally
to membrane lipids and thereby secondarily interrupt the struc-
ture and function of synaptic transmembrane transporters and
channels, leading to changes in the transduction of intracellular
signaling cascades. Such a mechanism would be consistent
with the direct effect of soluble Ab on glutamate uptake by iso-
lated synaptosomes in vitro (Figure 5H).
Calcium is a second messenger that controls many cellular
processes, including neuronal excitability, synaptic plasticity,
and neuronal death. The increase in postsynaptic calcium that
results in LTD can arise from a number of sources. For example,
extracellular Ca
2+ inﬂux can occur through NMDARs or VDCCs
(Kemp and Bashir, 2001), and intracellular Ca
2+ release can
stem from activation of the ryanodine receptor (RyR) and the
inositol 1,4,5-trisphosphate receptor (IP3R). Our data (Figures
6A–6C) show that conventional hippocampal LTD requires
extracellular Ca
2+ inﬂux through NMDARs and recruits intracel-
lular stores from IP3R and possibly RyR, in line with previous
studies on hippocampal LTD (Kemp and Bashir, 2001).
However, among these possible calcium sources, Ab-facilitated
LTD onlyrequired NMDARactivation andenhanced extracellular
calcium entry. An increase in cytosolic calcium can trigger
signaling cascades involved in LTD induction, including PP2B,
p38 MAPK, and GSK3 (Mulkey et al., 1994; Bolshakov et al.,
2000; Li et al., 2006; Peineau et al., 2007). The differences
between our study and previous reports implicating Ab in the
activation of p38 MAPK (Hsieh et al., 2006; Origlia et al., 2008)
could lie in the experimental conditions, for example, acute sli-
ces versus dissociated neuronal cultures or ﬁeld versus whole-
cell recordings.
Inconclusion,theﬁndingsdescribedheresuggestthatsoluble
Ab oligomers facilitate LTD through both NMDARs and mGluRs
by interfering with glutamate recycling at the synapse (Figure 7).
Our study also suggests that additional mechanisms may
underlie LTD in AD pathological states beyond those described
previously through the NMDAR-p38/MAPK pathway. The recep-
tors and signaling molecules activated by Ab as described in
this study could represent additional therapeutic targets in
Alzheimer’s disease.
EXPERIMENTAL PROCEDURES
Ab Preparations
Secreted human Ab peptides were collected and prepared from the condi-
tioned medium (CM) of a CHO cell line (7PA2) that stably expresses human
APP751 containing the V717F AD mutation (Podlisny et al., 1995). Cells were
grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing 10% fetal
bovine serum, 1% penicillin/streptomycin, 2 mM L-glutamine, and 200 mg/
ml G418 for selection. Upon reaching 95% conﬂuency, the cells were
washed and cultured overnight (15 hr) in serum-free medium. CM was
collected, spun at 1500 3 g to remove dead cells and debris, and stored at
4C. The CM was concentrated 10-fold with a YM-3 Centricon ﬁlter (Walsh
et al., 2005). Aliquots of concentrated 7PA2 CM were stored at 80C.
Synthetic Ab1-42 (Biopolymer Lab., Dept. of Neurology, UCLA) was dissolved
in water and incubated at 37C for 10 days, then aliquoted (50 ml) and stored
at 80C.
Hippocampal Slice Electrophysiology
The procedures for the hippocampal slice preparation and ﬁeld excitatory
postsynapticpotentials(fEPSPs)recordingsintheCA1regionofmousehippo-
campus were described previously (Li et al., 2006; Shankar et al., 2008). A
bipolar stimulating electrode (FHC Inc., Bowdoin, ME) was placed in the
Schaffer collaterals todelivertest and conditioning stimuli. A borosilicateglass
recording electrode ﬁlled with artiﬁcial cerebrospinal ﬂuid was positioned in
stratum radiatum of CA1. Test responses were recorded for 30–60 min prior
to beginning the experiment to ensure stable responses. The ﬁeld potentials
were ampliﬁed 1003 using an Axon Instruments 200B ampliﬁer and digitized
with Digidata 1322A. Traces were obtained by pClamp 9.2 and analyzed using
the Clampﬁt 9.2 program. To induce LTD, either 300 or 900 pulses at low
frequency (1 Hz) stimulation (LFS) were applied to the slices. LTP was induced
by two sequential high-frequency stimulations (HFS: 100 Hz for 1 s, then
repeated after 20 s). All LTD/LTP values represent fEPSP slopes measured
50 min after the conditioning stimulus unless stated otherwise. Two-tailed
Student’s ttest and one-way analysis of variance (ANOVA) wereusedto deter-
mine statistical signiﬁcance.
Whole-cell recordings were made from the soma of visually identiﬁed pyra-
midal neurons located in CA1 of the hippocampus. Patch pipettes (57M U)
were ﬁlled with an internal solution containing (in mM) 110 Cs-gluconate,
20 CsCl, 10 HEPES, 4 NaCl, 0.5 EGTA, 2 MgCl2,2N a 2ATP, and 0.25 NaGTP,
titrated with CsOH to pH 7.4. The excitatory postsynaptic currents (EPSCs)
were recorded following stimulation of Schaffer collaterals 150 mm from the
CA1cellbodywithabipolarelectrode.AMPA-mediatedEPSCswererecorded
at a holding potential of 70 mV in the presence of 10 mM bicuculline (BIC) and
50 mM AP5. NMDA-mediated EPSCs were recorded at +45 mV in ACSF con-
taining 20 mM BIC and 10 mM NBQX, or else at 70 mV in 0.1 mM Mg
2+
ACSF containing BIC and NBQX. Series resistance was kept 1530 MU and
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if the series resistance changed by >20% during the course of the experiment.
All patch-clamp experiments were performed at 24C.
Glutamate Uptake Assay
Preparation of crude synaptosomal fractions and glutamate uptake assay
were performed as described by Yang et al. (2005) with minor modiﬁcations.
Brieﬂy, hippocampal slices were treated for 2 hr with soluble Ab, TBOA, or
DMSO, then homogenized in 0.32 M sucrose, 1 mM EDTA, 4 mM Tris, and
10 mM glucose (pH 7.4) on ice. Homogenates were centrifuged at 1000 3 g
for 10 min, and subsequent supernatants were spun at 9000 3 g for 10 min.
Final pellets were resuspended in HEPES buffer solution to yield a protein
concentration of 0.25 mg/ml. To avoid treatment washout, crude synapto-
somes were treated with the same respective agents for 45 min at 37C.
Then, they were incubated with 10 nM [
3H]glutamate (20–60 Ci/mmol; Perkin
Elmer, Boston, MA) and 30 mM unlabeled glutamate for 5 min. The uptake
was stopped by placing the samples on ice and spinning at 15,000 rpm for
10 min at 4C. Pellets were washed and resuspended in ice-cold PBS. Gluta-
mate uptake was counted on an LS6500 multipurpose scintillation counter.
The absolute number of counts taken up varied from 500 to 40,000 counts
per minute (cpm), with a background of 20 cpm.
Drug Treatments
Paired control and experimental hippocampal slices from a single mouse were
maintained together in a single chamber, except during individual drug treat-
ments. The following antagonists were purchased from Tocris (Ellisville,
MO): DL-2-amino-5-phosphonopentanoic acid (AP5), MK-801, MCPG, cyclo-
thiazide, NBQX,(-)-bicuculline methiodide, SB203580, SB415286, Ryanodine,
U73122, DL-threo-b-benzyloxyaspartic acid (TBOA) and dihydrokainic acid
(DHK). Glutamic-pyruvic transaminase, pyruvic acid, Ifenprodil, and FK506
were purchased from Sigma (St Louis, MO).
SUPPLEMENTAL DATA
Supplemental Data include four ﬁgures and their legends and can be found
with this article online at http://www.cell.com/neuron/supplemental/S0896-
6273(09)00387-0.
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